PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16194481-2 2005 Prevention of breast cancer with tamoxifen, of squamous cell skin cancer with actinic keratosis by diclofenac gel and in familial polyposis with anti-inflammatory drug (COX-2) celecoxib is considered of health care clinical use. Celecoxib 176-185 mitochondrially encoded cytochrome c oxidase II Homo sapiens 169-174 16038624-4 2005 The first selective COX-2 inhibitor, celecoxib, entered the market in December 1998 [corrected] However, there are a few organs that physiologically and functionally express COX-2, particularly the glomeruli of the kidney and the cortex of the brain. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 20-25 16038624-4 2005 The first selective COX-2 inhibitor, celecoxib, entered the market in December 1998 [corrected] However, there are a few organs that physiologically and functionally express COX-2, particularly the glomeruli of the kidney and the cortex of the brain. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 174-179 16083531-5 2005 Highly selective COX-2 inhibitors including celecoxib, rofecoxib, valdecoxib, lumiracoxib, and etoricoxib were developed with the hope of significantly reducing the serious gastrointestinal toxicities associated with chronic high-dose NSAID use. Celecoxib 44-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 16710939-0 2005 PGE2 produced by lung cancer suppresses immune function through T-regulatory cells and can be blocked by the COX2 inhibitor Celebrex. Celecoxib 124-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 109-113 15870389-1 2005 We have already demonstrated that celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, has a proapoptotic effect on synovial fibroblasts obtained from patients with rheumatoid arthritis (RA). Celecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-79 15870389-10 2005 The order of potency of the COX-2 inhibitory activity of these drugs in RA synovial fibroblasts was celecoxib = SC-236 > rofecoxib > TT201 > TT101. Celecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 15998959-6 2005 RESULTS: Patients with a history of gastropathy were more likely to be prescribed COX-2 inhibitors than low-dose NSAIDs; the odds ratios were 1.73 (95%CI: 1.56-1.91) and 1.49 (1.33-1.66), respectively for celecoxib and rofecoxib. Celecoxib 205-214 mitochondrially encoded cytochrome c oxidase II Homo sapiens 82-87 15827035-2 2005 In 2001, the National Institute for Clinical Excellence (NICE) published guidance on the use of the COX-2 agents celecoxib, rofecoxib, meloxicam and etodolac for rheumatoid arthritis (RA) and osteoarthritis (OA). Celecoxib 113-122 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 15723448-4 2005 This investigation consists of a double-blind, randomized, placebo-controlled trial aimed at comparing the effects of the selective COX-2 inhibitor celecoxib (200 mg every 12 hours for a total of 5 doses) on platelet and renal function and the renal response to furosemide (40 mg intravenously) with those of naproxen (500 mg every 12 hours for a total of 5 doses) and placebo in 28 patients with cirrhosis and ascites. Celecoxib 148-157 mitochondrially encoded cytochrome c oxidase II Homo sapiens 132-137 15953441-3 2005 Results of treating 24 cases of diffuse anterior scleritis with the novel selective COX-2 inhibitor celecoxib are reported. Celecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 84-89 15742005-2 2005 Previous studies with the selective COX-2 inhibitors, rofecoxib and celecoxib, have shown that they do not alter the progression of AD. Celecoxib 68-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 15965068-5 2005 We report here that a COX-2 selective NSAID, celecoxib, induced a concentration- and time-dependent increase of HO-1 expression in glomerular mesangial cells. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 15867369-11 2005 In contrast, the COX-2-selective inhibitor celecoxib had little effect on tumor growth. Celecoxib 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 15867233-2 2005 Our study was designed to determine whether the COX-2 inhibitor celecoxib could be safely administered in doses within those approved by the Food and Drug Administration when used concurrently with thoracic radiotherapy in patients with poor prognosis non-small cell lung cancer (NSCLC). Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 15700047-0 2005 Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Celecoxib 23-32 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 15834426-3 2005 Among the more potent Abeta42-raising agents identified are fenofibrate, an antilipidemic agent, and celecoxib, a COX-2-selective NSAID. Celecoxib 101-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 15902876-6 2005 CONCLUSION: This observation, which constitutes, as far as we know, the first case report of hemorrhagic ulcerated colitis related to celecoxib, confirms the colic toxicity of anti-Cox2 and identify a new cause of acute colitis. Celecoxib 134-143 mitochondrially encoded cytochrome c oxidase II Homo sapiens 181-185 15826877-5 2005 Additionally we studied the effects of the pretreatment with the non-selective anti-inflammatory drug indomethacin (n = 13) or the selective COX-2 inhibitor celecoxib (n = 12) and compared the effects to those of the pretreatment with vehicle (n = 11). Celecoxib 157-166 mitochondrially encoded cytochrome c oxidase II Homo sapiens 141-146 15871445-3 2005 In this study, we evaluated the tolerability of celecoxib, a selective COX-2 inhibitor, in patients with analgesic intolerance. Celecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 15572651-2 2005 A number of COX-2 inhibitors, including celecoxib and rofecoxib, are already used in man for the treatment of inflammatory pain. Celecoxib 40-49 mitochondrially encoded cytochrome c oxidase II Homo sapiens 12-17 15741619-4 2005 Celecoxib, a COX-2 inhibitor, recently was approved for the treatment of acute pain. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 15494548-7 2005 The overall saturation binding affinity for COX-2 of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min). Celecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 15892673-5 2005 Selective cyclooxygenase-2 (COX-2) inhibitors represent a new group of pharmaceutical products termed "coxibs" that include meloxicam, nimesulide, etodolac and celecoxib. Celecoxib 160-169 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 15859361-4 2005 Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 15987447-2 2005 In the present study we evaluated the mechanisms by which a highly selective COX-2 inhibitor, celecoxib, affects tumor growth of two differentially invasive human breast cancer cell lines. Celecoxib 94-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-82 15987447-6 2005 Celecoxib treatment inhibited COX-2 activity, indicated by prostaglandin E2 secretion, and caused significant growth arrest in both breast cancer cell lines. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 15987447-13 2005 CONCLUSION: The disparate molecular mechanisms of celecoxib-induced growth inhibition in human breast cancer cells depends upon the level of COX-2 expression and the invasive potential of the cell lines examined. Celecoxib 50-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 141-146 15791193-0 2005 [Prevention of heterotopic ossifications in hip arthroplasty: effectiveness of selective Cox-2 inhibitors (celecoxib) versus ketoprofen]. Celecoxib 107-116 mitochondrially encoded cytochrome c oxidase II Homo sapiens 89-94 16185091-5 2005 Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. Celecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 32-37 15974939-4 2005 There are currently few randomized clinical trials comparing the efficacy of the 2 first-generation COX-2 selective inhibitors, celecoxib and rofecoxib, in osteoarthritis. Celecoxib 128-137 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 15974940-5 2005 COX-2-selective inhibitors (Coxibs) such as celecoxib, rofecoxib or valdecoxib have been developed to achieve an equal relief of pain and inflammation as classical NSAIDs but without their risk of gastrointestinal side effects. Celecoxib 44-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 15361550-4 2004 Suppression of R(+)-MA-induced prostaglandin (PG) E2 synthesis with the selective COX-2 inhibitor celecoxib (0.01-1 microM) or inhibition of COX-2 expression by COX-2-silencing small-interfering RNA was accompanied by inhibition of R(+)-MA-mediated DNA fragmentation and cell death. Celecoxib 98-107 mitochondrially encoded cytochrome c oxidase II Homo sapiens 82-87 16433205-3 2005 Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 15789535-5 2005 We report two cases of tubulointersticial nephritis confirmed by renal biopsy, associated with administration of the two Cox-2 inhibitors currently available on the market, celecoxib and rofecoxib. Celecoxib 173-182 mitochondrially encoded cytochrome c oxidase II Homo sapiens 121-126 16689132-3 2005 There are a lot data in the literature which suggest that selective COX-2 inhibitors (rofecoxib and celecoxib) produce the similar effects on the kidney as traditional nonsteroidal anti-inflammatory drugs (inhibitors of COX-1 and COX-2). Celecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 16689132-3 2005 There are a lot data in the literature which suggest that selective COX-2 inhibitors (rofecoxib and celecoxib) produce the similar effects on the kidney as traditional nonsteroidal anti-inflammatory drugs (inhibitors of COX-1 and COX-2). Celecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 230-235 15471850-5 2004 Co-incubation of rat and human islets with selective COX-2 inhibitors SC-58236 and Celecoxib, respectively, attenuated cytokine-induced PGE(2) formation. Celecoxib 83-92 mitochondrially encoded cytochrome c oxidase II Homo sapiens 53-58 15563357-6 2004 Final results of the celecoxib outcome study (CLASS study) attenuated the initial enthusiasm about the GI safety of selective COX-2 inhibitors, especially in patients concomitantly taking aspirin for cardiovascular prophylaxis. Celecoxib 21-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 126-131 17462298-6 2005 The COX-2 pathway may therefore be a useful target for chemoprevention of prostate cancer, and there is much interest in exploring this with the use of COX-2 inhibitor drugs such as celecoxib. Celecoxib 182-191 mitochondrially encoded cytochrome c oxidase II Homo sapiens 152-157 15477758-7 2004 Immunofluorescence analyses revealed high-level expression of COX-2 in endothelial cells in L3.6 pl xenografts that increased following therapy with celecoxib, whereas the tumor cells expressed uniformly low levels of COX-2. Celecoxib 149-158 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 15361550-11 2004 Furthermore, our data show that pharmacological concentrations of celecoxib may interfere with the proapoptotic action of R(+)-MA and anandamide, suggesting that cotreatment with COX-2 inhibitors could diminish glioma regression induced by these compounds. Celecoxib 66-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 179-184 15279596-2 2004 A recently developed class of pharmacological agents incorporating primary sulfamoyl moieties in their molecule is constituted by the COX-2 selective inhibitors, with at least two clinically used drugs, celecoxib and valdecoxib. Celecoxib 203-212 mitochondrially encoded cytochrome c oxidase II Homo sapiens 134-139 15494133-8 2004 Levels of PGE-M were found to be greatly increased in humans with unresectable non-small cell cancer of the lung, and this increase is dramatically reduced by administration of the COX-2 inhibitor celecoxib, implying that COX-2 contributes significantly to the overproduction of PGE2. Celecoxib 197-206 mitochondrially encoded cytochrome c oxidase II Homo sapiens 181-186 15494133-8 2004 Levels of PGE-M were found to be greatly increased in humans with unresectable non-small cell cancer of the lung, and this increase is dramatically reduced by administration of the COX-2 inhibitor celecoxib, implying that COX-2 contributes significantly to the overproduction of PGE2. Celecoxib 197-206 mitochondrially encoded cytochrome c oxidase II Homo sapiens 222-227 15533902-4 2004 OBJECTIVE/HYPOTHESIS: We administered the COX-2 inhibitor celecoxib (200 mg b.i.d.) Celecoxib 58-67 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 15865061-1 2004 The selective inhibition of COX-2 isozymes should lead to a new generation of NSAIDs with significantly reduced side effects; e.g. celecoxib (Celebrex) and rofecoxib (Vioxx). Celecoxib 131-140 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 15865061-1 2004 The selective inhibition of COX-2 isozymes should lead to a new generation of NSAIDs with significantly reduced side effects; e.g. celecoxib (Celebrex) and rofecoxib (Vioxx). Celecoxib 142-150 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 15265936-0 2004 Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. Celecoxib 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-22 15521372-8 2004 The SBPCOCs with the selective COX-2 inhibitors celecoxib and rofecoxib were well tolerated in all cases. Celecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 15475461-2 2004 The purpose of this study was to investigate the expression of 5-Lox in EAC of a rat model and in human samples as well as the chemopreventive effects of zileuton (a specific 5-Lox inhibitor) and celecoxib (a specific Cox2 inhibitor) in the rat EAC model. Celecoxib 196-205 mitochondrially encoded cytochrome c oxidase II Homo sapiens 218-222 15485309-5 2004 Celecoxib (Celebrex), Pfizer), a selective COX-2 inhibitor and potent anti-inflammatory agent, has been approved for the treatment of osteoarthritis and rheumatoid arthritis. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 15485309-5 2004 Celecoxib (Celebrex), Pfizer), a selective COX-2 inhibitor and potent anti-inflammatory agent, has been approved for the treatment of osteoarthritis and rheumatoid arthritis. Celecoxib 11-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 15485309-7 2004 Phase II clinical trials suggest that COX-2 inhibition by celecoxib would enhance response to cytotoxic chemotherapy or radiation therapy through interference with cellular proliferation and tumor angiogenic processes, promotion of apoptosis and immune surveillance, or other possible mechanisms. Celecoxib 58-67 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 15485309-8 2004 Celecoxib has shown promising antitumor efficacy in lung cancer and a large variety of solid tumors that rely on COX-2-related mechanisms for growth and survival. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 16137030-4 2004 The combination of celecoxib and hydroxyurea could evidently inhibit the expression of COX-2 protein or COX-2 mRNA of K562 cells. Celecoxib 19-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-92 16137030-4 2004 The combination of celecoxib and hydroxyurea could evidently inhibit the expression of COX-2 protein or COX-2 mRNA of K562 cells. Celecoxib 19-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-109 16137030-5 2004 CONCLUSION: Celecoxib can enhance the anti-proliferative effect of hydroxyurea on K562 cells, which is associated with the down-regulation of both COX-2 protein and COX-2 mRNA on K562 cells. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 16137030-5 2004 CONCLUSION: Celecoxib can enhance the anti-proliferative effect of hydroxyurea on K562 cells, which is associated with the down-regulation of both COX-2 protein and COX-2 mRNA on K562 cells. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 165-170 15377836-1 2004 Alpha-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-alpha-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice. Celecoxib 83-92 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110 15254428-14 2004 Our findings provide new informations about individual eicosanoids produced by HNSCC cells and their differential regulation by the selective COX-2 inhibitor celecoxib. Celecoxib 158-167 mitochondrially encoded cytochrome c oxidase II Homo sapiens 142-147 15278327-1 2004 AIMS: A post-marketing surveillance study using the technique of Prescription Event Monitoring was undertaken to monitor the safety of celecoxib, a cyclo-oxygenase (COX)-2 inhibitor, as prescribed in primary care in England. Celecoxib 135-144 mitochondrially encoded cytochrome c oxidase II Homo sapiens 148-171 15256475-0 2004 Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Celecoxib 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-22 15194006-0 2004 Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Celecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 15256475-0 2004 Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Celecoxib 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 250-255 15256475-3 2004 Whether the COX-2 inhibitor, celecoxib, approved for the treatment of colon carcinogenesis and rheumatoid arthritis, affects CS-induced NF-kappaB activation is not known, although the role of NF-kappaB in regulation of apoptosis, angiogenesis, carcinogenesis, and inflammation is established. Celecoxib 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 12-17 12898179-2 2004 In this study, we investigated the effect on cultured rheumatoid fibroblast-like synoviocytes (FLS) of the selective COX-2 inhibitor celecoxib on the expression of matrix metalloproteinases (MMPs), which play an important role in tissue degradation and angiogenesis in rheumatoid synovium. Celecoxib 133-142 mitochondrially encoded cytochrome c oxidase II Homo sapiens 117-122 15193741-0 2004 Isolation, synthesis and characterization of impurities in celecoxib, a COX-2 inhibitor. Celecoxib 59-68 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 15087416-0 2004 Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Celecoxib 89-98 mitochondrially encoded cytochrome c oxidase II Homo sapiens 53-58 15217972-4 2004 Treatment of humans with the selective COX-2 inhibitor celecoxib augments the antitumor effects of chemotherapy in patients with non-small cell lung cancer. Celecoxib 55-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-44 15160322-4 2004 Using a post-marketing surveillance study (PSS) efficacy and tolerability of the COX-2-selective drug Celecoxib was evaluated. Celecoxib 102-111 mitochondrially encoded cytochrome c oxidase II Homo sapiens 81-86 15239337-7 2004 Clinical trials are planed with the anti Cox2 celecoxib for breast cancer prevention, in adjuvant setting, in metastatic situation combined with exemestane or antitubulin drugs or in neoadjuvant therapy. Celecoxib 46-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-45 15899633-7 2004 Clinical trials are planed with the anti Cox2 celecoxib for breast cancer prevention, in adjuvant setting, in metastatic situation combined with exemestane or antitubulin drugs or in neoadjuvant therapy. Celecoxib 46-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-45 15117884-2 2004 Selective inhibitors of COX-2, such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, and valdecoxib have been developed and the greatest recent growth in our knowledge in this area has been come from the clinical use of these compounds. Celecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 15182793-1 2004 OBJECTIVES: Two selective COX2 inhibitors, rofecoxib and celecoxib, were introduced on the French market in 2000. Celecoxib 57-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-30 15133778-6 2004 After adjusting for potential confounding factors, the OR for switching to another NS-NSAID or COX-2 specific inhibitor ranged from 1.74 to 2.35 for the three NS-NSAIDs compared to celecoxib (all comparisons, p < 0.01). Celecoxib 181-190 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 15133778-9 2004 CONCLUSIONS: Patients on the COX-2 specific inhibitors (celecoxib and rofecoxib) were significantly less likely to switch their therapy than patients on NS-NSAIDS (ibuprofen, naproxen and diclofenac). Celecoxib 56-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 15041464-5 2004 The effect of celecoxib treatment on both, cell survival and induction of apoptosis in hCOX-2-as cells was less marked than in the COX-2-expressing cells. Celecoxib 14-23 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-93 14961568-3 2004 Unlike primary normal mesothelial cells, the selective cyclooxygenase (COX)-2 inhibitor celecoxib reduced the in vitro proliferation of several MM cells derived from previously untreated MM patients. Celecoxib 88-97 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-77 14961568-5 2004 Celecoxib was more efficient in inhibiting MM cell growth than acetylsalicylic acid (10(-6) M-10(-2) M), indometacin (10(-6) M-10(-2) M) and the COX-2 inhibitor NS-398 (10(-6) M-10(-4) M). Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 145-150 15020235-3 2004 We have observed that the COX-2 inhibitor celecoxib inhibits growth and induces apoptosis in the immortalized breast epithelial cell line 184htert. Celecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 15010021-10 2004 Nonsteroidal anti-inflammatory drug therapy with sulindac, a nonselective cyclooxygenase (COX) inhibitor, or celecoxib, a COX-2 selective inhibitor, may be of benefit after the development of duodenal polyposis by inducing the regression or stabilization of the polyposis, although there is limited evidence from randomized, controlled trials to support its routine use. Celecoxib 109-118 mitochondrially encoded cytochrome c oxidase II Homo sapiens 122-127 15290792-3 2004 Proliferation of both of the MCF-7/hCox-2 clones was significantly inhibited in a time- and dose-dependent manner by celecoxib. Celecoxib 117-126 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-41 15252926-5 2004 Treatment with the selective COX-2 inhibitor celecoxib has shown promising results in the prevention of CRC, Numerous studies show that this COX-2 selective inhibitor is a potent suppressor of colon polyps both in animal models for familial adenomatous polyposis and in patients with this condition. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 15252926-5 2004 Treatment with the selective COX-2 inhibitor celecoxib has shown promising results in the prevention of CRC, Numerous studies show that this COX-2 selective inhibitor is a potent suppressor of colon polyps both in animal models for familial adenomatous polyposis and in patients with this condition. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 141-146 14698190-0 2004 Polar substitutions in the benzenesulfonamide ring of celecoxib afford a potent 1,5-diarylpyrazole class of COX-2 inhibitors. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 108-113 14711936-4 2004 Here, we report that celecoxib, one of the new class of selective COX-2 inhibitors, has the potential to reverse tumor-mediated wasting and associated humoral factors such as interleukin (IL)-6 and hypercalcemia in preclinical models of cachexia. Celecoxib 21-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 66-71 15026550-2 2004 This study was designed to evaluate the effect and mechanisms of the selective COX-2 inhibitor celecoxib in the growth control of human cholangiocarcinoma cells. Celecoxib 95-104 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 14764122-1 2004 OBJECTIVES: To evaluate the efficacy of the cyclooxygenase (COX)-2 inhibitor celecoxib in prostate-specific antigen (PSA) recurrent prostate cancer after definitive radiation therapy (RT) or radical prostatectomy (RP), as recent evidence showed that COX-2 inhibitors have potent antitumour activity in prostate cancer both in vitro and in vivo but there are no human trials. Celecoxib 77-86 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-66 14991374-0 2004 COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Celecoxib 112-121 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 14713756-7 2004 Selective COX-2 inhibitors are currently under study to evaluate their potential roles in preventing prostate cancer in high-risk patients (rofecoxib) or the recurrence of bladder cancer (celecoxib). Celecoxib 188-197 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 14760808-12 2004 Among the COX-2-specific inhibitors, celecoxib has a longer survival time than rofecoxib. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 16146090-1 2004 Clinical and experimental studies have shown that renal and cardiovascular effects of most selective COX-2 inhibitors (rofecoxib, celecoxib) are similar to other traditional NSAIDs (dual COX inhibitors). Celecoxib 130-139 mitochondrially encoded cytochrome c oxidase II Homo sapiens 101-106 15068837-5 2004 Celecoxib is a potent COX-2 inhibitor being developed for the treatment of rheumatoid arthritis and osteoarthritis. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 14726653-8 2004 Taken together, our results show that celecoxib exerts COX-2-independent anti-proliferative effects on glioblastoma cell growth, which are more potent than those of other selective COX-2 inhibitors or traditional NSAIDs, and which are mediated via the transcriptional inhibition of two essential components of the cell cycle machinery, cyclin A and cyclin B. Celecoxib 38-47 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 14726653-8 2004 Taken together, our results show that celecoxib exerts COX-2-independent anti-proliferative effects on glioblastoma cell growth, which are more potent than those of other selective COX-2 inhibitors or traditional NSAIDs, and which are mediated via the transcriptional inhibition of two essential components of the cell cycle machinery, cyclin A and cyclin B. Celecoxib 38-47 mitochondrially encoded cytochrome c oxidase II Homo sapiens 181-186 14724542-1 2003 INTRODUCTION: Celecoxib (Celebrex) is a Cox 2 selective non steroidal anti-inflammatory agent. Celecoxib 14-23 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 14756580-7 2004 In patients treated with low-dose aspirin (acetylsalicylic acid) for cardiovascular prophylaxis, celecoxib (another selective COX-2 inhibitor) seems to have no obvious advantages over conventional NSAIDs, and similar conclusions may be applied to rofecoxib. Celecoxib 97-106 mitochondrially encoded cytochrome c oxidase II Homo sapiens 126-131 14716644-5 2004 Celecoxib, a selective COX-2 inhibitor, shows the same efficacy as indomethacin in the prevention of heterotopic ossification after hip prosthesis with significantly fewer side effects. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 14711953-2 2004 COX-2-specific inhibitors such as celecoxib have recently been approved for human use. Celecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 15124935-5 2004 Selective COX-2 inhibitors currently used in the clinic are the sulphonamides celecoxib and valdecoxib (parecoxib is a prodrug of valdecoxib), as well as the methylsulphones rofecoxib and etoricoxib. Celecoxib 78-87 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 15523159-4 2004 Nonsteroidal anitinflammatory drugs (NASIDs) such as celecoxib, are the most widely investigated COX-2 inhibitors. Celecoxib 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 14676104-2 2003 We hypothesized that treatment with oral celecoxib, a selective COX-2 inhibitor, would favorably alter biomarkers of lung cancer risk. Celecoxib 41-50 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-69 14655004-2 2003 Currently, there are four selective COX-2 inhibitors available in Germany: celecoxib, rofecoxib, valdecoxib and parecoxib. Celecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 14651817-2 2003 We evaluated celecoxib tolerance, a highly specific COX-2 inhibitor, in NSAIDs-sensitive patients. Celecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 52-57 14724542-1 2003 INTRODUCTION: Celecoxib (Celebrex) is a Cox 2 selective non steroidal anti-inflammatory agent. Celecoxib 25-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 14708615-7 2003 We further demonstrated by FACS analyses that NAPS- or TAPS-mediated apoptosis was greatly increased in cells treated with celecoxib, a selective COX-2 inhibitor. Celecoxib 123-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 146-151 14677191-1 2003 OBJECTIVE: To assess the effects of celecoxib, a cyclooxygenase (COX-2) selective inhibitor, on the metabolism of hyaluronan (HA) and proteoglycans (PG) in human cartilage explants with midrange severity of osteoarthritis (OA). Celecoxib 36-45 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-70 14730095-4 2003 Indomethacin (IND), an inhibitor preferentially acting on COX-1, as well as nimesulide (NIM) and celecoxib (CECOX), i.e. preferential and selective inhibitor of COX-2, respectively, administered icv almost completely blocked the antinociceptive effect of ACETA in Randall-Selitto method. Celecoxib 97-106 mitochondrially encoded cytochrome c oxidase II Homo sapiens 161-166 14730095-4 2003 Indomethacin (IND), an inhibitor preferentially acting on COX-1, as well as nimesulide (NIM) and celecoxib (CECOX), i.e. preferential and selective inhibitor of COX-2, respectively, administered icv almost completely blocked the antinociceptive effect of ACETA in Randall-Selitto method. Celecoxib 108-113 mitochondrially encoded cytochrome c oxidase II Homo sapiens 161-166 14585914-5 2003 Results demonstrate that the median duration of treatment was longer among patients initially prescribed COX-2-specific inhibitors (30 days and 23 days for celecoxib and rofecoxib respectively) than in those prescribed non-selective NSAIDs (10 days). Celecoxib 156-165 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110 14585916-5 2003 In comparative trials of celecoxib or valdecoxib with non-specific NSAIDs, COX-2-specific inhibitors were demonstrated to have superior dyspepsia tolerability than non-specific NSAIDs. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 12832284-5 2003 The production of PGE2 was also inhibited by indomethacin; a selective cyclooxygenase (COX)-2 inhibitor, celecoxib; and dexamethasone. Celecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-93 12960371-10 2003 These findings suggests that (i) aspirin and NCX-4016 trigger ATL formation in humans, (ii) celecoxib inhibits ATL formation and exacerbates the mucosal injury caused by low doses of aspirin, and (iii) the NO-donating moiety of NCX-4016 protects the gastric mucosa even in the presence of suppression of COX-1 and COX-2. Celecoxib 92-101 mitochondrially encoded cytochrome c oxidase II Homo sapiens 314-319 12975714-7 2003 The average total daily dose of COX-2 inhibitor was 219.2 mg for celecoxib and 25.23 mg for rofecoxib. Celecoxib 65-74 mitochondrially encoded cytochrome c oxidase II Homo sapiens 32-37 14500353-0 2003 Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Celecoxib 50-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 14500353-14 2003 Inhibition of COX-2 by celecoxib appears to alleviate this effect on p53 by reducing electrophilic PG synthesis. Celecoxib 23-32 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 12888902-2 2003 In this study, we investigated the effect of a selective COX-2 inhibitor, celecoxib, on growth and apoptosis induction of four human head and neck carcinoma cell lines, SCC25, KB, HSG and HSY, in comparison with frequently used COX inhibitor sulindac. Celecoxib 74-83 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 12888902-7 2003 The PGE2 production and COX-2 expression were inhibited more efficiently by celecoxib than by sulindac. Celecoxib 76-85 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 12888902-13 2003 These findings indicated that a selective COX-2 inhibitor celecoxib inhibits cell proliferation, induces apoptosis and augments sensitivity to anticancer drugs in human head and neck carcinoma cells. Celecoxib 58-67 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 14552704-2 2003 Rofecoxib and celecoxib are the first selective COX-2 inhibitors approved by the FDA and EMEA for the treatment of rheumatoid arthritis (RA), osteoarthritis (OA) and for relief of acute pain. Celecoxib 14-23 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 12874188-9 2003 In fact, immunoreactive COX-2 was increased 16-fold in platelets at day 5 after CABG, but the COX-2 selective inhibitor celecoxib did not alter aspirin-resistant thromboxane formation. Celecoxib 120-129 mitochondrially encoded cytochrome c oxidase II Homo sapiens 94-99 12902855-6 2003 Two specific COX-2 inhibitors, namely, rofecoxib (Vioxx) and celecoxib (Celebrex), both oral agents and FDA approved, have been shown preclinically and clinically to have efficacy comparable to that of NSAIDs for relief of pain and inflammation in osteoarthritis, with decreased risk of gastrointestinal damage. Celecoxib 61-70 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 12902855-6 2003 Two specific COX-2 inhibitors, namely, rofecoxib (Vioxx) and celecoxib (Celebrex), both oral agents and FDA approved, have been shown preclinically and clinically to have efficacy comparable to that of NSAIDs for relief of pain and inflammation in osteoarthritis, with decreased risk of gastrointestinal damage. Celecoxib 72-80 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 12902866-1 2003 The selective cyclooxygenase (COX)-2 inhibitor, celecoxib, alone and in combination with radiation was investigated in vitro and in vivo. Celecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-36 12902866-3 2003 Treatment of both tumor cells with celecoxib alone resulted in a dose- and time-dependent reduction of cell number (clonogenic cell death) and tumor cell growth rate in vitro; however, inhibition of tumor cell growth by celecoxib was not correlated with the reduction of COX-2 protein in tumor cells. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 271-276 12902866-12 2003 Our results indicate that the selective inhibition of COX-2 combined with radiation has potential application in radiotherapy, and celecoxib-mediated antitumor effects may act through different mechanisms including direct inhibition of tumor cell proliferation, alteration of tumor cell cycle, and antiangiogenesis. Celecoxib 131-140 mitochondrially encoded cytochrome c oxidase II Homo sapiens 54-59 12824303-1 2003 The cyclooxygenase (COX)-2 inhibitor Celecoxib may inhibit cancer cell growth independently of its capacity to block the COX-2 enzyme. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-26 12824303-1 2003 The cyclooxygenase (COX)-2 inhibitor Celecoxib may inhibit cancer cell growth independently of its capacity to block the COX-2 enzyme. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 121-126 12890715-5 2003 Treating HUVEC with selective COX-2 inhibitors, celecoxib and rofecoxib, caused an approximately 70% reversion of antiadhesive effect of aspirin. Celecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 14508092-3 2003 The clinical use of these agents is limited to patients with familial adenomatous polyposis (FAP), which may benefit from chemopreventive treatment with sulindac or the selective COX-2 inhibitor celecoxib. Celecoxib 195-204 mitochondrially encoded cytochrome c oxidase II Homo sapiens 179-184 12811211-0 2003 Celecoxib associated esophagitis: review of gastrointestinal side effects from cox-2 inhibitors. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 12811211-10 2003 SUMMARY: We report for the first time severe esophagitis caused by the COX-2 inhibitor Celecoxib. Celecoxib 87-96 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 12800245-18 2003 Celecoxib as a chemopreventive and chemotherapeutic agent might be effective primarily on COX-2-expressing cholangiocarcinoma. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 14552704-6 2003 The improved biochemical selectivity of valdecoxib vs celecoxib in vitro (COX-1/COX-2 ratio: 60 vs 30, respectively) may be clinically relevant leading to an improved GI safety. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-85 12743579-3 2003 OBJECTIVE: We investigated whether 33 subjects with a typical history of AIA tolerated the new COX-2-selective NSAID celecoxib. Celecoxib 117-126 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 12743579-10 2003 CONCLUSIONS: A group of subjects with clinically well-documented AIA tolerated acute challenge with the selective COX-2 inhibitor celecoxib. Celecoxib 130-139 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 15199473-3 2003 Aspirin is less effective in inhibiting COX-2 activity, whereas celecoxib and rofecoxib selectively inhibit COX-2 activity as they contain a side chain to anchor to the side pocket of COX-2 substrate channel. Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 108-113 15199473-3 2003 Aspirin is less effective in inhibiting COX-2 activity, whereas celecoxib and rofecoxib selectively inhibit COX-2 activity as they contain a side chain to anchor to the side pocket of COX-2 substrate channel. Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 108-113 12668898-5 2003 Furthermore, for patients with AERD and chronic urticaria, they can be given the new selective COX-2 inhibitors (rofecoxib and celecoxib) without any cross-reactivity. Celecoxib 127-136 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 12797547-0 2003 The cox-2-specific inhibitor celecoxib inhibits adenylyl cyclase. Celecoxib 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 12797547-3 2003 Celecoxib (Celebrex) is a COX-2 enzyme inhibitor and has emerged as a preferred therapeutic agent for the treatment of rheumatoid arthritis as compared to other NSAIDs. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 12797547-3 2003 Celecoxib (Celebrex) is a COX-2 enzyme inhibitor and has emerged as a preferred therapeutic agent for the treatment of rheumatoid arthritis as compared to other NSAIDs. Celecoxib 11-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 12797547-5 2003 In the present study, we report that celecoxib not only inhibited COX-2, but also exhibited the property of inhibiting adenylyl cyclase, an important enzyme forming the intracellular second messenger 3",5"-adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 66-71 12608557-2 2003 We report the first cases of membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib (Celebrex), a selective COX-2 inhibitor. Celecoxib 113-122 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 12723742-3 2003 COX-2 inhibitors such as celecoxib and rofecoxib appear to be as effective as non-selective NSAIDs in the treatment of chronic inflammatory disease but their analgesic efficacy and their safety at the higher doses required for analgesia are less certain. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 12644588-5 2003 The binding to COX-2 seems to be both rapid and slowly reversible with association rates of 5.8 x 10(6)/M/min and 4.5 x 10(6)/M/min and dissociation rates of 14 x 10(-3)/min (t(1/2) = 50 min) and 7.0 x 10(-3)/min (t(1/2) = 98 min) for [(3)H]celecoxib and [(3)H]valdecoxib, respectively. Celecoxib 241-250 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 12644588-9 2003 These binding studies provide direct insight into the properties and binding constants of celecoxib and valdecoxib to COX-2. Celecoxib 90-99 mitochondrially encoded cytochrome c oxidase II Homo sapiens 118-123 12868201-3 2003 Slow, time-dependent, irreversible, highly selective inhibitors of COX-2 such as celecoxib, etoricoxib, rofecoxib and valdecoxib, so-called coxibs, are a new group of drugs widely used in rheumatology as well as in other fields of medicine. Celecoxib 81-90 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 12608557-2 2003 We report the first cases of membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib (Celebrex), a selective COX-2 inhibitor. Celecoxib 124-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 12749519-10 2003 CONCLUSION: Celecoxib was a less costly treatment option than rofecoxib among OA patients with hypertension aged > or = 65 years, based on our model of the direct costs of COX-2 specific inhibitor therapy combined with those associated with physician monitoring and treatment of edema and BP destabilization. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 175-180 12605743-1 2003 BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs), used for the treatment of osteoarthritis, can produce serious gastrointestinal (GI) adverse reactions.Celecoxib, a specific COX-2 inhibitor, has a proven efficacy equivalent to that of traditional NSAIDs with an improved tolerance and safety profile. Celecoxib 162-171 mitochondrially encoded cytochrome c oxidase II Homo sapiens 184-189 12816152-4 2003 The goal of our study was to estimate the frequency of intolerance reactions due to ingestion of the two newly approved selective COX-2 inhibitors, rofecoxib or celecoxib. Celecoxib 161-170 mitochondrially encoded cytochrome c oxidase II Homo sapiens 130-135 12629931-1 2003 The discovery of the isoenzymes cyclooxygenase-(COX-) 1 and COX-2 led to the development of newer nonsteroidal anti-inflammatory drugs (NSAIDs) designed to block COX-2, such as rofecoxib, celecoxib, and valdecoxib. Celecoxib 188-197 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 12629931-1 2003 The discovery of the isoenzymes cyclooxygenase-(COX-) 1 and COX-2 led to the development of newer nonsteroidal anti-inflammatory drugs (NSAIDs) designed to block COX-2, such as rofecoxib, celecoxib, and valdecoxib. Celecoxib 188-197 mitochondrially encoded cytochrome c oxidase II Homo sapiens 162-167 12603175-1 2003 OBJECTIVE: To analyse the influence of age and cytochrome P450 (CYP) 2C9 genotype on the steady-state disposition of the standard NSAID diclofenac and the new COX-2 selective inhibitor celecoxib, both of which are metabolised by the polymorphically expressed CYP2C9. Celecoxib 185-194 mitochondrially encoded cytochrome c oxidase II Homo sapiens 159-164 12705064-4 2003 Because of their better gastrointestinal risk profile, the newly developed selective COX-2 inhibitors celecoxib and rofecoxib are discussed as cost-effective alternatives to common NSAIDs. Celecoxib 102-111 mitochondrially encoded cytochrome c oxidase II Homo sapiens 85-90 12861847-0 2003 Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 12861847-4 2003 OBJECTIVE: The purpose of this study is to demonstrate that celecoxib, a specific inhibitor of COX-2, does not cause asthmatic attacks in patients with aspirin and/or other nonsteroidal anti-inflammatory drug-induced asthma. Celecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 12485854-4 2002 To determine whether the induction of COX-2 by ET-18-O-CH(3) could contribute to apoptosis in MCF10A-ras cells, the selective COX-2 inhibitor celecoxib (SC-58635) was used. Celecoxib 142-151 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 12417326-2 2002 Celecoxib strongly suppressed the proliferation of COX-2 expressing HT-29 cells at 10-40 microM. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-56 12417326-5 2002 DNA fragmentation was also increasd in COX-2 non-expressing cell lines (SW-480 and HCT-116) by exposure to celecoxib for 6-24 h. All six COX-2 inhibitors suppressed the production of prostaglandin E(2) by HT-29 cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to inhibition of COX-2. Celecoxib 107-116 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-44 12417326-5 2002 DNA fragmentation was also increasd in COX-2 non-expressing cell lines (SW-480 and HCT-116) by exposure to celecoxib for 6-24 h. All six COX-2 inhibitors suppressed the production of prostaglandin E(2) by HT-29 cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to inhibition of COX-2. Celecoxib 107-116 mitochondrially encoded cytochrome c oxidase II Homo sapiens 137-142 12417326-5 2002 DNA fragmentation was also increasd in COX-2 non-expressing cell lines (SW-480 and HCT-116) by exposure to celecoxib for 6-24 h. All six COX-2 inhibitors suppressed the production of prostaglandin E(2) by HT-29 cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to inhibition of COX-2. Celecoxib 107-116 mitochondrially encoded cytochrome c oxidase II Homo sapiens 137-142 12417326-5 2002 DNA fragmentation was also increasd in COX-2 non-expressing cell lines (SW-480 and HCT-116) by exposure to celecoxib for 6-24 h. All six COX-2 inhibitors suppressed the production of prostaglandin E(2) by HT-29 cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to inhibition of COX-2. Celecoxib 262-271 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-44 12417326-5 2002 DNA fragmentation was also increasd in COX-2 non-expressing cell lines (SW-480 and HCT-116) by exposure to celecoxib for 6-24 h. All six COX-2 inhibitors suppressed the production of prostaglandin E(2) by HT-29 cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to inhibition of COX-2. Celecoxib 262-271 mitochondrially encoded cytochrome c oxidase II Homo sapiens 137-142 12417326-5 2002 DNA fragmentation was also increasd in COX-2 non-expressing cell lines (SW-480 and HCT-116) by exposure to celecoxib for 6-24 h. All six COX-2 inhibitors suppressed the production of prostaglandin E(2) by HT-29 cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to inhibition of COX-2. Celecoxib 262-271 mitochondrially encoded cytochrome c oxidase II Homo sapiens 137-142 12499282-2 2002 We observed that fetal bovine serum antagonizes growth inhibition and G(1) arrest induced by two COX-2 inhibitors (NS-398 and celecoxib) on BxPC-3 pancreatic cancer cells. Celecoxib 126-135 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 12438270-7 2002 Inhibition of COX-2 by celecoxib resulted in loss of intratumor PGE2 levels and reduced tumor growth in a dose-dependent manner. Celecoxib 23-32 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 12438270-11 2002 These data indicate that a major antitumor mechanism of action of celecoxib is inhibition of COX-2-derived prostaglandins, particularly PGE2, and suggest celecoxib as a novel therapeutic agent for human head and neck cancer. Celecoxib 66-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 93-98 12152003-10 2002 CONCLUSIONS: The suppression of products of COX-2 coincident with pain suppression and the absence of COX-1 inhibition suggest that celecoxib is a relatively selective COX-2 inhibitor in vivo. Celecoxib 132-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 12359744-2 2002 The aim of this study was to determine whether celecoxib, a selective Cox-2 inhibitor, protected against HER-2/neu-induced experimental breast cancer. Celecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 12395741-2 2002 ULCER COMPLICATIONS: The probability of developing a symptomatic, uncomplicated or complicated (perforation, gastric outlet obstruction, bleeding) gastroduodenal ulcer is significantly lower with a COX-2 selective inhibitor (Celecoxib, rofecoxib) than with a traditional NSAIDs, with a reduction in absolute risk of around 1-1.5 for 100 patient-years in clinical trials. Celecoxib 225-234 mitochondrially encoded cytochrome c oxidase II Homo sapiens 198-203 12498012-5 2002 In the future, selective COX-2 inhibitors such as celecoxib (GD Searle & Co), rofecoxib (Merck & Co Inc) and the recently developed etoricoxib (Merck & Co Inc) may play an important role in the treatment of a wider range of pain conditions in addition to their present use as anti-inflammatory and analgesic drugs. Celecoxib 50-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 12703120-3 2002 Two NSAIDs (celecoxib and rofecoxib) COX-2 specific inhibitors had considerably lower ulcerogenic rates and lower serious gastro-intestinal side effects when compared with other NSAIDs used in rheumatoid arthritis and osteoarthritis. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 12455713-7 2002 Therefore, rofecoxib and celecoxib, selective inhibitors of COX-2, at least in vitro, were introduced. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 12198983-6 2002 (The other selective COX-2 inhibitors, celecoxib and valdecoxib, do not carry label indications for short-term management of postoperative pain.) Celecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 12152003-10 2002 CONCLUSIONS: The suppression of products of COX-2 coincident with pain suppression and the absence of COX-1 inhibition suggest that celecoxib is a relatively selective COX-2 inhibitor in vivo. Celecoxib 132-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 168-173 12096231-8 2002 Celecoxib, by diminishing COX-2 activity, prevents these adverse effects without having a direct effect on healthy cartilage. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 12126328-1 2002 Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). Celecoxib 72-80 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 12102579-4 2002 Over the past decade, in vitro, preclinical, and clinical data have supported the hypothesis that cyclooxygenase (COX)-2 plays a central role in oncogenesis and that treatment with COX-2 inhibitors offers an effective chemoprevention strategy, as exemplified by the activity of celecoxib (Celebrex) in familial adenomatous polyposis. Celecoxib 278-287 mitochondrially encoded cytochrome c oxidase II Homo sapiens 98-120 12008128-0 2002 Determination of celecoxib, a COX-2 inhibitor, in pharmaceutical dosage forms by MEKC. Celecoxib 17-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 12008128-1 2002 A micellar electrokinetic chromatographic (MEKC) method was developed for the quantification of celecoxib, a COX-2 inhibitor in pharmaceutical dosage forms within the total analysis time of 7 min. Celecoxib 96-105 mitochondrially encoded cytochrome c oxidase II Homo sapiens 109-114 12008154-1 2002 A new UV spectrophotometric method (UV method) and a reversed phase liquid chromatographic method (LC method) for the quantitative estimation of celecoxib, a selective COX-2 inhibitor, in pure form and in solid dosage form were developed in the present study. Celecoxib 145-154 mitochondrially encoded cytochrome c oxidase II Homo sapiens 168-173 12102579-4 2002 Over the past decade, in vitro, preclinical, and clinical data have supported the hypothesis that cyclooxygenase (COX)-2 plays a central role in oncogenesis and that treatment with COX-2 inhibitors offers an effective chemoprevention strategy, as exemplified by the activity of celecoxib (Celebrex) in familial adenomatous polyposis. Celecoxib 278-287 mitochondrially encoded cytochrome c oxidase II Homo sapiens 181-186 12102579-4 2002 Over the past decade, in vitro, preclinical, and clinical data have supported the hypothesis that cyclooxygenase (COX)-2 plays a central role in oncogenesis and that treatment with COX-2 inhibitors offers an effective chemoprevention strategy, as exemplified by the activity of celecoxib (Celebrex) in familial adenomatous polyposis. Celecoxib 289-297 mitochondrially encoded cytochrome c oxidase II Homo sapiens 98-120 12102579-4 2002 Over the past decade, in vitro, preclinical, and clinical data have supported the hypothesis that cyclooxygenase (COX)-2 plays a central role in oncogenesis and that treatment with COX-2 inhibitors offers an effective chemoprevention strategy, as exemplified by the activity of celecoxib (Celebrex) in familial adenomatous polyposis. Celecoxib 289-297 mitochondrially encoded cytochrome c oxidase II Homo sapiens 181-186 11992745-4 2002 It is assumed therefore that the COX-2-selective inhibitors, rofecoxib and celecoxib, would have an effect on renal function similar to that of nonselective NSAIDs. Celecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 33-38 12047458-4 2002 All the patients were treated for the ISH with celecoxib, a COX-2 specific inhibitor, with full recovery from ISH up to 6 days after it was first administered. Celecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 11915030-6 2002 The exposure to lipopolysaccharide (LPS) or epidermal growth factor (EGF) determined an increase of PG and NO production in both cell lines and this increase was strongly reduced by COX-2 inhibitors such as celecoxib (CLX) and nimesulide (NIME). Celecoxib 207-216 mitochondrially encoded cytochrome c oxidase II Homo sapiens 182-187 11915030-6 2002 The exposure to lipopolysaccharide (LPS) or epidermal growth factor (EGF) determined an increase of PG and NO production in both cell lines and this increase was strongly reduced by COX-2 inhibitors such as celecoxib (CLX) and nimesulide (NIME). Celecoxib 218-221 mitochondrially encoded cytochrome c oxidase II Homo sapiens 182-187 11894121-12 2002 These findings further support the hypothesis that HMGCo-R and COX-2 activities play important roles in apoptosis and regulation of apoptosis by selective agents such as lovastatin and celecoxib would provide effective strategies for the prevention of colon cancer. Celecoxib 185-194 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 11819916-12 2001 Excepting two compounds recently marketed (celecoxib, rofecoxib) selective for COX-2, all other NSAID have few or no selective properties. Celecoxib 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 11909557-8 2002 Apparent differences between the COX-2 inhibitors celecoxib and rofecoxib may be functions of differences in study population susceptibilities to NSAID-mediated hypertensive effects. Celecoxib 50-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 33-38 11897764-4 2002 We report here that both a nonselective NSAID (aspirin, acetylsalicylic acid) and COX-2 selective NSAIDs (celecoxib and NS-398) diminished renal prostacyclin and thromboxane concentration in the renal medulla. Celecoxib 106-115 mitochondrially encoded cytochrome c oxidase II Homo sapiens 82-87 11814774-0 2002 Estimation of binding affinities for celecoxib analogues with COX-2 via Monte Carlo-extended linear response. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 11814774-1 2002 Monte Carlo (MC)-extended linear response (ELR) calculations have been used for prediction of binding affinities of celecoxib analogues with the COX-2 enzyme. Celecoxib 116-125 mitochondrially encoded cytochrome c oxidase II Homo sapiens 145-150 11965228-0 2002 Celecoxib: a specific COX-2 inhibitor with anticancer properties. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 12195419-0 2002 [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient]. Celecoxib 146-155 mitochondrially encoded cytochrome c oxidase II Homo sapiens 157-162 12195419-1 2002 BACKGROUND: We present the case of acute renal failure complicating the course of therapy with both ketorolac (non-selective Non-Steroidal Anti-inflammatory Drug, NSAID), and celecoxib (COX-2 Selective Inhibitor) in an elderly woman with chronic liver disease, heart failure and chronic renal failure. Celecoxib 175-184 mitochondrially encoded cytochrome c oxidase II Homo sapiens 186-191 12086291-9 2002 Clinical studies of the COX-2-selective inhibitors rofecoxib and celecoxib have demonstrated efficacy equivalent to nonselective NSAIDs with lower rates of GI side effects (for example, incidence of endoscopic ulcers equivalent to placebo). Celecoxib 65-74 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 11945113-5 2002 The recent introduction of selective COX-2 inhibitors, celecoxib and rofecoxib, appear to induce less gastrointestinal morbidity. Celecoxib 55-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 11789101-9 2001 We have now been studying the COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). Celecoxib 80-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 11742186-6 2001 Co-administration of the COX-2 selective NSAID, celecoxib, and low-dose aspirin, is associated with the same risk for upper gastrointestinal ulcer complications alone and combined with symptomatic ulcers, as the non-selective NSAIDs, ibuprofen and diclofenac. Celecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 11779086-9 2001 The selective COX-2 inhibitor celecoxib (Celebrex, Pharmacia) has been shown to reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis as an adjunct to usual care. Celecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 11779086-9 2001 The selective COX-2 inhibitor celecoxib (Celebrex, Pharmacia) has been shown to reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis as an adjunct to usual care. Celecoxib 41-49 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 11695246-2 2001 The cyclooxygenase (COX)-2 selective inhibitors celecoxib and rofecoxib have been found to be more effective than placebo and comparably effective to nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of patients with osteoarthritis and rheumatoid arthritis. Celecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-26 11412976-1 2001 Computational studies have yielded an analysis of the contributions to the free energy difference between the binding of celecoxib to COX-1 and to COX-2. Celecoxib 121-130 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 11695253-6 2001 Following the discovery of the two differentially distributed and regulated COXs, two non-acidic COX-2-selective compounds--celecoxib and rofecoxib--were introduced. Celecoxib 124-133 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 11695255-2 2001 A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac). Celecoxib 217-226 mitochondrially encoded cytochrome c oxidase II Homo sapiens 183-205 11695255-7 2001 Celecoxib selectively suppressed PGE2 but not TxB2 at time points consistent with COX-2 activity, while producing analgesia. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 82-87 11586092-6 2001 Two specific COX-2 inhibitors, namely rofecoxib (Vioxx) and celecoxib (Celebrex), both oral agents and U.S. Food and Drug Administration approved, have been shown preclinically and clinically to have efficacy comparable to that of NSAIDs for relief of pain and inflammation in osteoarthritis, with decreased risk of gastrointestinal damage. Celecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 11586092-6 2001 Two specific COX-2 inhibitors, namely rofecoxib (Vioxx) and celecoxib (Celebrex), both oral agents and U.S. Food and Drug Administration approved, have been shown preclinically and clinically to have efficacy comparable to that of NSAIDs for relief of pain and inflammation in osteoarthritis, with decreased risk of gastrointestinal damage. Celecoxib 71-79 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 11566043-5 2001 The selective COX-2 inhibitor celecoxib has been approved by the FDA for adjuvant treatment of familial adenomatous polyposis, and a large number of prevention and treatment trials of colorectal and other common cancers (prostate and breast cancer) have been started. Celecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 11576568-1 2001 OBJECTIVE: To compare the effects of three cyclooxygenase-2 (COX-2) inhibitors: nimesulide, meloxicam, and celecoxib, which exhibit varying COX-2 selectivity, on contractile activity in pregnant (before and after labor) and nonpregnant human myometrial tissue in vitro. Celecoxib 107-116 mitochondrially encoded cytochrome c oxidase II Homo sapiens 140-145 11576568-9 2001 Celecoxib, a COX-2 specific inhibitor, was more potent than nimesulide or meloxicam, COX-2 preferential inhibitors. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 11570615-6 2001 Reaction rates for COX-2 inhibitors were 21.3% for nimesulide, 17.3% for meloxicam, 33.3% for celecoxib, and 3.0% for rofecoxib. Celecoxib 94-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-24 11412976-0 2001 Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 11601668-2 2001 Cyclooxygenase (COX)-2 inhibitors (coxibs) rofecoxib and celecoxib are highly selective inhibitors of COX-2, differentiating them from nonselective NSAIDs, which substantially inhibit both COX-1 and COX-2. Celecoxib 57-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 11601668-2 2001 Cyclooxygenase (COX)-2 inhibitors (coxibs) rofecoxib and celecoxib are highly selective inhibitors of COX-2, differentiating them from nonselective NSAIDs, which substantially inhibit both COX-1 and COX-2. Celecoxib 57-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 199-204 11503270-4 2001 Selective COX-2 inhibitors i.e. meloxicam, nimesulid, etodolac or highly selective COX-2 inhibitors i.e. celecoxib, rofecoxib have antiinflammatory and analgesic properties with less or no gastrointestinal or other NSAIDs-typical adverse effects. Celecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 11503270-4 2001 Selective COX-2 inhibitors i.e. meloxicam, nimesulid, etodolac or highly selective COX-2 inhibitors i.e. celecoxib, rofecoxib have antiinflammatory and analgesic properties with less or no gastrointestinal or other NSAIDs-typical adverse effects. Celecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 11318071-5 2001 CONCLUSIONS: The safety and efficacy of two COX-2-selective inhibitors, rofecoxib and celecoxib, have been examined in a number of clinical trials, and these agents have been shown to offer efficacy similar to that of NSAIDs. Celecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 11718158-3 2001 (2) The clinical file on celecoxib, a drug promoted as a selective COX-2 inhibitor, is bulky but fails to answer several practical questions, mainly because it lacks comparative trials against paracetamol and low-dose NSAIDs. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 11266647-3 2001 Indeed, development of the new "super aspirins," such as Celebrex and Vioxx, that selectively inhibit the inducible COX-2, expressed in areas of inflammation, is a direct outgrowth of this concept. Celecoxib 57-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 116-121 11316141-2 2001 As compared to conventional NSAIDs, celecoxib, a COX-2 specific inhibitor, has been shown in previous single posttreatment endoscopy studies to be associated with lower gastroduodenal ulcer rates. Celecoxib 36-45 mitochondrially encoded cytochrome c oxidase II Homo sapiens 49-54 11383931-3 2001 Pharmacological COX-1 inhibition was performed with the prescription of acetylsalicylic acid (ASA) at a low dose, and COX-2 selective inhibition was performed with celecoxib. Celecoxib 164-173 mitochondrially encoded cytochrome c oxidase II Homo sapiens 118-123 11383931-10 2001 In conclusion, COX-2-selective inhibitor at a celecoxib dose of 200 mg daily increased insulin sensitivity in healthy subjects. Celecoxib 46-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 11367984-0 2001 [Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis]. Celecoxib 11-20 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 11301836-9 2001 Included are the rationale for use of such agents, results of a study showing a significant reduction in adenoma burden in familial adenomatous polyposis patients who received the selective COX-2 inhibitor celecoxib (Celebrex), and the design of other ongoing or planned clinical trials. Celecoxib 206-215 mitochondrially encoded cytochrome c oxidase II Homo sapiens 190-195 11301836-9 2001 Included are the rationale for use of such agents, results of a study showing a significant reduction in adenoma burden in familial adenomatous polyposis patients who received the selective COX-2 inhibitor celecoxib (Celebrex), and the design of other ongoing or planned clinical trials. Celecoxib 217-225 mitochondrially encoded cytochrome c oxidase II Homo sapiens 190-195 11085526-6 2000 The cytotoxic effects of high-dose celecoxib were independent of COX-2 inhibition because similar effects were observed in cox-2 (+/+), cox-2 (+/-) and cox-2 (-/-) fibroblasts. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 123-128 11275626-7 2001 This assertion is borne out by recent clinical studies showing that the COX-2 inhibitors rofecoxib and celecoxib procedure qualitative changes in urinary prostaglandin excretion, glomerular filtration rate, sodium retention, and their consequences similar to nonselective NSAIDs. Celecoxib 103-112 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 11256140-3 2001 Celecoxib (Celebrex, Pharmacia) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as nonsteroidal anti-inflammatory drug (NSAID). Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 11256140-3 2001 Celecoxib (Celebrex, Pharmacia) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as nonsteroidal anti-inflammatory drug (NSAID). Celecoxib 11-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 11276798-1 2000 Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 11151817-10 2000 The present review assesses concept and molecular mechanism underlying specific COX-2 inhibition as well as indications, pharmakokinetics and unwanted side effects of the recently approved specific COX-2 inhibitors celecoxib and rofecoxib. Celecoxib 215-224 mitochondrially encoded cytochrome c oxidase II Homo sapiens 198-203 11900314-1 2001 BACKGROUND: The selective COX-2 inhibitor celecoxib has a sulfonamide structure and is contraindicated for patients with known sulfa allergy. Celecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 11326316-9 2001 Indomethacin and celecoxib reversed the EGF- and LPS-dependent COX-2, VEGF, and PGE2 increases. Celecoxib 17-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 11273789-5 2001 Eight adult subjects with stable asthma underwent spirometry, bronchoprovocation challenge with methacholine, and cough challenge testing with capsaicin, before and after a 7 day course of the COX-2 inhibitor celecoxib (200 mg orally, twice daily) and placebo, in a randomized, double-blind, crossover fashion. Celecoxib 209-218 mitochondrially encoded cytochrome c oxidase II Homo sapiens 193-198 11085526-6 2000 The cytotoxic effects of high-dose celecoxib were independent of COX-2 inhibition because similar effects were observed in cox-2 (+/+), cox-2 (+/-) and cox-2 (-/-) fibroblasts. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 136-141 11085526-6 2000 The cytotoxic effects of high-dose celecoxib were independent of COX-2 inhibition because similar effects were observed in cox-2 (+/+), cox-2 (+/-) and cox-2 (-/-) fibroblasts. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 136-141 11005360-3 2000 Two NSAIDs (celecoxib and rofecoxib) with very high specificity for COX-2 and virtually no activity against COX-1 at therapeutic doses have been approved for clinical use. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 11252686-1 2001 OBJECTIVE: A clinical trial was conducted in 600 patients with OA of the knee to test the hypothesis that the specific COX-2 inhibitor, celecoxib, has equivalent efficacy and a superior tolerability/safety profile when compared to diclofenac, the current worldwide standard of care. Celecoxib 136-145 mitochondrially encoded cytochrome c oxidase II Homo sapiens 119-124 11078056-8 2000 Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. Celecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 11078056-8 2000 Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. Celecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 166-171 11078056-8 2000 Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. Celecoxib 58-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 11078056-8 2000 Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. Celecoxib 58-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 166-171 11032099-6 2000 The first COX-2 targeted agent approved by the US Food and Drug Administration (FDA) was celecoxib. Celecoxib 89-98 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 11032099-7 2000 This article reviews the risks of GI complications associated with conventional NSAID use and compares these risks with that of the new COX-2 specific inhibitor celecoxib. Celecoxib 161-170 mitochondrially encoded cytochrome c oxidase II Homo sapiens 136-141 11032962-5 2000 Available experimental and clinical data of selective COX-2 inhibitors, including flosulide, celecoxib or rofecoxib, suggest improved gastric tolerance as compared to conventional, non-selective NSAIDs. Celecoxib 93-102 mitochondrially encoded cytochrome c oxidase II Homo sapiens 54-59 11138599-4 2000 [symbol: see text]Rofecoxib (Vioxx--MSD) and [symbol: see text]celecoxib (Celebrex--Searle) have been developed as selective inhibitors of COX-2. Celecoxib 63-72 mitochondrially encoded cytochrome c oxidase II Homo sapiens 139-144 11138599-4 2000 [symbol: see text]Rofecoxib (Vioxx--MSD) and [symbol: see text]celecoxib (Celebrex--Searle) have been developed as selective inhibitors of COX-2. Celecoxib 74-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 139-144 10979111-4 2000 OBJECTIVE: To determine whether celecoxib, a COX-2-specific inhibitor, is associated with a lower incidence of significant upper GI toxic effects and other adverse effects compared with conventional NSAIDs. Celecoxib 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 10955327-0 2000 Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. Celecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 52-57 10925968-0 2000 Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 10925968-1 2000 OBJECTIVE: The aim of this study was to assess the rate of upper gastrointestinal (UGI) ulcer complications (bleeding, perforation, or gastric outlet obstruction) associated with celecoxib, a specific COX-2 inhibitor, compared with the rate associated with nonspecific, nonsteroidal anti-inflammatory drugs (NSAIDs). Celecoxib 179-188 mitochondrially encoded cytochrome c oxidase II Homo sapiens 201-206 10857564-1 2000 A new reversed-phase, isocratic LC method was developed for the quantitative determination of COX-2 inhibitor celecoxib in bulk drugs and in pharmaceutical dosages. Celecoxib 110-119 mitochondrially encoded cytochrome c oxidase II Homo sapiens 94-99 10914695-11 2000 Two medications that predominantly inhibit only COX-2, rofecoxib and celecoxib, are currently available by prescription in the United States. Celecoxib 69-78 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 12024624-2 2000 Clinical studies thus far have established that the selective COX-2 inhibitors, celecoxib (Celebrex) and rofecoxib (Vioxx) are effective in the treatment of OA and RA, as are conventional NSAIDs. Celecoxib 80-89 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 12024624-2 2000 Clinical studies thus far have established that the selective COX-2 inhibitors, celecoxib (Celebrex) and rofecoxib (Vioxx) are effective in the treatment of OA and RA, as are conventional NSAIDs. Celecoxib 91-99 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 10804043-1 2000 UNLABELLED: Celecoxib is a cyclo-oxygenase (COX) inhibitor that exhibits relative in vitro and ex vivo selectivity for COX-2 over COX-1. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 119-124 10811855-5 2000 Both celecoxib, a selective COX-2 inhibitor, and ibuprofen attenuated the pyrexial, but not the chronotropic, response to LPS. Celecoxib 5-14 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 10882157-7 2000 Two drugs that are claimed to be highly selective or specific in their ability to inhibit COX-2, rofecoxib and celecoxib, are now available on prescription in the US and rofecoxib is available in Europe. Celecoxib 111-120 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 10868317-1 2000 The objective of this study was to determine the effects of celecoxib, an anti-inflammatory/analgesic agent that primarily inhibits COX-2 and not COX-1 at therapeutic doses, on the steady-state pharmacokinetic profile and hypoprothrombinemic effect of racemic warfarin in healthy volunteers. Celecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 132-137 11317164-1 2000 Celecoxib is a cyclooxygenase- (COX)-1-sparing inhibitor of COX-2 that is indicated for the treatment of osteoarthritis and rheumatoid arthritis. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 11317165-1 2000 The novel cyclooxygenase- (COX)-2 inhibitor celecoxib is an effective treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis. Celecoxib 44-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-33 11317165-4 2000 As celecoxib inhibits COX-2 and spares COX-1 at therapeutic doses, we hypothesized that it may offer an improved renal safety profile in patients at risk for NSAID-induced renal toxicity. Celecoxib 3-12 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 10804043-15 2000 CONCLUSIONS: Celecoxib is the first COX-2 specific inhibitor approved for use in osteoarthritis and rheumatoid arthritis. Celecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 10701410-8 2000 CURRENT TRIALS: Clinical studies focusing on both the prevention and the slowing down of early AD are under way with two recently launched selective COX-2 inhibitors, celecoxib and rofecoxib. Celecoxib 167-176 mitochondrially encoded cytochrome c oxidase II Homo sapiens 149-154 10728691-4 2000 The contribution of COX-2 to human tumor growth was indicated by the ability of celecoxib, an agent that inhibits the COX-2 enzyme, to suppress growth of lung and colon tumors implanted into recipient mice. Celecoxib 80-89 mitochondrially encoded cytochrome c oxidase II Homo sapiens 20-25 10728691-4 2000 The contribution of COX-2 to human tumor growth was indicated by the ability of celecoxib, an agent that inhibits the COX-2 enzyme, to suppress growth of lung and colon tumors implanted into recipient mice. Celecoxib 80-89 mitochondrially encoded cytochrome c oxidase II Homo sapiens 118-123 10609815-3 1999 We compared the efficacy, safety, and tolerability of long-term therapy with celecoxib, a COX-1 sparing inhibitor of COX-2, with diclofenac, a non-specific COX inhibitor. Celecoxib 77-86 mitochondrially encoded cytochrome c oxidase II Homo sapiens 117-122 11213386-5 2000 Recently, highly selective COX-2 inhibitors have been developed such as celecoxib (Celebrex) and rofecoxib (Vioxx). Celecoxib 72-81 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 11213386-5 2000 Recently, highly selective COX-2 inhibitors have been developed such as celecoxib (Celebrex) and rofecoxib (Vioxx). Celecoxib 83-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 10859997-2 2000 Selective COX-2 inhibitors (i.e. celecoxib, rofecoxib) have demonstrated in clinical trials better gastrointestinal tolerability but their safety in patients with active ulcer, cardiovascular or renal disease has still to be further investigated. Celecoxib 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 10645754-1 1999 Celecoxib is primarily an inhibitor of cyclooxygenase (COX) 2 and, at therapeutic concentrations in humans, does not inhibit the COX-1 isoenzyme. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-61 10581086-6 1999 11), prompted the development of NSAIDs that selectively inhibit only COX-2 (such as celecoxib and rofecoxib). Celecoxib 85-94 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 10692773-2 1999 One truly selective COX-2 agent--celecoxib--is now being marketed in an ever increasing number of countries. Celecoxib 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 20-25 10664917-2 2000 Celecoxib, an antiarthritic agent that inhibits COX-2 but spares COX-1 at therapeutic doses, is expected to have minimal effects on platelet function. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 11055820-6 2000 The two recently developed and clinically available selective COX-2 inhibitors, celecoxib and rofecoxib, are about 100-1000 times more selective on the COX-2 than on the COX-1 isoform. Celecoxib 80-89 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 11055820-6 2000 The two recently developed and clinically available selective COX-2 inhibitors, celecoxib and rofecoxib, are about 100-1000 times more selective on the COX-2 than on the COX-1 isoform. Celecoxib 80-89 mitochondrially encoded cytochrome c oxidase II Homo sapiens 152-157 11199547-0 2000 The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex). Celecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 8-13 11199547-0 2000 The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex). Celecoxib 59-67 mitochondrially encoded cytochrome c oxidase II Homo sapiens 8-13 10506108-12 1999 The results show that the orally administered selective COX-2 inhibitor celecoxib prevents new tumor formation after the onset of photocarcinogenesis and suggest that treatment with celecoxib may be very useful in preventing UV-induced skin tumors in humans. Celecoxib 72-81 mitochondrially encoded cytochrome c oxidase II Homo sapiens 56-61 10506108-12 1999 The results show that the orally administered selective COX-2 inhibitor celecoxib prevents new tumor formation after the onset of photocarcinogenesis and suggest that treatment with celecoxib may be very useful in preventing UV-induced skin tumors in humans. Celecoxib 182-191 mitochondrially encoded cytochrome c oxidase II Homo sapiens 56-61 10509845-5 1999 In theory, a drug such as celecoxib that selectively inhibited COX-2 might block inflammation, pain, and fever while reducing the side effects (gastric erosions and ulcers) associated with inhibition of COX-1. Celecoxib 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 10509845-6 1999 In animal models of inflammation and pain, celecoxib has shown marked suppression of PG production and inflammation compared with indomethacin, the standard COX-1/COX-2 inhibitor. Celecoxib 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 163-168 10449029-9 1999 The dramatic protective effects of celecoxib suggests that specific COX-2 inhibitors may offer a way to safely reduce the risk of skin cancer in humans. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 10414247-5 1999 CLINICAL RESULTS: Celecoxib and rofecoxib are two COX-2 specific inhibitors. Celecoxib 18-27 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 10463513-5 1999 Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness. Celecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 10377455-5 1999 These comparisons of the actions of >40 NSAIDs and novel COX-2-selective agents, including celecoxib, rofecoxib and diisopropyl fluorophosphate, demonstrate a distribution of compound selectivities toward COX-1 that aligns with the risk of serious gastrointestinal complications. Celecoxib 94-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 16127636-2 1999 The introduction of celecoxib (Celebrex, Figure 1; GD Searle and Co) as the first cyclooxygenase (COX)2 selective inhibitor in the US and the expected introduction of rofecoxib (Vioxx; Merck and Co Inc) as the first COX2 inhibitor with an acute pain indication, has prompted interest in this class of drugs as a possible therapeutic improvement on dual COX1/COX2 inhibitor NSAIDs, currently on the market. Celecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 98-103 16127636-2 1999 The introduction of celecoxib (Celebrex, Figure 1; GD Searle and Co) as the first cyclooxygenase (COX)2 selective inhibitor in the US and the expected introduction of rofecoxib (Vioxx; Merck and Co Inc) as the first COX2 inhibitor with an acute pain indication, has prompted interest in this class of drugs as a possible therapeutic improvement on dual COX1/COX2 inhibitor NSAIDs, currently on the market. Celecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 216-220 16127636-2 1999 The introduction of celecoxib (Celebrex, Figure 1; GD Searle and Co) as the first cyclooxygenase (COX)2 selective inhibitor in the US and the expected introduction of rofecoxib (Vioxx; Merck and Co Inc) as the first COX2 inhibitor with an acute pain indication, has prompted interest in this class of drugs as a possible therapeutic improvement on dual COX1/COX2 inhibitor NSAIDs, currently on the market. Celecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 358-362 16127636-2 1999 The introduction of celecoxib (Celebrex, Figure 1; GD Searle and Co) as the first cyclooxygenase (COX)2 selective inhibitor in the US and the expected introduction of rofecoxib (Vioxx; Merck and Co Inc) as the first COX2 inhibitor with an acute pain indication, has prompted interest in this class of drugs as a possible therapeutic improvement on dual COX1/COX2 inhibitor NSAIDs, currently on the market. Celecoxib 31-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 98-103 10384106-5 1999 Interestingly, treatment with COX-2-specific inhibitors such as NS398 or Celecoxib severely diminished early and late events of T cell activation, including CD25 and CD71 cell surface expression, IL-2, TNF-alpha, and IFN-gamma production and cell proliferation, but not the expression of CD69, an immediate early gene. Celecoxib 73-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 10215599-2 1999 The discovery of a second COX isoform (COX-2) associated with inflammation led to agents that selectively inhibit COX-2, e.g. celecoxib. Celecoxib 126-135 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-44 10390127-4 1999 The recent development of COX-2-specific inhibitors, such as celecoxib, raises the possibility of relieving pain and inflammation with reduced risk of gastrointestinal complications. Celecoxib 61-70 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 10215599-2 1999 The discovery of a second COX isoform (COX-2) associated with inflammation led to agents that selectively inhibit COX-2, e.g. celecoxib. Celecoxib 126-135 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 10215599-5 1999 An initial competitive interaction with COX-2 can also be discerned with celecoxib (Ki=11-15 microM), followed by a time-dependent interaction leading to potent inhibition, characterized as inactivation (Kinact=0.03-0.5 s-1). Celecoxib 73-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 10391112-4 1999 Finally, the latest published clinical data of new selective and highly selective inhibitors of COX-2 (meloxicam, nimesulide, etodolac, celecoxib and MK966) are discussed. Celecoxib 136-145 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-101 33813964-5 2021 Compounds 3c, 5c, 5h and Celecoxib were subjected to in vitro COX-1 and COX-2 inhibition assay, showed selectivity index 45.04, 102.04, 131.58 and 185.18, respectively. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 10387389-0 1999 Celecoxib: a COX-2 inhibitor. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 10093892-4 1999 Meanwhile, the specific COX-2 inhibitors celecoxib and rofecoxib are being tested worldwide in phase III clinical trials on patients with rheumatoid arthritis and osteoarthritis. Celecoxib 41-50 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 10225538-0 1999 Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 10225538-13 1999 These preliminary trials show that celecoxib achieves analgesic and antiinflammatory efficacy in arthritis through specific COX-2 inhibition without showing evidence of two of the toxic effects of COX-1 inhibition associated with NSAID. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 124-129 10193997-3 1999 Unlike conventional nonsteroidal anti-inflammatory drugs, which inhibit both forms of the COX enzyme, celecoxib inhibits COX-2 preferentially to COX-1 in vitro. Celecoxib 102-111 mitochondrially encoded cytochrome c oxidase II Homo sapiens 121-126 9874808-9 1999 By contrast, both ibuprofen and celecoxib suppressed a biochemical index of COX-2 activity (endotoxin induced PGE2 in whole blood ex vivo) to a comparable degree (-93.3 +/- 2% vs. -83 +/- 6.1%). Celecoxib 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 76-81 10422544-0 1999 Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 10422544-13 1999 These preliminary trials show that celecoxib achieves analgesic and anti-inflammatory efficacy in arthritis through specific COX-2 inhibition without showing evidence of two of the toxic effects of COX-1 inhibition associated with NSAIDs. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 125-130 9249645-6 1997 At the doses employed, celecoxib inhibited only COX-2 and not COX-1. Celecoxib 23-32 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 9249645-7 1997 Specific COX-2 inhibition with celecoxib causes significant improvement in the signs and symptoms of RA. Celecoxib 31-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 9-14 33813964-6 2021 The computational finding supported those of in vitro, where the pyrazolylpyrazolines interacted with the COX-2 enzyme in a similar orientation to that of Celecoxib, while chlacones were found to exhibit similar orientation to that of Diclofenac. Celecoxib 155-164 mitochondrially encoded cytochrome c oxidase II Homo sapiens 106-111 34813026-7 2021 Celecoxib and roficoxib like selective COX-2 inhibitors also ameliorate neuroinflammation. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-44 34959176-4 2022 A molecular docking study showed that the hybrids8-13(L13-L18) fitted similarly with celecoxib in the COX-2 active site. Celecoxib 85-94 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 34959176-7 2022 Whereas the P-selectin is a promising target to the design of new anti-inflammatory drugs with antithrombotic properties, a distinct butterfly-like structure of 1,4-diaryl-1,2,3-triazole neolignan-celecoxib hybrids synthesized in this work may be a safer alternative to the traditional COX-2 inhibitors. Celecoxib 197-206 mitochondrially encoded cytochrome c oxidase II Homo sapiens 286-291 34688374-3 2022 We investigated the efficacy and safety of PD-1 blockade with toripalimab, with or without the COX-2 inhibitor celecoxib, as neoadjuvant treatment for mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancers. Celecoxib 111-120 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 34428217-6 2021 In contrast, indomethacin did not exhibit this capacity, whereas cyclooxygenase (COX)-2 selective NSAID, celecoxib, induced a similar pattern like Acetylsalicylic acid, suggesting a possible relevance of COX-2. Celecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-87 34338135-2 2021 The three synthesised series exhibited superior COX-2 selectivity compared with the previously reported quinazolinones and their NSAID analogue and had equipotent COX-2 selectivity as celecoxib. Celecoxib 184-193 mitochondrially encoded cytochrome c oxidase II Homo sapiens 163-168 34721382-8 2021 Further, blocking the skin inflammation with celecoxib reveals that the acquired fate of macrophages in the KO skin is dependent on its interaction with the epidermal compartment through COX2 dependent cytokine production. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 187-191 34216690-8 2021 AGR2 knockdown enhances therapeutic effects of a COX-2 inhibitor, celecoxib, in CRC metastasis. Celecoxib 66-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 49-54 34303896-6 2021 Compounds 5a-d and 5g displayed inhibitory activity against COX-2 nearly equal to Celecoxib with high selectivity index (SI). Celecoxib 82-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 34631154-1 2022 We describe the total flow synthesis of the widely prescribed anti-inflammatory COX-2 inhibitor Celecoxib from 2-bromo-3,3,3-trifluoropropene, as a convenient and available trifluoromethyl building block, to generate trifluoropropynyl lithium and to trap it immediately with an aldehyde. Celecoxib 96-105 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-85 34514981-7 2022 To this end, of the generation of non-steroidal anti-inflammatory drugs from "coxibs", celecoxib is the only potent selective COX-2 inhibitor that is still commercially available. Celecoxib 87-96 mitochondrially encoded cytochrome c oxidase II Homo sapiens 126-131 34514981-8 2022 Thus, the compound celecoxib became a commercial prototype inhibitor for the development of anti-inflammatory agents for COX-2 enzyme. Celecoxib 19-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 121-126 34110482-8 2021 BEPS showed a promising COX-2 inhibitory effect in comparison with the reference drug celecoxib. Celecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 34445685-4 2021 Celecoxib and GS alone or co-incubated with IL-1beta significantly reduced expression and release of cyclooxygenase (COX)-2, prostaglandin (PG)E2, IL-1beta, IL-6, tumor necrosis factor (TNF)-alpha, and MMPs, while it increased Col2a1, compared to baseline or IL-1beta. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 101-123 34447267-15 2021 Conclusion: Celecoxib oral solution is a safe, effective COX-2-selective nonsteroidal anti-inflammatory drug for the treatment of acute migraine. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 34376069-7 2022 Celecoxib, a COX-2 selective agent, seems safer for both the upper and the lower GI tract. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 34280124-5 2021 In contrast, celecoxib, a selective COX-2 inhibitor, significantly down-regulated the expression of CD82 in decidual stromal cells (DSCs). Celecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 34093801-8 2021 In addition, we found that using a COX-2 inhibitor, celecoxib, could enhance the anti-metastatic role of miR-30a-3p in MHCC-97H cells. Celecoxib 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 34304363-1 2021 Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) and a representative selective cyclooxygenase (COX)-2 inhibitor, which is commonly prescribed for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 91-113 34262619-12 2021 Conclusions: The combination treatment of the most commonly used SYSADOA drug, JOINS, and selective COX-2 inhibitor celecoxib as the representative NSAID for knee OA treatment, can be compared with celecoxib alone treatment to determine the safety or therapeutic effect. Celecoxib 116-125 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 34264123-4 2021 In this review, we provide an overview of the detailed mechanism and rationale of COX-2 inhibitors as anticancer agents and we highlight the most promising research efforts on nanotechnological approaches to enhance COX-2 inhibitors delivery with special focus on celecoxib as the most widely studied agent for chemoprevention or combined with chemotherapeutic and herbal drugs for combating various cancers. Celecoxib 264-273 mitochondrially encoded cytochrome c oxidase II Homo sapiens 216-221 34080112-7 2022 Further studies revealed that compound 11b exhibited effective COX-2 inhibitory activity, with half-maximal inhibitor concentration (IC50) value of 1.16 microM and selectivity index (SI = 64.66) value close to that of celecoxib (IC50 = 0.93 microM, SI = 65.47). Celecoxib 218-227 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 34168004-15 2021 The latter could be significantly inhibited by COX-2 inhibitor celecoxib. Celecoxib 63-72 mitochondrially encoded cytochrome c oxidase II Homo sapiens 47-52 34122428-4 2021 Celecoxib, a selective COX-2 inhibitor, and aspirin, a non-selective COX-1 and COX-2 inhibitor, are being used as anti-inflammatory, analgesic and anti-pyretic drugs. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 35585779-7 2022 The "traditional" NSAID diclofenac is as COX-2 selective as celecoxib and increases cardiovascular risk dose-dependently. Celecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 35453005-7 2022 Young patients, patients dealing with acute pain, or with active and/or chronic symptomatic gastritis, selective COX-2 inhibitors (celecoxib or etoricoxib) may be a better option (level of evidence 2). Celecoxib 131-140 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 35234840-4 2022 HYPOTHESIS: The selective COX-2 Inhibitor celecoxib has a superior cardiorenal safety profile when compared to ibuprofen or naproxen in the PRECISION population. Celecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 35389917-2 2022 Selective cyclooxygenase (COX)-2 inhibitors (e.g., celecoxib) are believed to have fewer gastrointestinal (GI) adverse effects than nonselective NSAIDS. Celecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-32 35373257-4 2022 Celecoxib is a selective inhibitor of COX-2. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 35065465-0 2022 Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on celecoxib scaffold supported with in vivo anti-inflammatory activity, ulcerogenic liability, ADME profiling and docking study. Celecoxib 99-108 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 34052736-4 2021 The same analogs were further investigated for their in vitro COX-1 and COX-2 inhibitory activity, where fifteen analogs demonstrated recognizable COX-2 inhibitory potential (IC50 values range 0.04 - 0.1 microM), when correlated with celecoxib (IC50 0.05 microM), together with appreciable selectivity indices. Celecoxib 234-243 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 35136486-11 2022 Inhibition of COX-2 with celecoxib decreased PACER expression, confirming this self-regulatory process. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 35105633-4 2022 The primary objective of this study is to determine the efficacy of the COX-2-selective inhibitor celecoxib as an adjunct to treatment-as-usual in children and youth with moderate-to-severe OCD. Celecoxib 98-107 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 34052736-7 2021 Docking of compounds 5a, 14b, 17, 19c, 19e and 21b with the active sites of XO and COX-2 isozymes demonstrated superior binding profile compared with the reported ligands (febuxostat and celecoxib, respectively). Celecoxib 187-196 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 33878358-5 2021 In comparison with the popular COX inhibitor Celecoxib, these hydrogels showed an inhibition activity towards COX enzymes with selective inhibition towards COX-2. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 156-161 33244799-3 2021 Enzyme inhibition studies revealed that most of the compounds showed a moderate-to-strong inhibitory activity (IC50 = 0.18-0.34 muM) against the COX-2 enzyme as compared with celecoxib (IC50 = 0.12 muM), ibuprofen (IC50 = 5.33 muM), and nimesulide (IC50 = 1.68 muM). Celecoxib 176-185 mitochondrially encoded cytochrome c oxidase II Homo sapiens 146-151 33618245-4 2021 OBSERVATIONS: This paper reviews randomized controlled trials that showed that celecoxib, a selective COX-2 inhibitor, or low-dose aspirin, which inhibits COX-1 and inhibits/acetylates COX-2, reduced bipolar symptoms in patients on mood stabilizers. Celecoxib 79-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 33618245-4 2021 OBSERVATIONS: This paper reviews randomized controlled trials that showed that celecoxib, a selective COX-2 inhibitor, or low-dose aspirin, which inhibits COX-1 and inhibits/acetylates COX-2, reduced bipolar symptoms in patients on mood stabilizers. Celecoxib 79-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 185-190 33618245-6 2021 CONCLUSIONS: This clinical evidence is consistent with the hypothesis that low-dose chronic aspirin and celecoxib, which can inhibit COX-2 and enter brain, can be repurposed in bipolar disorder to enhance mood stabilizer effects on arachidonic acid metabolism and neurotransmission. Celecoxib 104-113 mitochondrially encoded cytochrome c oxidase II Homo sapiens 133-138 33667839-1 2021 BACKGROUND: Celecoxib (CXB), a selective COX-2 inhibitor NSAID, has exhibited prominent anti-proliferative potential against numerous cancers. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 33667839-1 2021 BACKGROUND: Celecoxib (CXB), a selective COX-2 inhibitor NSAID, has exhibited prominent anti-proliferative potential against numerous cancers. Celecoxib 23-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 33011534-1 2020 To search for effective and selective COX-2 inhibitors, four novel series of tetrazole derivatives were designed based on bioisosteric replacement of SO2NH2 in celecoxib with tetrazole ring incorporating different central moieties as chalcone (2a-f), isoxazole (3a-c) or pyrazole (4a-c & 5a-c). Celecoxib 160-169 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 32966814-1 2020 AR12 is a derivative of celecoxib which no-longer acts against COX2 but instead inhibits the ATPase activity of multiple chaperone proteins, in particular GRP78. Celecoxib 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-67 33166844-2 2020 All target compounds showed good in vitro COX-2 inhibitory activity (IC50 = 0.043-0.17 microM) over COX-1 (IC50 = 7.8 - 15.4 microM) relative to celecoxib (COX-1/IC50 = 9.87, COX-2/IC50 = 0.055), with acceptable selectivity index values (SI = 50.6-253.1). Celecoxib 145-154 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 32013633-6 2020 Cyclic imides bearing 3-benzenesulfonamide (2-5, and 9), acetophenone oxime (11-14, 18, and 19) exhibited high selectivity against COX-2 with SI > 55.6-333.3 relative to that for celecoxib [SI > 387.6]. Celecoxib 179-188 mitochondrially encoded cytochrome c oxidase II Homo sapiens 131-136 33148606-13 2020 Western blotting showed that celecoxib could partially reverse MIF-induced COX-2 upregulation and P53 downregulation. Celecoxib 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 33040178-8 2021 The non-selective COX inhibitor aspirin and the selective COX-2 inhibitor celecoxib increased sensitivity of several human and mouse CRC cell lines to EPA in vitro. Celecoxib 74-83 mitochondrially encoded cytochrome c oxidase II Homo sapiens 58-63 28520369-2 2012 These enzymes catalyze pathways that play a key role in the generation of the inflammatory response; however, celecoxib, selectively inhibits COX-2. Celecoxib 110-119 mitochondrially encoded cytochrome c oxidase II Homo sapiens 142-147 33400072-1 2021 2,5-Dimethyl-celecoxib (DMC) is a close structural analog of the selective COX-2 inhibitor celecoxib that lacks COX-2-inhibitory function. Celecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 33011534-3 2020 All target compounds were more selective for COX-2 isozyme than COX-1 when compared to standard drugs indomethacin and celecoxib. Celecoxib 119-128 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 32899627-2 2020 Almost all of the COX2 imaging agents using celecoxib as backbone were chemically modified in the position of N-atom in the sulfonamide group. Celecoxib 44-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-22 33072916-4 2020 Proliferation was measured in presence of COX-2 inhibitor Celecoxib (10-20 muM) revealing a decreased in vGPCR cell number, displaying typically apoptotic features in a dose dependent manner similarly to 1alpha,25(OH)2D3. Celecoxib 58-67 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 32618021-2 2020 Celecoxib is the highly marketed coxib, so there is still a need for the synthesis of COX-2 inhibitors with less adverse effects. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 86-91 32658799-4 2020 Because papilloma cells overexpress the epidermal growth factor receptor (EGFR), together with an increased expression of COX-2 and prostaglandin E2, the combination of erlotinib and celecoxib seems plausible, and could be proposed for patients with poor response to previous lines of treatment. Celecoxib 183-192 mitochondrially encoded cytochrome c oxidase II Homo sapiens 122-127 32967672-9 2020 Similar effects were obtained by inhibiting COX2 by celecoxib, a clinically approved COX2 inhibitor. Celecoxib 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-48 32967672-9 2020 Similar effects were obtained by inhibiting COX2 by celecoxib, a clinically approved COX2 inhibitor. Celecoxib 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 85-89 33194674-9 2020 Unlike suprapharmacological dose, metronomic Celecoxib can only inhibit HCC cell invasion after a 7-day course of treatment via NF-kappaB/MMP9 dependent, COX2/PGE2 independent pathway. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 154-158 32801081-3 2020 The in vitro assay results revealed that the N-(4-(4-chlorophenyl)-3-cyanothiophen-2-yl)-2-morpholinoacetamide (5b) possesses the highest selectivity toward COX-2 (IC50 = 5.45 muM) with selectivity index value of 8.37 compared to celecoxib with COX-2 selectivity index value of 15.44. Celecoxib 230-239 mitochondrially encoded cytochrome c oxidase II Homo sapiens 157-162 32801081-3 2020 The in vitro assay results revealed that the N-(4-(4-chlorophenyl)-3-cyanothiophen-2-yl)-2-morpholinoacetamide (5b) possesses the highest selectivity toward COX-2 (IC50 = 5.45 muM) with selectivity index value of 8.37 compared to celecoxib with COX-2 selectivity index value of 15.44. Celecoxib 230-239 mitochondrially encoded cytochrome c oxidase II Homo sapiens 245-250 32546278-11 2020 DIM could inhibit COX2/PGE2 pathway by targeting AHR, and COX2 selective inhibitor Celecoxib could suppress EMT and metastasis. Celecoxib 83-92 mitochondrially encoded cytochrome c oxidase II Homo sapiens 58-62 32624377-2 2020 The hypothesis was that patients receiving the TDB patch would have less pain in comparison to those treated with the oral COX-2 inhibitor celecoxib without increasing side effects. Celecoxib 139-148 mitochondrially encoded cytochrome c oxidase II Homo sapiens 123-128 32705218-4 2020 We revealed by MTT and western blotting, respectively, that celecoxib (CCB), an NSAID, and 2,5-dimethyl celecoxib (DMC), a non-cyclooxygenase (COX)-2 inhibitor analog of CCB, were able to sensitize TRAIL-resistant HCC cells to TRAIL, implicating a COX-independent mechanism. Celecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 143-149 32705218-4 2020 We revealed by MTT and western blotting, respectively, that celecoxib (CCB), an NSAID, and 2,5-dimethyl celecoxib (DMC), a non-cyclooxygenase (COX)-2 inhibitor analog of CCB, were able to sensitize TRAIL-resistant HCC cells to TRAIL, implicating a COX-independent mechanism. Celecoxib 170-173 mitochondrially encoded cytochrome c oxidase II Homo sapiens 143-149 32905529-10 2020 Moreover, treatment with tamoxifen or a COX-2 inhibitor celecoxib increased cisplatin sensitivity even in resistant cells, while COX-2/EP2/EP4 inhibitor treatment resulted in reduced expression of ERbeta. Celecoxib 56-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 32251635-2 2020 Celecoxib, the first selective COX-2 inhibitor, was approved by the Food and Drug Administration (FDA) in December 1998 and was taken back from the market in 2004. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 33489855-8 2021 Treatment of cells with the COX-2 selective inhibitor celecoxib induced cell death of AGS FR cells in a time- and concentration-dependent manner. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 32589073-1 2020 OBJECTIVES: Celecoxib is a selective cyclooxygenase (COX)-2 inhibitor that is commonly used to reduce the incidence of gastrointestinal (GI) complications in patients with rheumatoid arthritis (RA). Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-59 32596281-1 2020 Celecoxib (CXB) is a COX-2-selective nonsteroidal anti-inflammatory drug used to control pain and various inflammatory conditions. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 32596281-1 2020 Celecoxib (CXB) is a COX-2-selective nonsteroidal anti-inflammatory drug used to control pain and various inflammatory conditions. Celecoxib 11-14 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 33489855-10 2021 This apoptotic induction was strongly supported by the expression profiles of apoptosis- and survival-associated proteins in response to celecoxib; pro-apoptotic cellular proteins increased while expressions of COX-2 and p-Akt were downregulated in a concentration-dependent manner. Celecoxib 137-146 mitochondrially encoded cytochrome c oxidase II Homo sapiens 211-216 33489855-12 2021 Based on the data that downregulation of COX-2 was correlated with the concentrations of celecoxib, COX-2 may play a key role in celecoxib-induced cell death of AGS FR cells. Celecoxib 89-98 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 33489855-12 2021 Based on the data that downregulation of COX-2 was correlated with the concentrations of celecoxib, COX-2 may play a key role in celecoxib-induced cell death of AGS FR cells. Celecoxib 89-98 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 33489855-12 2021 Based on the data that downregulation of COX-2 was correlated with the concentrations of celecoxib, COX-2 may play a key role in celecoxib-induced cell death of AGS FR cells. Celecoxib 129-138 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 33489855-12 2021 Based on the data that downregulation of COX-2 was correlated with the concentrations of celecoxib, COX-2 may play a key role in celecoxib-induced cell death of AGS FR cells. Celecoxib 129-138 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 31611604-4 2019 In addition, the inhibition of HCC827GR cell growth by combining COX2 inhibitor (celecoxib), TOPK inhibitor (pantoprazole), and gefitinib was verified ex vivo and in vivo. Celecoxib 81-90 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-69 32208383-6 2020 Importantly, the FDA-approved drug celecoxib, and its non-COX2-inhibiting analogue dimethyl-celecoxib, stimulated the PI3K/Akt-integrin alpha5beta1 axis and restored airway epithelial repair in cells from children with wheeze. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 58-62 32088417-1 2020 Selective COX-2 inhibitor celecoxib was found directly inhibiting the growth of tested phytopathogenic fungi with the inhibitory rate ranging from 30 to 40% at 100 microg/ml. Celecoxib 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 31982653-3 2020 In the present study, a hybridization strategy was adopted to combine the binding features of the non-selective COX inhibitor "sulindac" and the selective COX-2 inhibitor "celecoxib" which show 5-LOX inhibitory activity with that of licofelone and a celecoxib pyridone analogue which show dual COX-2/5-LOX inhibitory activity to design new series of pyrazole sulfonamide derivatives which, by design, should possess dual COX-2/5-LOX inhibitory activity. Celecoxib 172-181 mitochondrially encoded cytochrome c oxidase II Homo sapiens 155-160 31982653-3 2020 In the present study, a hybridization strategy was adopted to combine the binding features of the non-selective COX inhibitor "sulindac" and the selective COX-2 inhibitor "celecoxib" which show 5-LOX inhibitory activity with that of licofelone and a celecoxib pyridone analogue which show dual COX-2/5-LOX inhibitory activity to design new series of pyrazole sulfonamide derivatives which, by design, should possess dual COX-2/5-LOX inhibitory activity. Celecoxib 172-181 mitochondrially encoded cytochrome c oxidase II Homo sapiens 294-299 31982653-3 2020 In the present study, a hybridization strategy was adopted to combine the binding features of the non-selective COX inhibitor "sulindac" and the selective COX-2 inhibitor "celecoxib" which show 5-LOX inhibitory activity with that of licofelone and a celecoxib pyridone analogue which show dual COX-2/5-LOX inhibitory activity to design new series of pyrazole sulfonamide derivatives which, by design, should possess dual COX-2/5-LOX inhibitory activity. Celecoxib 172-181 mitochondrially encoded cytochrome c oxidase II Homo sapiens 294-299 32468468-7 2020 Molecular docking studies showed that compound 3 m exhibited good binding affinity against COX-2 with docking score 9.328 kcal/mol, when compared to the standard celecoxib. Celecoxib 162-171 mitochondrially encoded cytochrome c oxidase II Homo sapiens 91-96 31623608-3 2019 Celecoxib (CXB), a selective COX-2 inhibitor, can dramatically enhance the cytotoxicity of doxorubicin (DOX) in breast cancer cells overexpressing P-gp. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 31623608-3 2019 Celecoxib (CXB), a selective COX-2 inhibitor, can dramatically enhance the cytotoxicity of doxorubicin (DOX) in breast cancer cells overexpressing P-gp. Celecoxib 11-14 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 32127262-5 2020 Benzimidazole-thiazole hybrid 15b was the most potent dual COX-2 (IC50 = 0.045 microM, SI = 294) inhibitor approximate to celecoxib (COX-2; IC50 = 0.045 microM, SI = 327), with double inhibitory activity versus 15-LOX enzyme (IC50 = 1.67 microM) relative to quercetin (IC50 = 3.34 microM). Celecoxib 122-131 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 32127262-5 2020 Benzimidazole-thiazole hybrid 15b was the most potent dual COX-2 (IC50 = 0.045 microM, SI = 294) inhibitor approximate to celecoxib (COX-2; IC50 = 0.045 microM, SI = 327), with double inhibitory activity versus 15-LOX enzyme (IC50 = 1.67 microM) relative to quercetin (IC50 = 3.34 microM). Celecoxib 122-131 mitochondrially encoded cytochrome c oxidase II Homo sapiens 133-138 32741915-7 2020 In addition, to explore the binding mode and selectivity of our compounds, 8d and celecoxib were docked into the active site of COX-1 and COX-2. Celecoxib 82-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 138-143 32741915-8 2020 It was found that compound 8d exhibited a binding pattern and interactions similar to that of celecoxib with COX-2 active site, while bitter manner of interaction than celecoxib to COX-1 active site. Celecoxib 94-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 109-114 31123968-1 2019 Cilostazol (an inhibitor of phosphodiesterase type III) has potent anti-inflammatory effects, and celecoxib (a COX-2 specific inhibitor) has been reported to improve the unsatisfactory profile of NSAIDs. Celecoxib 98-107 mitochondrially encoded cytochrome c oxidase II Homo sapiens 111-116 31123968-3 2019 Increased COX-2 protein expression and PGE2 synthesis by LPS (1 mug/ml) were significantly and synergistically attenuated by cotreatment with 3 muM cilostazol and 30 muM celecoxib, whereas monotherapy with either cilostazol or celecoxib showed little effects. Celecoxib 170-179 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 31123968-3 2019 Increased COX-2 protein expression and PGE2 synthesis by LPS (1 mug/ml) were significantly and synergistically attenuated by cotreatment with 3 muM cilostazol and 30 muM celecoxib, whereas monotherapy with either cilostazol or celecoxib showed little effects. Celecoxib 227-236 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 31123968-8 2019 Summarizing, cotreatment with cilostazol and celecoxib exhibited a synergistic increase in IL-10 production and SOCS3 expressions, thereby resulted in synergistic decreases in IL-1beta mRNA, IL-6 mRNA expression and TNF-alpha synthesis in association with synergistic decreases in COX-2 and PGE2 protein expression in the RA synovial fibroblasts. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 281-286 31339385-1 2019 Introduction: The cyclooxygenase (COX)-2 inhibitor celecoxib is an approved compound for rheumatoid (RA) and osteoarthritis (OA), combining both anti-inflammatory and analgesic properties with a good gastrointestinal tolerability. Celecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-40 31214060-5 2019 The COX-2 inhibitor celecoxib was found to have a significant positive effect on major depression, not only in single studies but also in meta-analyses. Celecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 31022559-7 2019 However, in PIV3-infected epithelial cells celecoxib inhibited PGE2 release and COX-2 expression to significantly higher degree as compared to non-infected cells. Celecoxib 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-85 31212177-0 2019 Design, synthesis of celecoxib-tolmetin drug hybrids as selective and potent COX-2 inhibitors. Celecoxib 21-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-82 31336734-1 2019 Celecoxib (CLX), a selective COX-2 inhibitor, is a biopharmaceutics classification system (BCS) class II drug with its bioavailability being limited by thepoor aqueoussolubility. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 31336734-1 2019 Celecoxib (CLX), a selective COX-2 inhibitor, is a biopharmaceutics classification system (BCS) class II drug with its bioavailability being limited by thepoor aqueoussolubility. Celecoxib 11-14 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 31075742-5 2019 Moreover, the target derivatives 9a-l demonstrated moderate to high potent inhibitory action towards COX-2 (IC50 = 0.87-3.78 microM), in particular, the derivatives 9e (IC50 = 0.92 microM), 9g (IC50 = 0.87 microM) and 9k (IC50 = 1.02 microM) recorded higher COX-2 inhibitory effect than the selective COX-2 inhibitor drug celecoxib (IC50 = 1.11 microM). Celecoxib 322-331 mitochondrially encoded cytochrome c oxidase II Homo sapiens 101-106 31048000-14 2019 The COX-2 specific celecoxib was identified as the most potent drug to reduce IL-6, IL-8 and TNF-alpha formation after SM exposures in vitro. Celecoxib 19-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 31277138-16 2019 CONCLUSION: Celecoxib combined with chemotherapy offers more clinical benefits for COX-2 positive advanced gastric cancer patients. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 31019986-15 2019 However, celecoxib (a selective COX-2 inhibitor) may inhibit tendon-to-bone healing in rotator cuff repair. Celecoxib 9-18 mitochondrially encoded cytochrome c oxidase II Homo sapiens 32-37 30763886-4 2019 Our best hit, 4d (COX-1 IC50 of 28 microM, COX-2 IC50 of 23 microM), appears to adopt similar binding modes to the standard COX-2 inhibitor, celecoxib, proposing room for possible selectivity. Celecoxib 141-150 mitochondrially encoded cytochrome c oxidase II Homo sapiens 124-129 30763886-6 2019 Four compounds 3a (COX-2 IC50 of 42 microM), 3d, 4d and 4f were notable for their anti-inflammatory activity that was comparable to that of the clinically available COX-2 inhibitor celecoxib. Celecoxib 181-190 mitochondrially encoded cytochrome c oxidase II Homo sapiens 165-170 30673592-0 2019 Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation. Celecoxib 40-49 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 30878890-2 2019 Compounds 3b-g exhibited superior inhibitory activity than celecoxib as COX-2 inhibitors. Celecoxib 59-68 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 30807897-6 2019 Docking studies into COX-2 active site (PDB code 3LN1) revealed that compounds 3, 6a, 6c, 9, 10, 11 and 13 had binding modes and energies comparable to that of celecoxib. Celecoxib 160-169 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 30878890-3 2019 Compounds 3b-d and 3g were the most potent COX-2 inhibitors with IC50 range of 6.4 - 8.13 nM and higher selectivity indexes (3b, SI = 26.19; 3c, SI = 13.73; 3d, SI = 29.27; 3g, SI = 18.00) comparing to celecoxib (IC50 = 42.60 nM, SI = 8.05). Celecoxib 202-211 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 30929580-0 2019 Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA. Celecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 30391698-6 2019 For compound 25, it showed about 340 and 198 times more potent than celecoxib and naproxen respectively as COX-1 inhibitor (IC50 value 0.044 vs. 15.000 and 8.700 microM), and 10 and 115 times more potent than the same drugs as COX-2 inhibitor (IC50 value 4.52 vs. 40.00 and 520.00 nM). Celecoxib 68-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 227-232 30508771-6 2019 The selectivity index (SI) range was >200-490 and was comparable to that for celecoxib [COX-2 (SI) > 416.7]. Celecoxib 77-86 mitochondrially encoded cytochrome c oxidase II Homo sapiens 88-93 30398124-4 2019 OBJECTIVE: Performed a systematic review and meta-analysis to evaluate the potential effect of the cyclo- oxygenases (Cox)-2 inhibitor Celecoxib adjunct treatment in BD through randomized controlled trials (RCT). Celecoxib 135-144 mitochondrially encoded cytochrome c oxidase II Homo sapiens 99-124 30602073-6 2019 Herein we report the synthesis of three carborane-containing derivatives of the COX-2-selective NSAID celecoxib. Celecoxib 102-111 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-85 31139556-6 2019 Celecoxib, an FDA-approved COX-2 inhibitor, is employed as a structural and functional element to confer MSCPs with redox-responsiveness and COX-2/PGE2 inhibitory activity. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 31139556-6 2019 Celecoxib, an FDA-approved COX-2 inhibitor, is employed as a structural and functional element to confer MSCPs with redox-responsiveness and COX-2/PGE2 inhibitory activity. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 141-146 30278282-6 2019 (8.69-9.26) than the COX-2 selective drug celecoxib (COX-2 S.I. Celecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 30073924-4 2019 Celecoxib, a COX-2 selective inhibitor, has been utilized for over 20 years, particularly as an anti-inflammatory, analgesic and antipyretic medication. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 30288088-6 2018 The meta-analysis showed no significant difference between celecoxib and ns-NSAIDs in the rate of acute myocardial infarction, and celecoxib was the only COX2-selective NSAID with a lower risk of adverse CV and GI events vs ns-NSAIDs. Celecoxib 131-140 mitochondrially encoded cytochrome c oxidase II Homo sapiens 154-158 30349293-8 2018 For this purpose, several drugs may have a role: specific COX-2 inhibitors such as celecoxib or other anti-inflammatory drugs such as lenalidomide may further inhibit lipopolysaccharide-mediated induction of COX-2. Celecoxib 83-92 mitochondrially encoded cytochrome c oxidase II Homo sapiens 58-63 30349293-8 2018 For this purpose, several drugs may have a role: specific COX-2 inhibitors such as celecoxib or other anti-inflammatory drugs such as lenalidomide may further inhibit lipopolysaccharide-mediated induction of COX-2. Celecoxib 83-92 mitochondrially encoded cytochrome c oxidase II Homo sapiens 208-213 30349293-9 2018 Moreover, lenalidomide and COX-2 inhibitors (celecoxib) have been tested in solid tumors with encouraging results. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 30216848-5 2018 Furthermore, in vitro COX-1/COX-2 inhibition testing showed that the compounds 4b, 6c, 10b, and 10c exhibited effective COX-2 inhibition, with IC50 values of 0.40-1.20 muM, and selectivity index (SI) values of >62.50-20.83, using celecoxib as a reference drug (IC50 = 0.11 muM; COX-2 SI: >227.20). Celecoxib 233-242 mitochondrially encoded cytochrome c oxidase II Homo sapiens 120-125 30216848-5 2018 Furthermore, in vitro COX-1/COX-2 inhibition testing showed that the compounds 4b, 6c, 10b, and 10c exhibited effective COX-2 inhibition, with IC50 values of 0.40-1.20 muM, and selectivity index (SI) values of >62.50-20.83, using celecoxib as a reference drug (IC50 = 0.11 muM; COX-2 SI: >227.20). Celecoxib 233-242 mitochondrially encoded cytochrome c oxidase II Homo sapiens 120-125 30106307-9 2018 Also, it possessed better affinity value, -7.80518 kcal/mol and energy binding -85.08 kcal/mol, in inhibition of COX-2 with PDB Id: 1CVU rather than other compounds and significantly the higher dock score than aspirin, close to celecoxib. Celecoxib 228-237 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 29550530-3 2018 Compounds 5d, 5f and 5i were found to be the most potent COX-2/5-LOX inhibitors with superior COX-2 selectivity index values (SI = 5.29-5.69) to reference standard celecoxib (SI = 3.52). Celecoxib 164-173 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 29608639-2 2018 Concomitant use of selective cyclooxygenase (COX)-2 inhibitor celecoxib and anticonvulsant gabapentin have been proposed to adequately control acute postoperative pain. Celecoxib 62-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-51 30570856-6 2018 Celecoxib, a COX-2 selective inhibitor, was used to inhibit the COX-2 of HC8693 cells, and the inhibiting effect of TSIIA on HC8693 cell growth was assessed. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 30570856-6 2018 Celecoxib, a COX-2 selective inhibitor, was used to inhibit the COX-2 of HC8693 cells, and the inhibiting effect of TSIIA on HC8693 cell growth was assessed. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-69 30131758-2 2018 Cyclooxygenase (COX)-2 inhibitor celecoxib is used for the treatment of acute pain due to its potent anti-inflammatory and analgesic effects. Celecoxib 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-22 30083389-7 2018 Furthermore, a strong correlation was found between pain relief observed in patients as well as celecoxib- and diclofenac-induced decrease in prostaglandins after 6 h. The findings presented reveal insights about drug-induced modulation of cellular networks in a whole-body context, thereby describing complex pharmacokinetic/pharmacodynamic behavior of COX-2 and 5-LOX inhibitors in therapeutic situations. Celecoxib 96-105 mitochondrially encoded cytochrome c oxidase II Homo sapiens 354-365 29550533-6 2018 Compounds 34 &35 exhibited significant COX-2 inhibition (IC50 = 0.10 microM) with significant COX-2 selectivity indices (SI = 135 & 145 respectively) approximate to celecoxib (IC50 = 0.049 microM, SI = 308.16) and exceeding indomethacin (IC50 = 0.51 microM, SI = 0.08). Celecoxib 173-182 mitochondrially encoded cytochrome c oxidase II Homo sapiens 98-103 29487225-9 2018 A patient with a CDKN2A-inactivating and a CTNNB1-activating mutation received matched treatment: palbociclib (CDK4/6 inhibitor) and celecoxib (COX-2/Wnt inhibitor); des-gamma-carboxy prothrombin level decreased by 84% at 2 months (1,410 to 242 ng/mL [normal: <=7.4 ng/mL]; alpha fetoprotein [AFP] low at baseline). Celecoxib 133-142 mitochondrially encoded cytochrome c oxidase II Homo sapiens 144-149 29936228-2 2018 For this purpose, ZINC database was screened on the basis of 50% structural similarity with celecoxib and indomethacin as the representative of COX-2 and COX-1/COX-2 inhibitors, respectively. Celecoxib 92-101 mitochondrially encoded cytochrome c oxidase II Homo sapiens 144-149 29936228-2 2018 For this purpose, ZINC database was screened on the basis of 50% structural similarity with celecoxib and indomethacin as the representative of COX-2 and COX-1/COX-2 inhibitors, respectively. Celecoxib 92-101 mitochondrially encoded cytochrome c oxidase II Homo sapiens 160-165 30038944-1 2018 Recent work suggests the selective Cox-2 inhibitor celecoxib delays progression to androgen independence in hormone sensitive prostate cancer (HSPC) through inhibition of the androgen receptor (AR) and ErbB signaling. Celecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 30038488-1 2018 Introduction: In this study, the radiation-enhancing effects of combined treatment with nimotuzumab, a humanized EGFR-blocking antibody, and celecoxib, a COX-2 selective inhibitor, in human nasopharyngeal carcinoma (NPC) cells were investigated. Celecoxib 141-150 mitochondrially encoded cytochrome c oxidase II Homo sapiens 154-159 29974839-1 2018 Dimethyl-celecoxib (DMC), a close derivative of celecoxib (CXB) with a low COX-2 inhibitory function, exhibits significant anti-neoplastic properties. Celecoxib 9-18 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 29974839-1 2018 Dimethyl-celecoxib (DMC), a close derivative of celecoxib (CXB) with a low COX-2 inhibitory function, exhibits significant anti-neoplastic properties. Celecoxib 59-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 29974839-7 2018 Down-regulation of the COX-2 mRNA expression in the celecoxib-treated group was significant compared with that in the DMC-treated group. Celecoxib 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 29853736-8 2018 In our multivariate Cox model, high coexpression of cytoplasmic IDO1/COX2 was found to be an independent predictor of poor outcome in CRC (HR = 2.218, 95%CI: 1.011-4.48, P = 0.047) and celecoxib subgroup patients (HR = 3.210, 95%CI: 1.074-9.590, P = 0.037). Celecoxib 185-194 mitochondrially encoded cytochrome c oxidase II Homo sapiens 69-73 29351170-11 2018 After adjustment for maternal autoimmune diseases, concomitant medication use, and other risk factors, COX-2 inhibitor use in late pregnancy was associated with a 2.46-fold increased risk of prematurity (adjusted OR, 2.46; 95% confidence interval, 1.28-4.72) compared to nonuse; only late pregnancy exposure to celecoxib was found to increase the risk (adjusted OR, 3.41; 95% confidence interval, 1.29-9.02). Celecoxib 311-320 mitochondrially encoded cytochrome c oxidase II Homo sapiens 103-108 29674687-0 2018 Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 29674687-4 2018 Celecoxib derivative 2,5-dimethyl-celecoxib (DMC) which lacks COX-2 inhibition also upregulated HO-1, implicating a COX-2-independent mechanism. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 29674687-4 2018 Celecoxib derivative 2,5-dimethyl-celecoxib (DMC) which lacks COX-2 inhibition also upregulated HO-1, implicating a COX-2-independent mechanism. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 116-121 29400411-5 2018 The synthesized compounds showed selectivity toward COX-2 rather than COX-1, and the IC50 values (0.25-1.7 microM) were lower than that of indomethacin (IC50 = 9.47 microM) and somewhat higher than that of celecoxib (IC50 = 0.071 microM). Celecoxib 207-216 mitochondrially encoded cytochrome c oxidase II Homo sapiens 52-57 29732985-9 2018 The optimal pharmacologic treatment for chronic articular pain in these patients is paracetamol and COX-2 inhibitors (celecoxib and rofecoxib). Celecoxib 118-127 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 29593389-5 2018 The expression of key proteins such as AKT and COX-2 was suppressed, which suggests that doxorubicin and celecoxib synergistically inhibit multiple key signaling pathways. Celecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 47-52 29515134-7 2018 COX-2 siRNA and celecoxib were used to inhibit COX-2. Celecoxib 16-25 mitochondrially encoded cytochrome c oxidase II Homo sapiens 47-52 29515134-9 2018 In conclusion, celecoxib partially restores autophagic flux via downregulation of COX-2 and alleviates steatosis in vitro and in vivo. Celecoxib 15-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 82-87 29884091-2 2018 Here, we reported that celecoxib, a selective COX-2 inhibitor in the NSAID class, exhibits strong antitumor activity in dose dependent manner in two OS cell lines-143B and U2OS. Celecoxib 23-32 mitochondrially encoded cytochrome c oxidase II Homo sapiens 46-51 29199735-6 2017 Six compounds had potencies in the submicromolar range against COX-2 and higher selectivity for COX-2 vs. COX-1 compared to the currently used drug celecoxib. Celecoxib 148-157 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 28881160-11 2017 Genetic testing reported the presence of a p.T41A mutations on the CTNNB1 gene, which predicted that he is sensitive to the COX-2 inhibitor celecoxib. Celecoxib 140-149 mitochondrially encoded cytochrome c oxidase II Homo sapiens 124-129 28929561-5 2017 Analogues of the sulfonamide-containing COX-2 inhibitor Celecoxib were prepared and evaluated. Celecoxib 56-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 29031075-5 2017 9-(4-chlorobenzoyl)-6-(methylsulfonyl)-1,2,3,9-tetrahydro-4H-carbazol-4-one 12a showed the most potential and selective activity against COX-2 (IC50 = 0.23 mumol) to be with superior potency to Celecoxib (IC50 = 0.30 mumol). Celecoxib 194-203 mitochondrially encoded cytochrome c oxidase II Homo sapiens 137-142 29290997-7 2017 MUC2 expression was reduced in vitro by small molecule inhibitors targeting EP4/PKA/CREB molecules and celecoxib (COX-2 inhibitor), and this was mediated by reduced CREB transcription factor binding to the MUC2 promoter. Celecoxib 103-112 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 29024866-1 2017 BACKGROUND AND AIMS: We aimed at investigating the effect of celecoxib (COX-2 selective inhibitor) and diclofenac (non-selective COX inhibitor) on endothelial function, and at identifying the underlying mechanisms in adjuvant-induced arthritis (AIA). Celecoxib 61-70 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 28851389-3 2017 METHODS: Between 2003 and 2015, 40 patients with extra-peritoneal sporadic DF were prospectively treated with meloxicam or celecoxib, a COX-2 inhibitor, therapy. Celecoxib 123-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 136-141 29066864-8 2017 The pharmacodynamic analysis revealed that the maximum effect of COX-2 inhibition was achieved at 2.0 hours for all genotypes of COX-2 SNPs after a single oral administration of 200 mg celecoxib. Celecoxib 185-194 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-70 29066864-8 2017 The pharmacodynamic analysis revealed that the maximum effect of COX-2 inhibition was achieved at 2.0 hours for all genotypes of COX-2 SNPs after a single oral administration of 200 mg celecoxib. Celecoxib 185-194 mitochondrially encoded cytochrome c oxidase II Homo sapiens 129-134 29066864-10 2017 CONCLUSION: Our results demonstrated that inhibitory effects of celecoxib on COX-2 induction were different according to the genotype of COX-2 SNPs. Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-82 29066864-10 2017 CONCLUSION: Our results demonstrated that inhibitory effects of celecoxib on COX-2 induction were different according to the genotype of COX-2 SNPs. Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 137-142 29066864-11 2017 In the present study, rs689466 is responsible for the variability of the response to celecoxib, suggesting that a subject with the GG genotype of rs689466 would be more responsive to celecoxib in terms of COX-2 inhibition. Celecoxib 85-94 mitochondrially encoded cytochrome c oxidase II Homo sapiens 205-210 29066864-11 2017 In the present study, rs689466 is responsible for the variability of the response to celecoxib, suggesting that a subject with the GG genotype of rs689466 would be more responsive to celecoxib in terms of COX-2 inhibition. Celecoxib 183-192 mitochondrially encoded cytochrome c oxidase II Homo sapiens 205-210 28528242-2 2017 Celecoxib, a nonsteroidal anti-inflammatory drug that acts via the selective inhibition of cyclooxygenase (COX)-2, has shown favorable effects in several psychiatric disorders. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 91-113 29152087-10 2017 Consistently, the COX-2 inhibitor Celecoxib blocked the invasive phenotype induced by the Rho-activating toxins. Celecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-23 28650862-2 2017 Celecoxib (Cel) is a COX-2-selective nonsteroidal anti-inflammatory drug and its antitumoral effect has been shown widely in a variety of cancers including OS cells in vitro. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 28650862-2 2017 Celecoxib (Cel) is a COX-2-selective nonsteroidal anti-inflammatory drug and its antitumoral effect has been shown widely in a variety of cancers including OS cells in vitro. Celecoxib 0-3 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 28368394-7 2017 In addition, the inhibition of COX-2-mediated matriptase activation by Celebrex and sulindac sulfide suppressed the androgen-independent and COX2-overexpressing PCa PC-3 cell invasion, tumor growth and lung metastasis in an orthotopic xenograft model. Celecoxib 71-79 mitochondrially encoded cytochrome c oxidase II Homo sapiens 141-145 28605057-2 2017 The synthesized compounds showed good selectivity for COX-2; compounds 8a, 8d, 8f, 11a, and 11c exhibited the highest COX-2 selectivity indexes (SI = 4.77-5.43) compared to the reference drug celecoxib (SI = 7.8). Celecoxib 192-201 mitochondrially encoded cytochrome c oxidase II Homo sapiens 54-59 28605057-2 2017 The synthesized compounds showed good selectivity for COX-2; compounds 8a, 8d, 8f, 11a, and 11c exhibited the highest COX-2 selectivity indexes (SI = 4.77-5.43) compared to the reference drug celecoxib (SI = 7.8). Celecoxib 192-201 mitochondrially encoded cytochrome c oxidase II Homo sapiens 118-123 28418202-6 2017 A molecular docking study was performed to investigate the possible binding mode of compounds 11, 17, and 26 with the active sites of the COX-2 and 5-LOX enzymes, where they showed nearly the same binding pattern as that of celecoxib and meclofenamic acid, respectively. Celecoxib 224-233 mitochondrially encoded cytochrome c oxidase II Homo sapiens 138-143 28450158-2 2017 The purpose of this work was to determine the ability of the COX-2 inhibitor Celecoxib to modulate the EGFR-AR signaling pathway in androgen-dependent PCa cells and to provide a rationale for its beneficial use in chemopreventive strategies. Celecoxib 77-86 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 28626213-1 2017 BACKGROUND To observe and demonstrate therapeutic effects and side effects of two selective COX-2 inhibitors, imrecoxib and celecoxib, on patients with axial spondyloarthritis (axSpA) and observe the correlation between imaging scores and serum DKK-1 levels. Celecoxib 124-133 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 28591155-9 2017 In protocol 2, seven volunteers were administered COX-2 inhibitor celecoxib (200 mg orally twice daily) for five days. Celecoxib 66-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 28500957-3 2017 Most of the derivatives showed good inhibitory activity against COX-2 enzyme specifically compounds IIIc, IIIe, IVd and IVg with IC50 values 0.024, 0.019, 0.011 and 0.014microM compared to celecoxib as reference drug with IC50 value of 0.05microM. Celecoxib 189-198 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-69 28676124-10 2017 Another finding was the concomitant use of COX-2 inhibitors (Etoricoxib or Celecoxib) and PPIs. Celecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 28668885-8 2017 CONCLUSION: The TX-1123-binding pocket of COX2 differs from that of the COX2-selective celecoxib-binding pocket. Celecoxib 87-96 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-46 28668885-8 2017 CONCLUSION: The TX-1123-binding pocket of COX2 differs from that of the COX2-selective celecoxib-binding pocket. Celecoxib 87-96 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-76 28536229-3 2017 On clinical history, she indicated that 3 weeks prior, she had been initiated on a cyclooygenase-2 (COX-2) inhibitor, celecoxib, for her osteoarthritis of her knees. Celecoxib 118-127 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 28212885-4 2017 These suppressive effects of epinephrine were counteracted by celecoxib, a selective inhibitor of COX-2 activity, which inhibited the induction of immunosuppressive factors (including the elevated expression of COX-2 itself) and the ability of epinephrine-exposed macrophages to suppress CD8+ T cell responses. Celecoxib 62-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 98-103 28212885-4 2017 These suppressive effects of epinephrine were counteracted by celecoxib, a selective inhibitor of COX-2 activity, which inhibited the induction of immunosuppressive factors (including the elevated expression of COX-2 itself) and the ability of epinephrine-exposed macrophages to suppress CD8+ T cell responses. Celecoxib 62-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 211-216 28212885-5 2017 The activation of the COX-2/PGE2 system and COX-2-dependent suppressive events were also observed in ex vivo human breast and colon cancer explant cultures and were similarly counteracted by celecoxib. Celecoxib 191-200 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 28212885-5 2017 The activation of the COX-2/PGE2 system and COX-2-dependent suppressive events were also observed in ex vivo human breast and colon cancer explant cultures and were similarly counteracted by celecoxib. Celecoxib 191-200 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 28231855-8 2017 Lastly the BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cell lines were used to evaluate the effect of COX-2 inhibition by celecoxib on expression of PD-L1 in vitro. Celecoxib 124-133 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-109 28285845-11 2017 COX-2 expression in cervical biopsies declined from pre-treatment to the end of treatment with celecoxib; it did not change with placebo. Celecoxib 95-104 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 27864660-1 2017 Celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, is used for the treatment of rheumatoid arthritis and osteoarthritis. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-45 26982261-3 2017 Celecoxib, rofecoxib, and valdecoxib are well-known specific COX-2 inhibiting drugs. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 28126288-4 2017 The present work aims to summarize the current approaches adopted for the synthesis of the 1,2,3-triazole and medicinal significance of these architectures as a lead structure for the discovery of drug molecules such as COX-1/COX-2 inhibitors (celecoxib, pyrazofurin), HIV protease inhibitors, CB1 cannabinoid receptor antagonist and much more which are in the pipeline of clinical trials. Celecoxib 244-253 mitochondrially encoded cytochrome c oxidase II Homo sapiens 226-231 28283800-3 2017 While the selective COX-2 inhibitor celecoxib showed anti-neoplastic activity against several malignant tumors, its effects against LGG remain to be elucidated. Celecoxib 36-45 mitochondrially encoded cytochrome c oxidase II Homo sapiens 20-25 27666139-1 2017 OBJECTIVES: The role of celecoxib in preventing and treating tumors has attracted broad attention in recent years because of its selective and specific inhibition of COX-2 activity. Celecoxib 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 166-171 28423516-1 2017 Here we showed that the addition of the COX-2 inhibitor celecoxib improved the antitumor efficacy in colorectal cancer (CRC) of the monoclonal anti-EGFR antibody cetuximab. Celecoxib 56-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 28386348-7 2017 Importantly, inhibition of COX-2 via a specific COX-2 inhibitor celecoxib markedly blocked cisplatin-induced mesangial cell apoptosis as evidenced by the decreased number of apoptotic cells, blocked increments of cleaved caspase-3 and Bax, and reversed Bcl-2 downregulation. Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 28386348-7 2017 Importantly, inhibition of COX-2 via a specific COX-2 inhibitor celecoxib markedly blocked cisplatin-induced mesangial cell apoptosis as evidenced by the decreased number of apoptotic cells, blocked increments of cleaved caspase-3 and Bax, and reversed Bcl-2 downregulation. Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 28231855-14 2017 Lastly, inhibition of COX-2 activity by celecoxib down-regulated the expression of PD-L1 in both BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cell lines. Celecoxib 40-49 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 28053596-6 2017 METHODS: We have attempted to identify the anti-proliferation of celecoxib, a selective COX-2 inhibitor, and the combination of celecoxib and cisplatin in MG-63 cells, and to explore the potential molecular mechanisms involved. Celecoxib 65-74 mitochondrially encoded cytochrome c oxidase II Homo sapiens 88-93 27837994-2 2017 Compounds 19 and 27 exhibited the highest potency and selectivity for COX-2 inhibitory activity (IC50 = 1.21 and 1.13 muM, respectively; selectivity index (COX-1/COX-2) = 6.52 and 7.61, respectively) in comparison to the reference drug celecoxib (COX-2 IC50 = 0.88 muM; selectivity index (COX-1/COX-2) = 8.31). Celecoxib 236-245 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 27569276-6 2017 Intervention was perioperative use of any available COX-2 inhibitors in current practice (celecoxib, parecoxib, or etoricoxib), compared to non-selective NSAIDs, analgesics, or placebo. Celecoxib 90-99 mitochondrially encoded cytochrome c oxidase II Homo sapiens 52-57 27769779-4 2017 Plumbagin and Celecoxib are two agents that were identified to synergistically kill melanoma cells by inhibiting the COX-2 and STAT3 pathways, which are constitutively activated in up to 70% of melanomas. Celecoxib 14-23 mitochondrially encoded cytochrome c oxidase II Homo sapiens 117-122 27769779-7 2017 Mechanistically, combination of Celecoxib and Plumbagin decreased melanoma cell proliferation and retarded vascular development of tumors mediated by inhibition of COX-2 and STAT3 leading to decreased levels of key cyclins key on which melanoma cell were dependent for survival. Celecoxib 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 164-169 28057325-0 2017 Design, synthesis and biological screening of some novel celecoxib and etoricoxib analogs with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile. Celecoxib 57-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110 28119811-6 2017 Molecular docking studies on the most active compound 3f revealed a binding mode similar to that of celecoxib in the active site of the COX-2 enzyme. Celecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 136-141 29250535-12 2017 Inhibition of COX-2 by siCOX-2 or Celecoxib attenuated the proliferation of breast cancer cells with HPV16 E6 expression; and the upregulation of COX-2 could be suppressed by the inhibition of NF-kappaB activity. Celecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 27761963-1 2017 We previously reported that celecoxib, a selective COX-2 inhibitor, strongly inhibited human colon cancer cell proliferation by suppressing the Wnt/beta-catenin signaling pathway. Celecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-56 27894402-3 2016 Celecoxib, a selective COX-2 inhibitor, is the only non-steroidal anti-inflammatory drug (NSAID) that has been approved for cancer therapy and prevention. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 28007462-2 2017 We previously reported that in colon cancer cells, celecoxib, a COX-2-selective NSAID, inhibited the canonical Wnt/beta-catenin signaling pathway. Celecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-69 27835591-8 2016 Finally, it suppressed colony formation of CD34+ cells from CML patients, while sparing most CD34+ progenitors from healthy donors, and induced apoptosis of primary Ph+ ALL cells.Together, these findings indicate that celecoxib may serve as a COX2-independent lead compound to simultaneously target the mTOR and beta-catenin pathways, key players in the resistance of CML stem cells to TKIs. Celecoxib 218-227 mitochondrially encoded cytochrome c oxidase II Homo sapiens 243-247 27541263-6 2016 The inhibitory activity of COX-2 and 5-LOX were tested for 5a-h. Three compounds, 5c, 5d and 5f showed excellent COX-2 inhibitory activity with IC50 ranging from 0.98 to 1.23 muM compared to the reference celecoxib (1.54 muM). Celecoxib 205-214 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 27541263-6 2016 The inhibitory activity of COX-2 and 5-LOX were tested for 5a-h. Three compounds, 5c, 5d and 5f showed excellent COX-2 inhibitory activity with IC50 ranging from 0.98 to 1.23 muM compared to the reference celecoxib (1.54 muM). Celecoxib 205-214 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-38 27835884-0 2016 Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer. Celecoxib 93-102 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 27835884-3 2016 Based on an interesting study of aspirin efficacy in colorectal cancer, we hypothesized that celecoxib antitumoral activity may be restricted to PIK3CA mutated BC.COX-2 mRNA expression was analyzed in 446 BC samples and in 61 BC patient-derived xenografts (PDX) using quantitative RT-PCR. Celecoxib 93-102 mitochondrially encoded cytochrome c oxidase II Homo sapiens 163-168 27835884-5 2016 The antitumoral activity of celecoxib was tested in two triple-negative (TN) PDX with a PIK3CA wild-type (wt) or mutated genotype.COX-2 mRNA was overexpressed in 2% of BC and significantly associated with TN subtype. Celecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 130-135 27835884-9 2016 Celecoxib antitumoral activity involved S6 ribosomal protein and AKT phosphorylation.Low expression of COX-2 has a significant negative impact on the MFS/DFS of BC patients. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 103-108 27835591-3 2016 The anti-inflammatory COX2 inhibitor celecoxib has been utilized as anti-tumour drug due to its anti-proliferative activity. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-26 26610257-4 2016 Based on phenols previously identified, and taking as reference the crystallographic structures of COX-1 and COX-2 in complex with the commercial drug Celecoxib, a molecular docking procedure was devised to adjust 123 phenolic molecular models at the enzyme-binding sites. Celecoxib 151-160 mitochondrially encoded cytochrome c oxidase II Homo sapiens 109-114 27072288-6 2016 In addition, molecular docking studies were performed for compounds 13d, 13f, 13k and 13o inside COX-2 active site which showed acceptable binding interactions (affinity in kcal/mol -2.1774, -6.9498) in comparison with celecoxib (affinity in kcal/mol -6.5330). Celecoxib 219-228 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 27826185-7 2016 These selective COX2 inhibitors were docked into the active site of COX2, and showed the same orientation and binding mode to that of celecoxib (selective COX2 inhibitor). Celecoxib 134-143 mitochondrially encoded cytochrome c oxidase II Homo sapiens 16-20 27826185-7 2016 These selective COX2 inhibitors were docked into the active site of COX2, and showed the same orientation and binding mode to that of celecoxib (selective COX2 inhibitor). Celecoxib 134-143 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-72 27826185-7 2016 These selective COX2 inhibitors were docked into the active site of COX2, and showed the same orientation and binding mode to that of celecoxib (selective COX2 inhibitor). Celecoxib 134-143 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-72 27826185-8 2016 Docking studies also showed that the SO2NH2 of 5u and 5s is inserted deep inside the selective pocket of the COX2-active site and formed a hydrogen-bond interaction with His90, Arg513, Phe518, Ser353, Gln192, and Ile517, which was further validated by superimposed docked pose with celecoxib. Celecoxib 282-291 mitochondrially encoded cytochrome c oxidase II Homo sapiens 109-113 27430377-2 2016 Nevertheless, the precise biological mechanism of how celecoxib, a selective COX-2 inhibitor, regulates the growth and invasion of pancreatic tumors is not completely understood. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-82 27432344-1 2016 Treatment with celecoxib, a selective COX-2 inhibitor, reduces formation of premalignant adenomatous polyps in the gastrointestinal tracts of humans and mice. Celecoxib 15-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 27259813-10 2016 SIGNIFICANCE: These findings indicate that celecoxib enhances the degranulation of CD8(+) T cells on HPV16-induced lesions, suggesting the potential clinical use of COX-2 inhibitors. Celecoxib 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 165-170 30051682-2 2016 Celecoxib is a selective COX-2 inhibitor and has a lower effect of platelet aggregation compared with conventional non-steroidal anti-inflammatory drugs (NSAIDs). Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 27547824-6 2016 Finally, the in vitro results were extrapolated to ex vivo studies by administration of the COX-2 inhibitor, celecoxib, to volunteers, illustrating how this approach can be used to integrate preclinical and clinical studies during drug development. Celecoxib 109-118 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 27385366-5 2016 Additionally, elevated levels of cyclo-oxygenase 2 (PTGS2; COX-2) and prostaglandin E2 (PGE2) secretion were observed in senescent fibroblasts, and inhibition of COX-2 by celecoxib reduced the expression of miR-335, restored PTEN expression and decreased the pro-tumourigenic effects of the SASP. Celecoxib 171-180 mitochondrially encoded cytochrome c oxidase II Homo sapiens 162-167 26895560-8 2016 Downstream of PAR2, the cyclooxygenase (COX) inhibitor indomethacin, the COX2 inhibitor celecoxib or the thromboxane receptors blocker SQ29548 prevented the deleterious effects of sDPP4. Celecoxib 88-97 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-77 27074576-1 2016 Our objective was to evaluate the effect of the COX-2 inhibitor, celecoxib, on (1) proliferation and apoptosis in human ovarian cancer cell lines and primary cultures of ovarian cancer cells, and (2) inhibition of tumor growth in a genetically engineered mouse model of serous ovarian cancer under obese and non-obese conditions. Celecoxib 65-74 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 26538205-3 2016 METHODS: Fifty-seven healthy subjects were randomly assigned groups given the cyclooxygenase (COX) 2 inhibitor celecoxib (200 mg, twice daily) plus placebo for 2 weeks (COX-2 + placebo group, n = 30), or celecoxib plus the PPI rabeprazole (20 mg, once daily) for 2 weeks (COX-2 + PPI group, n = 27). Celecoxib 111-120 mitochondrially encoded cytochrome c oxidase II Homo sapiens 78-100 27020655-1 2016 To explore the epigenetic mechanisms underlying the effects of anti-Helicobacter pylori (H. pylori) alone and combined with COX-2 inhibitor (celecoxib), we dynamically evaluated the associations between COX-2 methylation alterations and gastric lesion evolution during the process of interventions. Celecoxib 141-150 mitochondrially encoded cytochrome c oxidase II Homo sapiens 124-129 27020655-1 2016 To explore the epigenetic mechanisms underlying the effects of anti-Helicobacter pylori (H. pylori) alone and combined with COX-2 inhibitor (celecoxib), we dynamically evaluated the associations between COX-2 methylation alterations and gastric lesion evolution during the process of interventions. Celecoxib 141-150 mitochondrially encoded cytochrome c oxidase II Homo sapiens 203-208 27020655-4 2016 With placebo group as reference, COX-2 methylation levels were decreased in anti-H. pylori [OR, 3.30; 95% confidence interval (CI), 2.16-5.02], celecoxib (OR, 2.04; 95% CI, 1.36-3.07), and anti-H. pylori followed by celecoxib (OR, 2.10; 95% CI, 1.38-3.17) groups. Celecoxib 144-153 mitochondrially encoded cytochrome c oxidase II Homo sapiens 33-38 27020655-4 2016 With placebo group as reference, COX-2 methylation levels were decreased in anti-H. pylori [OR, 3.30; 95% confidence interval (CI), 2.16-5.02], celecoxib (OR, 2.04; 95% CI, 1.36-3.07), and anti-H. pylori followed by celecoxib (OR, 2.10; 95% CI, 1.38-3.17) groups. Celecoxib 216-225 mitochondrially encoded cytochrome c oxidase II Homo sapiens 33-38 27020655-5 2016 When stratified by baseline histology, the three active arms significantly decreased COX-2 methylation levels in indefinite dysplasia/dysplasia subjects, and ORs were 3.65 (95% CI, 1.96-6.80) for anti-H. pylori, 2.43 (95% CI 1.34-4.39) for celecoxib, and 2.80 (95% CI, 1.52-5.15) for anti-H. pylori followed by celecoxib, respectively. Celecoxib 240-249 mitochondrially encoded cytochrome c oxidase II Homo sapiens 85-90 27020655-5 2016 When stratified by baseline histology, the three active arms significantly decreased COX-2 methylation levels in indefinite dysplasia/dysplasia subjects, and ORs were 3.65 (95% CI, 1.96-6.80) for anti-H. pylori, 2.43 (95% CI 1.34-4.39) for celecoxib, and 2.80 (95% CI, 1.52-5.15) for anti-H. pylori followed by celecoxib, respectively. Celecoxib 311-320 mitochondrially encoded cytochrome c oxidase II Homo sapiens 85-90 27020655-8 2016 These findings suggest that anti-H. pylori or celecoxib treatment alone could decrease COX-2 methylation levels in gastric mucosa. Celecoxib 46-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-92 26166140-2 2016 BACKGROUND: RCT studies report that COX-2 selective inhibitor celecoxib induces fewer small intestinal injuries than nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). Celecoxib 62-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 26631035-7 2016 Celecoxib showed anti-cancer effects in both COX-2 dependent and independent pathways and used to act as a radiosensitizing enhancer. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 26931344-1 2016 PURPOSE: In our previous study, we found that celecoxib, a kind of COX-2 inhibitor, led to cell apoptosis while up-regulating the expression of vascular endothelial growth factor (VEGF) in colorectal cancer HCT116 cells (COX-2 deficient), and endoplasmic reticulum (ER) stress was involved in the mechanism. Celecoxib 46-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 26931344-1 2016 PURPOSE: In our previous study, we found that celecoxib, a kind of COX-2 inhibitor, led to cell apoptosis while up-regulating the expression of vascular endothelial growth factor (VEGF) in colorectal cancer HCT116 cells (COX-2 deficient), and endoplasmic reticulum (ER) stress was involved in the mechanism. Celecoxib 46-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 221-226 26931344-8 2016 CONCLUSIONS: Celecoxib, both in vitro and in vivo, induced apoptosis of colorectal cancer cells but increased the VEGF levels at the same time in a COX-2-independent manner, namely by activating ER stress. Celecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 148-153 26098693-5 2016 S1P significantly enhanced COX-2 expression and PGE2 secretion, and this was repressed by the selective COX-2 inhibitor celecoxib, the corticosteroid dexamethasone, or small interfering RNA (siRNA) knockdown of COX-2 expression. Celecoxib 120-129 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 26950454-11 2016 Caspase-3 and COX-2 dependent molecular targets seem to be involved in mediating the anti-proliferative effects of IM and CX combination. Celecoxib 122-124 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 26929740-10 2016 Reagents which inhibit inflammation, such as the Cox2 inhibitor celecoxib, block the feed-forward loop and prevent induction of PDAC in models with endogenous oncogenic K-Ras(mt). Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 49-53 26098693-5 2016 S1P significantly enhanced COX-2 expression and PGE2 secretion, and this was repressed by the selective COX-2 inhibitor celecoxib, the corticosteroid dexamethasone, or small interfering RNA (siRNA) knockdown of COX-2 expression. Celecoxib 120-129 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-109 26098693-5 2016 S1P significantly enhanced COX-2 expression and PGE2 secretion, and this was repressed by the selective COX-2 inhibitor celecoxib, the corticosteroid dexamethasone, or small interfering RNA (siRNA) knockdown of COX-2 expression. Celecoxib 120-129 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-109 27221835-0 2016 Celecoxib, a COX-2 Selective Inhibitor, Induces Cell Cycle Arrest at the G2/M Phase in HeLa Cervical Cancer Cells. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 27221835-1 2016 Celecoxib, a selective inhibitor of COX-2, showed cytotoxic effects in many cancer cell lines including cervical cancer cells. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 26780018-5 2015 All eligible patients were given a COX-2 inhibitor--celecoxib 100 mg--twice daily starting on the day of surgery until the seventh day post-operatively or discharge, whichever was earlier. Celecoxib 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 26474693-1 2016 It has been demonstrated that COX-2-selective inhibitor celecoxib shows synergy with oxaliplatin for suppressing tumor growth. Celecoxib 56-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 26462142-3 2015 All the bioactive compounds showed in vitro high affinity and selectivity toward the COX-2 isoenzyme, compared to the reference celecoxib with IC50 values ranging from 0.31 to 0.78 muM. Celecoxib 128-137 mitochondrially encoded cytochrome c oxidase II Homo sapiens 85-90 26586936-8 2015 When As4S4 was combined with chemotherapy drug cisplatin or COX2 inhibitor celecoxib, its inhibition of COX2, BCL2, and p38 expression was enhanced. Celecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-64 26545734-5 2015 RESULTS: For COX-2 inhibitors, celecoxib dispensing halved after rofecoxib withdrawal, but meloxicam dispensing increased by 60 %. Celecoxib 31-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 26592832-1 2015 OBJECTIVE: The goal of this study was to determine the effect of celecoxib, a selective COX-2 inhibitor, on the growth inhibition of osteosarcoma and its potential anticancer mechanisms. Celecoxib 65-74 mitochondrially encoded cytochrome c oxidase II Homo sapiens 88-93 26885023-8 2015 All volunteers received the COX-2 inhibitor celecoxib (200 mg orally twice daily) for 5 days. Celecoxib 44-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 26586936-8 2015 When As4S4 was combined with chemotherapy drug cisplatin or COX2 inhibitor celecoxib, its inhibition of COX2, BCL2, and p38 expression was enhanced. Celecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-108 25869511-9 2015 Therefore, nonselective COX inhibition with ASA 325mg and ibuprofen completely inhibit the protective effects of rosuvastatin in the setting of IR injury, as does therapy with the specific COX-2 antagonist celecoxib. Celecoxib 206-215 mitochondrially encoded cytochrome c oxidase II Homo sapiens 189-194 26087400-7 2015 Furthermore, COX2 inhibitor celecoxib strongly reduced growth and invasiveness following hypoxic PCA cells reoxygenation, and inhibited invasiveness induced by hypoxic PCA EVs. Celecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-17 26139640-2 2015 Celecoxib, a nonsteroidal anti-inflammatory drug, which acts via the selective inhibition of cyclo-oxygenase (COX)-2, has been shown to have antidepressive effects. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 93-116 26139640-3 2015 OBJECTIVES: Here, we aimed to compare the efficacy and safety of celecoxib, a selective inhibitor of COX-2, with diclofenac, a nonselective inhibitor of both COX-1 and COX-2 in reducing depressive symptoms and pain in breast cancer patients. Celecoxib 65-74 mitochondrially encoded cytochrome c oxidase II Homo sapiens 101-106 25945055-7 2015 Treatment with the selective COX-2 inhibitor celecoxib, or transient transfection of gastric cancer cells with COX-2 siRNA, also inhibited cell proliferation and induced apoptosis. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 26009874-9 2015 In a combination regimen, Sabutoclax and COX-2 inhibitor, Celecoxib, synergistically inhibited the growth of OSCC in vitro and also significantly reduced OSCC tumor growth in vivo. Celecoxib 58-67 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 25691007-4 2015 The MDR phenotype is associated with the constitutive expression of COX-2 and iNOS, whereas celecoxib, a specific inhibitor of COX-2 activity, reverses drug resistance of MDR cells by releasing cytochrome c from mitochondria. Celecoxib 92-101 mitochondrially encoded cytochrome c oxidase II Homo sapiens 127-132 25691007-8 2015 Low and moderate concentrations of celecoxib modulate the expression of iNOS and P-gp in mitochondria of MDR cancer cells independently from inhibition of COX-2 activity. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 155-160 25898179-9 2015 Pharmacological targeting of cyclooxygenase-1 and -2 (COX-1 and -2) using the nonselective inhibitor indomethacin, COX-1 inhibitor SC-560, and COX-2 inhibitor celecoxib revealed a contribution of COX-2 activity to the NMDA receptor"s downstream signaling events affecting BCRP. Celecoxib 159-168 mitochondrially encoded cytochrome c oxidase II Homo sapiens 143-148 25770423-4 2015 In this study, we showed that COX-2 selective inhibitor celecoxib enhanced the radiation-induced inhibition of cell proliferation and apoptosis in HeLa and SACC-83 cells. Celecoxib 56-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 25866240-3 2015 Among the compounds, compound 48 exhibited the most potent and selective COX-2 inhibitor (COX-2 IC50=0.33 muM; COX-1 IC50=68.49 muM) relative to the reference drugs celecoxib (IC50=0.052 muM). Celecoxib 165-174 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 25303541-5 2015 The effects of celecoxib were COX2 independent. Celecoxib 15-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-34 25333664-6 2014 Pretreatment with a COX-2 or NF-kappaB-selective inhibitor (celecoxib or ammonium pyrrolidinedithiocarbamate) had an additive effect on the effusanin E-mediated inhibition of proliferation, while pretreatment with an activator of NF-kappaB/COX-2 (lipopolysaccharides) abrogated the effusanin E-mediated inhibition of proliferation. Celecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 20-25 25907945-8 2015 CONCLUSION: With a lower efficacy than Sou-Medrol in decreasing postoperative inflammation, celecoxib produces a better effect in inhibiting COX-2 expression, but it does not lower postoperative recurrence rate of rectal cancer. Celecoxib 92-101 mitochondrially encoded cytochrome c oxidase II Homo sapiens 141-146 25433956-3 2015 Thus, the question arises, how NSAIDs do exert their damaging effects especially in the lower GI tract and how to explain the reduced risk of a COX-2 selective inhibitor, celecoxib. Celecoxib 171-180 mitochondrially encoded cytochrome c oxidase II Homo sapiens 144-149 25218028-0 2015 COX-2- and endoplasmic reticulum stress-independent induction of ULBP-1 and enhancement of sensitivity to NK cell-mediated cytotoxicity by celecoxib in colon cancer cells. Celecoxib 139-148 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 25218028-2 2015 Celecoxib and its non-coxib analog, 2,5-dimethyl celecoxib, induced ULBP-1 and DR5 in both COX-2 negative HCT-15 cells and COX-2 positive HT-29 cells. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 91-96 25218028-2 2015 Celecoxib and its non-coxib analog, 2,5-dimethyl celecoxib, induced ULBP-1 and DR5 in both COX-2 negative HCT-15 cells and COX-2 positive HT-29 cells. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 123-128 25218028-7 2015 Taken together, these findings suggest that celecoxib induces the expression of ULBP-1 as well as DR5 in clonogenic colon cancer cells via COX-2 and ER stress-independent pathways, and increases their susceptibility to NK cells. Celecoxib 44-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 139-144 26521945-4 2015 Beneficial effect of COX-2 inhibitor celecoxib add-on therapy has been reported in early stage of schizophrenia. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 24964373-8 2014 RESULTS: The follow-up of our original case of a patient with rapid cycling who had shown impressive psychopathological improvement under celecoxib revealed complete loss of this effect upon discontinuation of the COX2 inhibitor. Celecoxib 138-147 mitochondrially encoded cytochrome c oxidase II Homo sapiens 214-218 25209136-7 2014 Selective cyclooxygenase (COX)-2 inhibitors, like celecoxib at usual doses, carry the lowest GI risk and are the best option in patients with moderate/high GI risk without high CV risk. Celecoxib 50-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-32 25333664-6 2014 Pretreatment with a COX-2 or NF-kappaB-selective inhibitor (celecoxib or ammonium pyrrolidinedithiocarbamate) had an additive effect on the effusanin E-mediated inhibition of proliferation, while pretreatment with an activator of NF-kappaB/COX-2 (lipopolysaccharides) abrogated the effusanin E-mediated inhibition of proliferation. Celecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 240-245 25066075-2 2014 Celecoxib (CXB), a selective COX-2 inhibitor, is able to control inflammation and pain, to improve the efficacy of radiotherapy, and to inhibit at high doses the growth of cancer cells. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 25299780-10 2014 Finally, TRAIL-induced expression of COX-2 was diminished through siRNA targeting c-Rel or NFATc2 and pharmacologic inhibition of COX-2 with celecoxib or siRNA targeting COX-2, enhanced TRAIL apoptosis. Celecoxib 141-150 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 25299780-10 2014 Finally, TRAIL-induced expression of COX-2 was diminished through siRNA targeting c-Rel or NFATc2 and pharmacologic inhibition of COX-2 with celecoxib or siRNA targeting COX-2, enhanced TRAIL apoptosis. Celecoxib 141-150 mitochondrially encoded cytochrome c oxidase II Homo sapiens 130-135 25299780-10 2014 Finally, TRAIL-induced expression of COX-2 was diminished through siRNA targeting c-Rel or NFATc2 and pharmacologic inhibition of COX-2 with celecoxib or siRNA targeting COX-2, enhanced TRAIL apoptosis. Celecoxib 141-150 mitochondrially encoded cytochrome c oxidase II Homo sapiens 130-135 25066075-2 2014 Celecoxib (CXB), a selective COX-2 inhibitor, is able to control inflammation and pain, to improve the efficacy of radiotherapy, and to inhibit at high doses the growth of cancer cells. Celecoxib 11-14 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 25587329-6 2014 The COX-2 inhibitor celecoxib up-regulated the expression of ABCG2 mRNA in MCF-7 and MCF7-MX cells, which was accompanied by increased ABCG2 protein expression. Celecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 25587329-7 2014 While celecoxib was able to block the 12-O-tetradecanoylphorbol-13-acetate (TPA)-mediated increase in COX-2 expression in MDA-MB-231 cells, it increased the expression of ABCG2 up to 4.27 times to the control level at mRNA level and with less intensity at protein level. Celecoxib 6-15 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 24867695-6 2014 Furthermore, treatment with conventional chemotherapeutic drugs (e.g., gemcitabine and doxorubicin) or COX-2 inhibitor, celecoxib, sensitised the cells to 2-DG treatment. Celecoxib 120-129 mitochondrially encoded cytochrome c oxidase II Homo sapiens 103-108 25587329-2 2014 Specific COX-2 inhibitor celecoxib has been shown to enhance the sensitivity of cancer cells to anticancer drugs. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 9-14 24934992-1 2014 Twenty four pyrazoline derivatives modified from Celecoxib were designed and synthesized as bi-inhibitor of COX-2 and B-Raf. Celecoxib 49-58 mitochondrially encoded cytochrome c oxidase II Homo sapiens 108-113 24859418-3 2014 The treatment of neuroblastoma cells in vitro with celecoxib, a COX2 inhibitor, induces apoptosis. Celecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-68 24220749-1 2014 The present work was conducted to examine whether celecoxib, a selective COX-2 inhibitor, 200 mg administered 1 h preoperatively to patients undergoing arthroscopic hip surgery reduces postoperative pain. Celecoxib 50-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 26839798-2 2015 In vitro COX-1/COX-2 isozyme inhibition structure-activity studies identified 3-(benzyloxy)-2-[4-(methylsulfonyl)phenyl]-4H-chromen-4-one (5d) as a potent COX-2 inhibitor (IC50 = 0.07 muM) with a high COX-2 selectivity index (SI = 287.1) comparable to the reference drug celecoxib (COX-2 IC50 = 0.06 muM; COX-2 SI = 405). Celecoxib 271-280 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 25202054-0 2014 LLW-3-6 and celecoxib impacts growth in prostate cancer cells and subcellular localization of COX-2. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 94-99 25559449-6 2014 The IC50 values of celecoxib, rofecoxib, sinomenine, bulleyaconitine A, tetrandrine, fangchinoline, berberine hydrochloride and sophocarpidine towards COX-2 were determined. Celecoxib 19-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 151-156 24874483-8 2014 Concomitant reduction in COX-2 expression was statistically significant in the exemestane and celecoxib arm (P<0.03) only. Celecoxib 94-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 24874483-10 2014 A combination of an aromatase inhibitor and celecoxib has significant biological effect and may be integrated into treatment of COX2-positive DCIS at high risk of recurrence. Celecoxib 44-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 128-132 25107843-0 2014 The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor. Celecoxib 85-94 mitochondrially encoded cytochrome c oxidase II Homo sapiens 98-103 25006185-9 2014 Selective cox-2 inhibitors were associated with a modest increased hazard for cardiovascular events (hazard ratio, 1.13; 1.04-1.23; P=0.004 and celecoxib only: HR, 1.13; 1.01-1.27; P=0.031). Celecoxib 144-153 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 24474408-0 2014 Effect of a selective COX-2 inhibitor, celecoxib, on heterotopic ossification after total hip arthroplasty: a case-controlled study. Celecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 24721459-4 2014 This study evaluated the effect of celecoxib, a selective COX-2 inhibitor, on extracellular matrix (ECM) metabolism of mandibular condylar chondrocytes under CTS. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 58-63 24721459-8 2014 RESULTS: The presence of celecoxib normalized the release of PGE2 and diminished the CTS-induced COX-2, MMP-1, MMP-3, MMP-9 and ADAMTS-5 gene expressions while recovered the downregulated type II collagen and aggrecan gene expressions. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 24989281-0 2014 [Effect of COX-2 inhibitor celecoxib on proliferation, apoptosis of HL-60 cells and its mechanism]. Celecoxib 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 11-16 24989281-1 2014 This study was aimed to investigate the effect of COX-2 inhibitor celecoxib on proliferation, apoptosis of human acute myeloid leukemia cell line HL-60 and its mechanism. Celecoxib 66-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 24989281-7 2014 It is concluded that celecoxib can inhibit the proliferation of HL-60 cells in dose-dependent manner, celecoxib causes cell G0/G1 arrest and induces cell apoptosis possibly through down-regulation of the cyclin D1 and cyclin E1 expression, and down-regulation of COX-2 expression respectively. Celecoxib 21-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 263-268 24989281-7 2014 It is concluded that celecoxib can inhibit the proliferation of HL-60 cells in dose-dependent manner, celecoxib causes cell G0/G1 arrest and induces cell apoptosis possibly through down-regulation of the cyclin D1 and cyclin E1 expression, and down-regulation of COX-2 expression respectively. Celecoxib 102-111 mitochondrially encoded cytochrome c oxidase II Homo sapiens 263-268 24637636-0 2014 COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis. Celecoxib 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 24637636-5 2014 This production is abrogated after celecoxib treatment, targeting the COX-2 isoenzyme involved in PGE2 synthesis. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 24637636-8 2014 We provide evidence that celecoxib affects proliferation and sensitizes NHL B-cell lines to apoptosis through COX-2-independent effects by slowing down the cell cycle and decreasing the expression of survival proteins, such as Mcl-1. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 110-115 24802614-3 2014 METHODS: Prostate cancer LNCaP, 22Rv1, and PC3 cells were cultured and treated with the COX-2 inhibitors celecoxib and CAY10404. Celecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 88-93 24802614-8 2014 RESULTS: Treatment with the COX-2 inhibitors celecoxib and CAY10404 or knockdown of COX-2 significantly inhibited prostate cancer cell proliferation. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 24959102-2 2014 The combinations of retinoids and celecoxib as a COX-2 inhibitor were reported to be effective in some regimens of metronomic therapy of relapsed solid tumors with poor prognosis. Celecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 49-54 24959102-7 2014 Caffeic acid (an inhibitor of 5-LOX) and celecoxib (an inhibitor on COX-2) were used in combined treatment with ATRA. Celecoxib 41-50 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 24794773-5 2014 Compound 15d appeared selectivity index (COX-2/COX-1) almost the half of celecoxib while 15c is non-selective for COX-2. Celecoxib 73-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 24474408-2 2014 In this study, we examined the effect of the selective COX-2 inhibitor, celecoxib, on the rates of HO after THA. Celecoxib 72-81 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 24640603-1 2014 Celecoxib is a selective inhibitor of COX-2, whose connection with the development and progression of human tumors has been extensively studied. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 24518515-2 2014 Celecoxib is a selective COX-2 inhibitor and reported to prevent the progression of prostate cancer. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 24518515-9 2014 CONCLUSIONS: Celecoxib exerts antitumor activity through EP2 signaling regulating AR and COX-2 expression. Celecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 89-94 24156425-0 2013 [COX-2 inhibitor celecoxib can suppress the proliferation of FLT3-ITD positive acute myeloid leukemia cells with prominent down regulation of MEK/MCL-1 expression in vitro]. Celecoxib 17-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 1-6 24460806-2 2014 We hypothesized that the COX-2 inhibitor celecoxib alters atrial electrophysiology, and thus promotes the development of AF. Celecoxib 41-50 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 24854838-5 2014 RESULTS: Celecoxib enhances radiation cytotoxicity in C666-1 and CNE-1 nasopharyngeal carcinoma cells that expressed high COX-2 but not in CNE-2 cells that expressed low COX-2. Celecoxib 9-18 mitochondrially encoded cytochrome c oxidase II Homo sapiens 122-127 24854838-5 2014 RESULTS: Celecoxib enhances radiation cytotoxicity in C666-1 and CNE-1 nasopharyngeal carcinoma cells that expressed high COX-2 but not in CNE-2 cells that expressed low COX-2. Celecoxib 9-18 mitochondrially encoded cytochrome c oxidase II Homo sapiens 170-175 24854838-6 2014 The radiosensitization of celecoxib in C666-1 cells disappeared after the COX-2 knocked down, while the CNE-2 cells were radiosensitized by celecoxib after the transfection of COX-2. Celecoxib 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 176-181 25258584-2 2014 Previous studies showed that the selective cyclooxygenase (COX)-2 inhibitor celecoxib can enhance the tumor response to radiotherapy. Celecoxib 76-85 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-65 24570829-10 2013 The COX-2 inhibition potency and selectivity index for test compounds 2a-b were as follows; celecoxib > 2b > 2a. Celecoxib 92-101 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 24854838-6 2014 The radiosensitization of celecoxib in C666-1 cells disappeared after the COX-2 knocked down, while the CNE-2 cells were radiosensitized by celecoxib after the transfection of COX-2. Celecoxib 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 74-79 23778325-0 2013 Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. Celecoxib 88-97 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-76 23001685-3 2013 The aim of this study was to evaluate the effects of a selective cyclooxygenase (COX)-2 inhibitor, celecoxib, on synovial fluids and tissues in severely osteoarthritic knees. Celecoxib 99-108 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-87 23817417-6 2013 Importantly, treatment with celecoxib, a COX-2 inhibitor, resulted in significantly lower PGE2 and IL-17A, but not IFN-gamma, production. Celecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 23899748-2 2013 This study assesses the chronic effects of celecoxib (selective COX-2 inhibitor) versus diclofenac (non-selective NSAID) therapy on arterial dysfunction in patients with rheumatoid arthritis (RA). Celecoxib 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-69 23682075-2 2013 The ability of celecoxib, a selective COX-2 inhibitor, to redirect arachidonic acid into the 5-LO pathway can potentially reduce its efficacy as a chemopreventive agent and increase the risk of cardiovascular complications. Celecoxib 15-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 23682075-10 2013 Combining celecoxib and zileuton was associated with inhibition of both the COX-2 and 5-LO pathways manifested as reduced levels of urinary PGE-M and LTE4. Celecoxib 10-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 76-87 23331485-11 2013 CONCLUSION: The COX inhibitors indomethacin and celecoxib reduce the expression of inflammatory factors, such as COX-2 and IL-6, in FLS from the TMJ via suppression of PGE2 production. Celecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 23167625-12 2013 Reduced COX-2 expression was found with decreased p53 in LNCaP and PC-3 cells that were exposed to >= 20 muM of celecoxib for 72 h, but COX-2 expression was increased in DU145 cells. Celecoxib 115-124 mitochondrially encoded cytochrome c oxidase II Homo sapiens 8-13 23670888-5 2013 Compound 2b had a better selectivity ratio (COX-1/COX-2) compared to that of celecoxib and can be used as a novel template for the design of selective COX-2 inhibitors. Celecoxib 77-86 mitochondrially encoded cytochrome c oxidase II Homo sapiens 151-156 23307337-2 2013 In this work, we interfere pharmacologically with those states that produce peripheral and central sensitisation after an acute inflammatory process, inhibiting at the periphery the COX-2 with celecoxib and using taurine (glycine A receptor agonist) for central pain relief. Celecoxib 193-202 mitochondrially encoded cytochrome c oxidase II Homo sapiens 182-187 23454135-1 2013 Selective COX-2 inhibitors (COXib) belonging to the class of diaryl heterocycles (e.g., celecoxib, rofecoxib, etc. Celecoxib 88-97 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 23031659-8 2013 COX-2 inhibitors were well tolerated in the majority of the patients [nimesulide: 91.9%; meloxicam: 90.2%; rofecoxib: 94.9%; and celecoxib: 94.9%)]. Celecoxib 129-138 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 23565678-1 2013 Celecoxib, a tricyclic compound having pyrazole ring exhibits an excellent level of antiinflammatory action against COX-2 enzymes and some of its analogs act as anticancer and antibacterial agents. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 116-121 23167625-0 2013 Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. Celecoxib 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 23167625-1 2013 Celecoxib is a clinically available COX-2 inhibitor that has been reported to have antineoplastic activity. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 23010081-1 2013 The COX-2 inhibitor Celecoxib, tested in phase III trials for the prevention of sporadic colon adenomas, reduced the appearance of new adenomas, but was unable to affect the incidence of colon cancer. Celecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 23731702-3 2013 Celecoxib (CXB), a selective COX-2 inhibitor, suppresses VEGF gene expression by targeting the VEGF promoter responsible for its inhibitory effect. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 23731702-3 2013 Celecoxib (CXB), a selective COX-2 inhibitor, suppresses VEGF gene expression by targeting the VEGF promoter responsible for its inhibitory effect. Celecoxib 11-14 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 23737956-8 2013 Pretreatment with a COX-2 inhibitor (celecoxib) abrogated the UA-induced cell proliferation. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 20-25 23706161-4 2013 RESULTS: Treatment of breast cancer cell lines with lapatinib and OSU-03012 (a small molecule derivative of the Cox-2 inhibitor celecoxib) induced synergistic cytotoxic/cytostatic effects. Celecoxib 128-137 mitochondrially encoded cytochrome c oxidase II Homo sapiens 112-117 23067366-2 2013 Short-term 8-week celecoxib, a selective COX-2 inhibitor, exerts a preliminary hint to improve regression in part for persistent IM after Helicobacter pylori eradication. Celecoxib 18-27 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 23067366-10 2013 Even in the patients without IM regression, the mean IM scores and COX-2 expressions were significantly more decreased in the celecoxib group than in the controls (p < .005). Celecoxib 126-135 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 24520457-3 2013 Celecoxib is a selective inhibitor of COX-2 with numerous pharmacologic functions. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 23268707-10 2013 Apoptosis was induced in irradiated cells 48 hours after treatment with celecoxib dependent of COX-2. Celecoxib 72-81 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 23402310-1 2013 BACKGROUND: Celecoxib is a selective cyclooxygenase (COX)-2 inhibitor that has been reported to reduce the risk of breast cancer. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-59 23245395-2 2013 The aim of the present study was to investigate the effect of celecoxib, a COX-2 inhibitor, on CD133 expression in HT29 and DLD1 cells. Celecoxib 62-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 24211633-2 2013 The compound 3f exhibited potent selective COX-2 inhibition of 59.48% in comparison to standard drug celecoxib (66.36% inhibition). Celecoxib 101-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 23036953-6 2012 COX-2 docking score of the active compound 5i was found to be better than standard celecoxib. Celecoxib 83-92 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 23358696-1 2013 BACKGROUND AND PURPOSE: Celecoxib (CXB) is a widely prescribed COX-2 inhibitor used clinically to treat pain and inflammation. Celecoxib 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 23358696-1 2013 BACKGROUND AND PURPOSE: Celecoxib (CXB) is a widely prescribed COX-2 inhibitor used clinically to treat pain and inflammation. Celecoxib 35-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 23358696-2 2013 Recently, COX-2 independent mechanisms have been described to be the targets of CXB. Celecoxib 80-83 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 23358696-6 2013 Our study was aimed at establishing the role of COX-2 independent M current activation in the analgesic action of CXB. Celecoxib 114-117 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 23358696-9 2013 We found that CXB, UMC and DMC concentration-dependently activated Kv7.2/7.3 channels expressed in HEK293 cells and the M-type current in dorsal root ganglia neurons, negatively shifted I-V curve of Kv7.2/7.3 channels, with a potency and efficiency inverse to their COX-2 inhibitory potential. Celecoxib 14-17 mitochondrially encoded cytochrome c oxidase II Homo sapiens 266-271 23249419-3 2012 This study investigated the antitumor effects of the selective COX-2 inhibitor, Celecoxib, on breast cancer in vitro and in vivo. Celecoxib 80-89 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 23249419-11 2012 Celecoxib effectively down-regulated the expression of COX-2. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 23114124-0 2012 [Effects of COX-2 inhibitor celecoxib on expressions of VEGF, b-FGF and TGF-beta mRNA in acute leukemia cells]. Celecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 12-17 22890064-6 2012 A clinical trial showed that celecoxib, a cyclooxygenase (COX)-2 inhibitor, significantly reduced the number of colorectal polyps in children with familial adenomatous polyposis (FAP). Celecoxib 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-64 22735362-1 2012 AIM: To prospectively study the clinical renal effects of daily high-dose celecoxib, a COX-2 inhibitor, in a cohort of elderly sick men (mean age 74.5 years) with advanced prostate cancer. Celecoxib 74-83 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-92 23114124-6 2012 It is concluded that COX-2 inhibitor celecoxib can inhabit vascular endothelial growth through down-regulating the mRNA expression of VEGF, b-FGF and TGF-beta in acute leukemia cells. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 22159752-7 2012 RESULTS: The co-treatment with celecoxib enhanced NPC-16-induced apoptosis in HCT116 (COX-2 no expression), HT29 (COX-2 higher expression) and Caco-2 (COX-2 higher expression) colorectal cancer cells, which was mediated by the elevated NPC-16 uptake via the effect of celecoxib on polyamine metabolism, including the up-regulated spermidine/spermine N(1)-acetyltransferase (SSAT) activity and reduced intracellular polyamine levels. Celecoxib 31-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 86-91 22159752-0 2012 COX-2-independent induction of apoptosis by celecoxib and polyamine naphthalimide conjugate mediated by polyamine depression in colorectal cancer cell lines. Celecoxib 44-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 23174742-0 2012 Three concerns with regards to the utilization of COX-2 inhibitor (celecoxib) in combination with standard chemoradiotherapy for nasopharyngeal carcinoma. Celecoxib 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 22632102-0 2012 Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis. Celecoxib 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 134-139 22632102-2 2012 N-succinylglutam-1 or 5-yl celecoxib (SG1C and SG5C) were prepared as a colon-specific prodrug of celecoxib, a selective Cox-2 inhibitor, and investigated whether the celecoxib derivatives could deliver celecoxib to the target site and improve cardiovascular toxicity and therapeutic effectiveness for the treatment of familiar adenomatous polyposis. Celecoxib 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 121-126 22898640-10 2012 Strikingly, we also discovered that Sulindac (a COX-1/COX-2 inhibitor) or Celecoxib (a more specific COX-2 inhibitor) block xenograft tumorigenesis from pancreatic cancer cells expressing high levels of HMGA1. Celecoxib 74-83 mitochondrially encoded cytochrome c oxidase II Homo sapiens 101-106 21940785-2 2012 Some clinicians think that HFS is a type of inflammation limited to the hands and feet and can be prevented with a COX-2 inhibitor (celecoxib). Celecoxib 132-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 115-120 22415852-3 2012 In the present study, we explored novel effects of celecoxib (CXB), a COX-2 specific inhibitor, on primary cultures of human ADPKD cyst-lining epithelial cells. Celecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 22159752-7 2012 RESULTS: The co-treatment with celecoxib enhanced NPC-16-induced apoptosis in HCT116 (COX-2 no expression), HT29 (COX-2 higher expression) and Caco-2 (COX-2 higher expression) colorectal cancer cells, which was mediated by the elevated NPC-16 uptake via the effect of celecoxib on polyamine metabolism, including the up-regulated spermidine/spermine N(1)-acetyltransferase (SSAT) activity and reduced intracellular polyamine levels. Celecoxib 31-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 22159752-7 2012 RESULTS: The co-treatment with celecoxib enhanced NPC-16-induced apoptosis in HCT116 (COX-2 no expression), HT29 (COX-2 higher expression) and Caco-2 (COX-2 higher expression) colorectal cancer cells, which was mediated by the elevated NPC-16 uptake via the effect of celecoxib on polyamine metabolism, including the up-regulated spermidine/spermine N(1)-acetyltransferase (SSAT) activity and reduced intracellular polyamine levels. Celecoxib 31-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 22159752-11 2012 CONCLUSIONS: Co-treatment of celecoxib and NPC-16 could induce colorectal cancer cell apoptosis via COX-2-independent and caspase-dependent mechanisms. Celecoxib 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 21699540-6 2012 COX-2 gene deletion, chronic treatment with the COX-2 selective inhibitor celecoxib, or with the EP2 receptor antagonist AH6809 reduced cuprizone-induced oligodendrocyte apoptosis, the degree of demyelination and motor dysfunction. Celecoxib 74-83 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 21835258-0 2012 The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function. Celecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 22934397-7 2012 Patients of the control group were treated by oral administration of Celebrex (a specific inhibitor of COX-2, 200 mg/time, once daily, 4 weeks together). Celecoxib 69-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 103-108 22262921-11 2012 In conclusion, inhibition of tumor COX-2-dependent PGE(2) by celecoxib may reduce tumor progression. Celecoxib 61-70 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 21983014-1 2012 Dimethylcelecoxib, a non-COX-2 inhibiting derivative of celecoxib, inhibits PGE(2) synthesis by transcriptional inhibition of mPGES-1. Celecoxib 8-17 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 22891999-14 2012 Furthermore, celecoxib, a selective COX-2 inhibitor, regulated numerous genes in cartilage, which are linked to the NFkB and AP-1 pathways at the mRNA level. Celecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 23394447-8 2012 Pretreatment with celecoxib inhibited nicotine-induced change in the expression of VEGF and COX-2. Celecoxib 18-27 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 23394447-10 2012 This effect can be blocked by celecoxib, suggesting an interaction of nicotine and COX-2 pathways. Celecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 21847707-2 2012 Celecoxib, the selective COX-2 nonsteroidal anti-inflammatory drug, has anti-neoplastic activity against several malignancies. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 21847707-3 2012 Accumulating evidence suggests that several COX-2-independent mechanisms may also be involved in the anti-tumor effects of celecoxib. Celecoxib 123-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 22366264-2 2012 We investigated the in vitro effects on cell proliferation, apoptosis, and COX-2 expression of the potential chemopreventives celecoxib and tauro-ursodeoxycholic acid (UDCA). Celecoxib 126-135 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 23552603-5 2012 We demonstrate that COX-2 inhibition, via its chemical inhibitors (NS-398 or celecoxib), reduced v-FLIP/K13-mediated NF-kappaB induction, and extracellular matrix (ECM) interaction-mediated signaling, mitochondrial antioxidant enzyme manganese superoxide dismutase (MnSOD) levels, and subsequently downregulated detachment-induced apoptosis (anoikis) resistance. Celecoxib 77-86 mitochondrially encoded cytochrome c oxidase II Homo sapiens 20-25 21835258-3 2012 Using the MTT method, we investigated the influence of the COX-2 selective inhibitor Celecoxib on the proliferation of KB/VCR oral cancer cell lines and analyzed the effect of Celecoxib on the regulation of P-glycoprotein (P-gp) expression and function. Celecoxib 85-94 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 22187234-2 2012 We investigated the effect of a short-term therapy of celecoxib, a COX-2 inhibitor, with or without doxycycline, an MMP inhibitor, after coronary stenting on inflammatory biomarkers and neointimal hyperplasia. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 22141388-1 2011 Celecoxib (Celebrex ) was the first cyclo-oxygenase (COX)-2 selective inhibitor (coxib) to be introduced into clinical practice. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-59 22141388-1 2011 Celecoxib (Celebrex ) was the first cyclo-oxygenase (COX)-2 selective inhibitor (coxib) to be introduced into clinical practice. Celecoxib 11-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-59 21778329-7 2011 Is the efficacy of celecoxib in particular or NSAIDs in general due to their off-target effects or to their effects on COX-1 and COX-2? Celecoxib 19-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 129-134 21807123-7 2011 The COX-2 inhibitor celecoxib blocked IFN-alpha-induced COX-2 expression, 5-HT uptake and activation of Akt, ERK and STAT. Celecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 21807123-7 2011 The COX-2 inhibitor celecoxib blocked IFN-alpha-induced COX-2 expression, 5-HT uptake and activation of Akt, ERK and STAT. Celecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 56-61 21993002-2 2011 COX-2 inhibitor celecoxib displays inhibitory effects in pancreatic cancer cell growth. Celecoxib 16-25 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 21896649-3 2011 In this issue of the journal (beginning on page 1580), Sabichi and colleagues report the first phase II randomized controlled trial of the COX-2 inhibitor celecoxib in bladder cancer. Celecoxib 155-164 mitochondrially encoded cytochrome c oxidase II Homo sapiens 139-144 21886896-3 2011 It was more selective than the reference drug celecoxib (COX-2 IC(50) = 0.060 muM; selectivity index = 405). Celecoxib 46-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 21868755-1 2011 Celecoxib is a COX-2 inhibitor that reduces the risk of colon cancer. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 21729671-1 2011 PURPOSE: Within breast tissue, aromatase expression and activity is increased by prostaglandin E2, providing a rationale for combining the COX-2 inhibitor celecoxib with an aromatase inhibitor. Celecoxib 155-164 mitochondrially encoded cytochrome c oxidase II Homo sapiens 139-144 21567098-1 2011 Increasing evidence suggests that celecoxib, a COX-2 inhibitor with potent anticancer activity exerts its effects not only through COX-2, but also through COX-2-independent mechanisms. Celecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 47-52 21567098-1 2011 Increasing evidence suggests that celecoxib, a COX-2 inhibitor with potent anticancer activity exerts its effects not only through COX-2, but also through COX-2-independent mechanisms. Celecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 131-136 21567098-1 2011 Increasing evidence suggests that celecoxib, a COX-2 inhibitor with potent anticancer activity exerts its effects not only through COX-2, but also through COX-2-independent mechanisms. Celecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 131-136 21936449-0 2011 COX-2 inhibitor, celecoxib, may prevent lung cancer. Celecoxib 17-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 21796157-0 2011 Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 103-108 21796157-4 2011 ABL enhanced the apoptotic effect of celecoxib in COX-2-expressing cells, but had little effect in COX-2-negative cells. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 21946257-10 2011 The antiviral drug valganciclovir and the specific COX-2 inhibitor celecoxib prevented HCMV replication in vitro and inhibited PGE2 production and reduced medulloblastoma tumor cell growth both in vitro and in vivo. Celecoxib 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-56 21763744-5 2011 COX-2 inhibitor Celecoxib reduced self renewal capacity and increased apoptosis of both control and IL-1beta treated CSCs. Celecoxib 16-25 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 21488638-5 2011 We then performed late-stage, site-selective diversification of a sulfonamide drug candidate containing multiple potentially reactive C-H bonds to synthesize directly novel celecoxib analogues as potential cyclooxygenase-II (COX-2)-specific inhibitors. Celecoxib 173-182 mitochondrially encoded cytochrome c oxidase II Homo sapiens 225-230 21113620-3 2011 Based on this, we believed that a selected COX-2 inhibitor (celecoxib, Pfizer Pharmaceuticals LLC) could ease HFS. Celecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 21688615-4 2011 Two drugs recently approved for health insurance reimbursement, celecoxib, a cyclooxygenase (COX)-2 specific inhibitor and low-dose lansoprazole for prevention of recurrent peptic ulcer due to LDA/NSAIDs will be instrumental in mitigating the gastrointestinal injuries. Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-99 21627839-2 2011 We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients. Celecoxib 103-112 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-92 21826992-7 2011 CONCLUSION: Celecoxib has reversal effect on MDR in MCF-7/Taxol cells, it"s possible mechanism might be related to reduce the protein expression of COX-2, the inhibition of P-gp, BCRP mRNA and protein overexpression. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 148-153 21540248-4 2011 Furthermore, N-acetyl-l-cysteine (NAC, a radical scavenger) and celecoxib (a Cox-2 inhibitor) were used to explore the molecular mechanism. Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-82 21540248-9 2011 Moreover, celecoxib significantly decreased Cox-2, MMP-2 and PGE2 expression and inhibited invasion/migration activity in As(2)O(3)-treated cells (P < 0.05), indicating that As(2)O(3) inhibits invasion/migration by regulating the expression of Cox-2/PGE2/MMP-2. Celecoxib 10-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 21540248-9 2011 Moreover, celecoxib significantly decreased Cox-2, MMP-2 and PGE2 expression and inhibited invasion/migration activity in As(2)O(3)-treated cells (P < 0.05), indicating that As(2)O(3) inhibits invasion/migration by regulating the expression of Cox-2/PGE2/MMP-2. Celecoxib 10-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 247-252 21140284-0 2011 Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Celecoxib 45-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 21140284-3 2011 Here, we evaluated the antiproliferative activity of celecoxib, a selective COX-2 inhibitor, and its nitro-oxy derivative on human breast cancer cells characterized by low and high COX-2 expression, respectively. Celecoxib 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 76-81 22104269-1 2011 To investigate genes regulated by COX-2 or a COX-2 specific inhibitor, celecoxib, in irradiated cancer cells, we analyzed changes in gene expression using complementary DNA microarray following celecoxib or combined celecoxib and ionizing radiation (IR) treatment in a stable COX-2 knockdown A549 (AS) and a mock cell line (AN). Celecoxib 71-80 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 20817448-4 2011 The assay was validated using four COX inhibitors, celecoxib, indomethacin, resveratrol, and diclofenac that exhibit different selectivities towards COX-1 and COX-2. Celecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 159-164 20817448-5 2011 The IC(50) values of celecoxib and resveratrol for ovine and human COX-2 were compared, and the K(m) values were determined. Celecoxib 21-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 21955617-3 2011 Besides its anti-inflammatory properties, evidence is accumulating that celecoxib, one of the selective COX-2 inhibitors, has additional disease-modifying effects. Celecoxib 72-81 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-109 21955617-5 2011 As well as COX-2 inhibition, evidence indicates that celecoxib also modulates COX-2-independent signal transduction pathways. Celecoxib 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 11-16 21955617-5 2011 As well as COX-2 inhibition, evidence indicates that celecoxib also modulates COX-2-independent signal transduction pathways. Celecoxib 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 78-83 22114493-1 2011 BACKGROUND: Celecoxib, a cyclo-oxygenase (COX)-2 inhibitor, has been reported to mediate growth inhibitory effects and to induce apoptosis in various cancer cell lines. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-48 20974686-5 2011 Treatment of cells with celecoxib, a COX-2 inhibitor, or transient transfection of cells with COX-2 small interfering RNA, also inhibited cell migration. Celecoxib 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 21084865-1 2011 Celecoxib is a drug designed to selectively inhibit COX-2, an inflammation-inducible cyclooxygenase isoform, over the constitutively expressed COX-1 isoform. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 52-57 20880055-3 2011 OBJECTIVES: Primarily, to assess whether treatment with the COX-2 selective inhibitor celecoxib inhibited biosynthesis of PGD(2) , monitored as urinary excretion of its major tetranor metabolite (PGDM). Celecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 21548865-12 2011 Suppression of COX-2 activity by selective COX-2 inhibitors such as rofecoxib or celecoxib was shown to abolish the production of ATL and to diminish the gastric tolerability of ASA and gastric adaptation developed in response to repetitive administration of this NSAID. Celecoxib 81-90 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 21548865-12 2011 Suppression of COX-2 activity by selective COX-2 inhibitors such as rofecoxib or celecoxib was shown to abolish the production of ATL and to diminish the gastric tolerability of ASA and gastric adaptation developed in response to repetitive administration of this NSAID. Celecoxib 81-90 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 21546775-1 2011 BACKGROUND: The Cox-2 inhibitor, celecoxib (Pfizer Inc., N.Y., USA), is a promising chemopreventive agent [Arber et al. Celecoxib 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 16-21 22104269-1 2011 To investigate genes regulated by COX-2 or a COX-2 specific inhibitor, celecoxib, in irradiated cancer cells, we analyzed changes in gene expression using complementary DNA microarray following celecoxib or combined celecoxib and ionizing radiation (IR) treatment in a stable COX-2 knockdown A549 (AS) and a mock cell line (AN). Celecoxib 71-80 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 22104269-1 2011 To investigate genes regulated by COX-2 or a COX-2 specific inhibitor, celecoxib, in irradiated cancer cells, we analyzed changes in gene expression using complementary DNA microarray following celecoxib or combined celecoxib and ionizing radiation (IR) treatment in a stable COX-2 knockdown A549 (AS) and a mock cell line (AN). Celecoxib 194-203 mitochondrially encoded cytochrome c oxidase II Homo sapiens 34-39 22104269-1 2011 To investigate genes regulated by COX-2 or a COX-2 specific inhibitor, celecoxib, in irradiated cancer cells, we analyzed changes in gene expression using complementary DNA microarray following celecoxib or combined celecoxib and ionizing radiation (IR) treatment in a stable COX-2 knockdown A549 (AS) and a mock cell line (AN). Celecoxib 194-203 mitochondrially encoded cytochrome c oxidase II Homo sapiens 34-39 22104269-5 2011 Among these, celecoxib regulated ras homolog gene family B and mitosin protein expression in a COX-2 dependent manner, especially in irradiated cells. Celecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 22104269-8 2011 We also identified candidate molecules that may be responsible for COX-2-dependent radiosensitization by celecoxib. Celecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 22022384-5 2011 Treatment of cells with celecoxib, a COX-2 inhibitor, also inhibited melanoma cell migration. Celecoxib 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 21220497-2 2011 This led to our interest in assessing the response of glioma cell lines to treatment with celecoxib, a selective COX-2 inhibitor. Celecoxib 90-99 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 20958135-8 2010 Another selective COX-2 inhibitor, celecoxib, did not show potent inhibitory effects as strong as those of NS-398. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-23 21738696-5 2011 Treatment of cells with 12-O-tetradecanoylphorbol-13-acetate, an inducer of COX-2, enhanced the phosphorylation of ERK1/2, a protein of mitogen-activated protein kinase family, and subsequently cell migration whereas both GSPs and celecoxib significantly inhibited 12-O-tetradecanoylphorbol-13-acetate-promoted cell migration as well as phosphorylation of ERK1/2. Celecoxib 231-240 mitochondrially encoded cytochrome c oxidase II Homo sapiens 76-81 20883674-1 2010 Celecoxib is a selective cyclooxygenase (COX)-2 inhibitor used to treat inflammation, while selenium is known to down-regulate the transcription of COX-2 and other pro-inflammatory genes. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-47 20830783-4 2010 The COX-2-specific inhibitor Celecoxib suppressed VEGF-C expression whereas the main COX-2 metabolite PGE(2) elevated VEGF-C expression in Anip973 and AGZY83-a cells in positive and negative experiments. Celecoxib 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 21110338-1 2010 Pyrazolylbenzotriazinones are endowed with a structural analogy with the COX-2 selective inhibitor celecoxib. Celecoxib 99-108 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 21112464-3 2010 Here, we present the case of an elderly depressed woman with acute cognitive deficit who was refractory to multiple antidepressants but only responsive to celecoxib, a COX-2 inhibitor, in acute treatment and sustaining remission for a 5-year treatment course. Celecoxib 155-164 mitochondrially encoded cytochrome c oxidase II Homo sapiens 168-173 20858500-1 2010 Celecoxib is a COX-2 inhibitor that has been related to an increased cardiovascular risk and that exerts several actions on different targets. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 20496179-2 2010 This study was designed to investigate whether celecoxib, a selective COX-2 inhibitor, has effects on retinoid sensitivity in human colon cancer cell lines, and to determine the possible mechanism of said effects. Celecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 21138631-6 2010 Trypan blue exclusion was performed to examine the inhibitory effects of COX-2 selective inhibitor (celecoxib). Celecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 21215211-8 2010 RT-PCR showed that celecoxib reduced the expression of Cox-2 mRNA expression in 25, 50 micromol/L group decreased significantly compared with the control group (respectively, t were 23.950 and 36.651, P < 0.01), but it enhanced the expression of E-cadherin mRNA expression in 25, 50 micromol/L group was significantly higher (respectively, t were 35.829 and 81.497, P < 0.01). Celecoxib 19-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 21036716-2 2010 The aim of this study was to investigate the effects of the COX2 inhibitor celecoxib and the mTOR antagonist rapamycin on angiosarcoma cell lines. Celecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-64 20883058-6 2010 NSAIDs currently available in the US fall into three categories: nonselective NSAIDs that act via inhibition of cyclo-oxygenase (COX)-1 and COX-2; celecoxib, a selective inhibitor of COX-2; and topical NSAIDs that inhibit both COX-1 and COX-2 but result in much less systemic NSAID exposure than oral formulations. Celecoxib 147-156 mitochondrially encoded cytochrome c oxidase II Homo sapiens 183-188 20883058-6 2010 NSAIDs currently available in the US fall into three categories: nonselective NSAIDs that act via inhibition of cyclo-oxygenase (COX)-1 and COX-2; celecoxib, a selective inhibitor of COX-2; and topical NSAIDs that inhibit both COX-1 and COX-2 but result in much less systemic NSAID exposure than oral formulations. Celecoxib 147-156 mitochondrially encoded cytochrome c oxidase II Homo sapiens 183-188 20496179-7 2010 The results showed that celecoxib enhanced the inhibitory effect of ATRA in both COX-2 high-expressing HT-29 and COX-2 low-expressing SW480 cell lines. Celecoxib 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 81-86 20496179-7 2010 The results showed that celecoxib enhanced the inhibitory effect of ATRA in both COX-2 high-expressing HT-29 and COX-2 low-expressing SW480 cell lines. Celecoxib 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 20496179-11 2010 In conclusion, celecoxib increased the expression of RARbeta and the level of cellular ATRA sensitivity through COX-2-independent mechanisms. Celecoxib 15-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 112-117 20678677-3 2010 OBJECTIVE: The aim of this study was to assess the annual incidence of and identify the risk factors for clinical upper GI events in chronic COX-2 inhibitor (celecoxib and etoricoxib) users. Celecoxib 158-167 mitochondrially encoded cytochrome c oxidase II Homo sapiens 141-146 21373319-9 2010 Non-steroidal analgesics and other COX-2 inhibitors (rofecoxib and celecoxib) have been known to precipitate renal failure and hyperkalemia specially in patients at risk for the same; although not unexpected, this may be the first reported case of life-threatening hyperkalemia precipitated by etoricoxib in a previously stable patient having increased risk of renal failure and hyperkalemia. Celecoxib 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 20682995-0 2010 Antiproliferative effect of a novel nitro-oxy derivative of celecoxib in human colon cancer cells: role of COX-2 and nitric oxide. Celecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 107-112 20682995-4 2010 The main findings were that the nitro-oxy derivative behaved like celecoxib in HT-29 cells in terms of COX-2 and ERK/MAPK inhibition, as well as induction of apoptosis, while the benzyl nitrate had no such effects. Celecoxib 66-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 103-108 20539104-3 2010 Selective NSAIDs act on COX-1 (eg, aspirin) or COX-2 (eg, celecoxib) isoenzymes, respectively. Celecoxib 58-67 mitochondrially encoded cytochrome c oxidase II Homo sapiens 47-52 20678677-4 2010 METHODS: A prospective, hospital-based, observational cohort study was conducted in patients taking COX-2 inhibitors (celecoxib or etoricoxib) without comorbidity. Celecoxib 118-127 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 20514441-4 2010 COX-2 inhibitors such as celecoxib are widely recognized to have antitumor activity, but can cause adverse effects. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 20514441-8 2010 NG-nitro-L-arginine-methyl ester (L-NAME) was used as a NOS inhibitor, dihydrochloride (1400W) as an iNOS inhibitor, and celecoxib as a selective COX-2 inhibitor. Celecoxib 121-130 mitochondrially encoded cytochrome c oxidase II Homo sapiens 146-151 20514441-10 2010 Prostaglandin E2 (PGE2) production and COX-2 expression in KB/COX-2 were inhibited not only by celecoxib, but also by L-NAME and 1400W. Celecoxib 95-104 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-44 20514441-10 2010 Prostaglandin E2 (PGE2) production and COX-2 expression in KB/COX-2 were inhibited not only by celecoxib, but also by L-NAME and 1400W. Celecoxib 95-104 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 20514441-11 2010 The decreases in PGE2 production and COX-2 expression were most prominent with celecoxib and L-NAME. Celecoxib 79-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 20514441-12 2010 In vivo, L-NAME and celecoxib significantly inhibited the proliferation of KB/COX-2-xenografted tumors. Celecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 78-83 19739114-6 2010 The anti-proliferative effects were equivalent to those produced by COX-2 inhibitory concentrations of celecoxib and NS-398. Celecoxib 103-112 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 20578837-9 2010 The PI3K/Akt/COX-2 pathway was activated by radiation, whereas celecoxib inhibited the activation of the PI3K/Akt/COX-2 axis through several targets. Celecoxib 63-72 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 20112284-6 2010 Moreover, COX-2-derived PGE(2) production appeared to involve in LPS-induced VCAM-1 expression which was attenuated by pretreatment with selective COX-2 inhibitors (NS-398 and celecoxib), transfection with COX-2 siRNA, or PGE(2) receptor antagonists. Celecoxib 176-185 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 20112284-6 2010 Moreover, COX-2-derived PGE(2) production appeared to involve in LPS-induced VCAM-1 expression which was attenuated by pretreatment with selective COX-2 inhibitors (NS-398 and celecoxib), transfection with COX-2 siRNA, or PGE(2) receptor antagonists. Celecoxib 176-185 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 20112284-6 2010 Moreover, COX-2-derived PGE(2) production appeared to involve in LPS-induced VCAM-1 expression which was attenuated by pretreatment with selective COX-2 inhibitors (NS-398 and celecoxib), transfection with COX-2 siRNA, or PGE(2) receptor antagonists. Celecoxib 176-185 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 21504136-5 2010 The addition of selective COX2 inhibitors Celebrex and curcumin to the culture medium resulted in a significant and comparable inhibition of PGE2 release, but did not inhibit Abeta42 secretion, and even significantly increased Abeta42 production in this cell system. Celecoxib 42-50 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-30 19954924-7 2010 However, combined treatment with subeffective doses of gamma-tocotrienol (0.25 microM) and celecoxib (2.5 microM) resulted in a synergistic antiproliferative effect, as determined by isobologram analysis, and this growth inhibitory effect was associated with a reduction in PGE(2) synthesis, and decrease in COX-2, phospho-Akt (active), and phospho-NFkappaB (active) levels. Celecoxib 91-100 mitochondrially encoded cytochrome c oxidase II Homo sapiens 308-313 19954924-8 2010 These results demonstrate that the synergistic anticancer effects of combined celecoxib and gamma-tocotrienol therapy are mediated by COX-2 dependent and independent mechanisms. Celecoxib 78-87 mitochondrially encoded cytochrome c oxidase II Homo sapiens 134-139 19685055-0 2010 Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 19685055-2 2010 Celecoxib, a selective inhibitor of COX-2, at 25 microM concentration increased the accumulation of doxorubicin in HepG2 cells and enhanced the sensitivity of the cells to doxorubicin by tenfold. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 19685055-3 2010 The induction of MDR1 expression by PGE2 and its downregulation by celecoxib or by COX-2 knockdown suggests that the enhanced sensitivity of HepG2 cells to doxorubicin by celecoxib is mediated by the downregulation of MDR1 expression, through COX-2-dependent mechanism. Celecoxib 171-180 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 19954924-1 2010 The selective cyclooxygenase (COX)-2 inhibitor, celecoxib, and the vitamin E isoform, gamma-tocotrienol, both display potent anticancer activity. Celecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-36 20202516-5 2010 In a separate protocol, 18 volunteers received the COX-2 inhibitor celecoxib (200 mg orally twice daily) for 5 days. Celecoxib 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-56 20233202-2 2010 We tested the hypothesis that the co-administration of aspirin with either the selective COX-2 inhibitor celecoxib or the nonselective COX inhibitor ibuprofen reduces ATL biosynthesis. Celecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 89-94 20193113-1 2010 BACKGROUND AND OBJECTIVE: Celecoxib, one of the new generation of non-steroidal anti-inflammatory drugs (NSAIDs), has a specific inhibitory effect on COX-2. Celecoxib 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 150-155 20197018-4 2010 This case report describes our experience with Celecoxib, a COX-2 inhibitor, in a 12-year-old boy. Celecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 20061161-3 2010 Among the 2,3-diarylquinolines, 2-(4-(methylsulfonyl) phenyl)-3-phenylquinoline-4-carboxylic acid (8) exhibited the highest potency and selectivity for COX-2 inhibitory activity (COX-2 IC(50)=0.07 microM; selectivity index=687.1) that was more selective than the reference drug celecoxib (COX-2 IC(50)=0.06 microM; selectivity index=405). Celecoxib 278-287 mitochondrially encoded cytochrome c oxidase II Homo sapiens 152-157 20004565-0 2010 COX-2 expression in chondrosarcoma: a role for celecoxib treatment? Celecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 20004565-12 2010 We confirmed the expression of COX-2 in 65% of chondrosarcomas, and COX-2 inhibition by celecoxib diminished cell viability in vitro. Celecoxib 88-97 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 19923064-1 2009 OBJECTIVE: To investigate the role of COX-2 inhibitor celecoxib in inhibiting the migration of human tongue squamous cell carcinoma Tca8113 cells. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 21351468-2 2009 The present study was designed to investigate whether celecoxib (selective COX-2 inhibitor) has effects on cellular retinoid sensitivity of human colon cancer cell lines and its possible mechanism. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 21351468-7 2009 The results showed that celecoxib enhanced the inhibitory effect of ATRA in both COX-2 high-expressing HT-29 and COX-2 low-expressing SW480 cell lines. Celecoxib 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 81-86 21351468-7 2009 The results showed that celecoxib enhanced the inhibitory effect of ATRA in both COX-2 high-expressing HT-29 and COX-2 low-expressing SW480 cell lines. Celecoxib 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 21351468-12 2009 In conclusion, celecoxib increased expression of RARbeta and cellular ATRA sensitivity through COX-2-independent mechanisms, which may provide a potential strategy for combination therapy. Celecoxib 15-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 19673886-2 2009 We evaluated the antitumor effect of irinotecan (CPT-11) treatment combined with prolonged very low-dose administration of celecoxib, a selective COX-2 inhibitor, against three human NB xenografts, TNB9, TS-N-2nu, and TS-N-5nu. Celecoxib 123-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 146-151 19558494-4 2009 Baicalein (a 12-LOX inhibitor) and celecoxib (a COX-2 inhibitor) significantly reduced thymidine incorporation, whereas 12-(R)-HETE and 12-(S)-HETE (12-LOX metabolites) and PGE(2) (COX-2 metabolite) significantly enhanced thymidine incorporation, suggesting a role for these enzymes in the regulation of A431 cell proliferation. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 19558494-4 2009 Baicalein (a 12-LOX inhibitor) and celecoxib (a COX-2 inhibitor) significantly reduced thymidine incorporation, whereas 12-(R)-HETE and 12-(S)-HETE (12-LOX metabolites) and PGE(2) (COX-2 metabolite) significantly enhanced thymidine incorporation, suggesting a role for these enzymes in the regulation of A431 cell proliferation. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 181-186 19802504-0 2010 Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. Celecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 19802504-3 2010 We carried out a prospective phase II clinical trial to test the safety and effectiveness of an intervention with the COX-2 inhibitor celecoxib (300 mg/day for 4 months) on key variables of cachexia (lean body mass, resting energy expenditure, serum levels of proinflammatory cytokines, and fatigue) in patients with advanced cancer at different sites. Celecoxib 134-143 mitochondrially encoded cytochrome c oxidase II Homo sapiens 118-123 19802504-9 2010 Our results showed that the COX-2 selective inhibitor celecoxib is an effective single agent for the treatment of cancer cachexia. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 21351468-0 2009 [Celecoxib increased cellular ATRA sensitivity of human colon cancer cell lines through COX-2-independent mechanisms]. Celecoxib 1-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 88-93 19923064-5 2009 CONCLUSION: COX-2 inhibitor celecoxib can inhibit Tca8113 cell migration, the mechanism of which awaits further investigation. Celecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 12-17 19999807-6 2009 In in vivo studies performed on animals exposed to chemical carcinogens, the chemopreventive effect was achieved exclusively after administration of experimental selective COX-2 inhibitors, but in the only human trial, supplementation of selective COX-2 inhibitor--celecoxib turned out ineffective. Celecoxib 265-274 mitochondrially encoded cytochrome c oxidase II Homo sapiens 248-253 19769252-1 2009 OBJECTIVE: To observe whether Celecoxib could inhibit the growth, regulate the expression of COX-2 and induce apoptosis of Tca8113 cells. Celecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 93-98 19641861-1 2009 Celecoxib is a selective cyclooxygenase-2-(COX-2)-inhibitor used to treat inflammation and pain and prevents colorectal cancer in patients at high doses by affecting several non-COX-2 proteins. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 19641861-1 2009 Celecoxib is a selective cyclooxygenase-2-(COX-2)-inhibitor used to treat inflammation and pain and prevents colorectal cancer in patients at high doses by affecting several non-COX-2 proteins. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 178-183 19641861-3 2009 Therefore, we speculated that celecoxib might accumulate in human cells, which may facilitate the drug"s interaction with non-COX-2 proteins. Celecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 126-131 19641861-6 2009 Consequently, celecoxib disturbed the plasma membrane integrity of HCT-116 cells and displayed an increased COX-2-inhibitory potency in HCA-7 cells. Celecoxib 14-23 mitochondrially encoded cytochrome c oxidase II Homo sapiens 108-113 19641861-8 2009 Accumulation of celecoxib in human cells may provide a novel molecular basis for the ability of the drug to interact with non-COX-2 targets in vivo despite comparatively low plasma concentrations. Celecoxib 16-25 mitochondrially encoded cytochrome c oxidase II Homo sapiens 126-131 19796390-6 2009 BER shows synergistic effects with some existing anticancer agents such as trichostatin A (TSA, the histone deacetylase inhibitor), celecoxib (the inhibitor of COX-2), and carmofur against the growth of MDA-MB-231 cells. Celecoxib 132-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 160-165 19563267-6 2009 CONCLUSION: Structural analogues of the COX-2 inhibitors celecoxib and valdecoxib, and novel potential pyridazine, triazole, indole and thione derivatives emerge as promising leads for the treatment of inflammation, pain and other diseases. Celecoxib 57-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 20120857-2 2009 METHOD: A combination of tarceva (EGFR-selective tyrosine kinase inhibitors) with celecoxib (Cox-2 inhibitor) was studied on its effects on cell growth, cell cycle progression, apoptosis and protein expression in CNE-2 cell lines by cell growth assay, flow cytometric analysis assay and Western blotting. Celecoxib 82-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 93-98 19706164-3 2009 The role of p53 mutation in the anti-tumour responses of the selective COX-2 inhibitor celecoxib in human glioblastoma cells is unknown. Celecoxib 87-96 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 19747744-1 2009 PURPOSE: To assess the feasibility and efficacy of the COX-2 inhibitor celecoxib in conjunction with preoperative chemoradiation for patients with locally advanced rectal cancer in a double blind randomized phase II study. Celecoxib 71-80 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 19769252-5 2009 RESULTS: COX-2 protein was strongly expressed in Tca8113 cells and was suppressed by Celecoxib. Celecoxib 85-94 mitochondrially encoded cytochrome c oxidase II Homo sapiens 9-14 19769252-9 2009 CONCLUSION: Celecoxib shows a significant effect on inhibiting expression of COX-2 in Tca8113 cells, this is probably related to growth inhibition and inducing apoptosis of Tca8113 cells. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-82 19734595-12 2009 CONCLUSION: The multimodal use of the specific COX-2 inhibitor celecoxib in the postoperative period of orthopaedic procedures clearly improves postoperative pain, reduces the opioid consumption, releases the sleep disturbance, demonstrates more satisfaction in patients and lower chronic pain rate after discharge, without affecting the platelet and coagulation function. Celecoxib 63-72 mitochondrially encoded cytochrome c oxidase II Homo sapiens 47-52 19635408-6 2009 We identified novel mechanisms for existing drugs, confirmed previously reported calcium modulating activity for COX-2 inhibitor celecoxib, and identified an additional mechanism for the experimental compound monastrol. Celecoxib 129-138 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 19155154-1 2009 The determination of two sulphur-containing drugs, the COX-2 inhibitors celecoxib and etoricoxib, in the serum and synovial fluid of inflammatory arthritis patients, is described using a sensitive ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy (UPLC/ICPMS) method. Celecoxib 72-81 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 19426794-3 2009 Nanosuspensions of celecoxib, a selective COX-2 inhibitor with low water solubility, were produced by the emulsion-diffusion method using three different stabilizers (Tween) 80, PVP K-30 and SDS) and characterized by particle size analysis, dissolution testing, scanning electron microscopy imaging, differential scanning calorimetry and X-ray powder diffraction. Celecoxib 19-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 19530988-3 2009 Attempts to identify selective inhibitors of COX-2, led to the identification of celecoxib and rofecoxib. Celecoxib 81-90 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 19363520-9 2009 Furthermore, forced expression of DeltaNp73(AS) results in diminished apoptosis in response to the selective COX-2 inhibitor celecoxib. Celecoxib 125-134 mitochondrially encoded cytochrome c oxidase II Homo sapiens 109-114 19266367-1 2009 We performed a phase II trial to test whether a cyclooxygenase (COX-2) inhibitor, celecoxib, added to standard first-line combination chemotherapy (CT) and as maintenance therapy would improve outcomes in extensive-stage (ES) small-cell lung cancer (SCLC). Celecoxib 82-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-69 21556247-3 2009 Raloxifene analogue, Ly117018, a selective estrogen receptor modulator and celecoxib, a specific COX-2 inhibitor have been shown to inhibit breast cancer cell proliferation when used alone in vitro and in vivo. Celecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 19254941-4 2009 This review describes the utility of AI plus COX-2 inhibitor therapy and discusses the completed and ongoing clinical trials investigating treatment with the AI exemestane and the COX-2 inhibitor celecoxib in the neo-adjuvant and metastatic breast cancer settings. Celecoxib 196-205 mitochondrially encoded cytochrome c oxidase II Homo sapiens 180-185 19336730-1 2009 The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer. Celecoxib 118-127 mitochondrially encoded cytochrome c oxidase II Homo sapiens 84-106 19048457-2 2009 Since selective inhibition of COX-2, for example, by celecoxib has been shown to suppress both tumour formation and progression, we investigated COX-2 protein expression in a series of ATC and AST (26 cases each) using immunohistochemistry. Celecoxib 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 18926729-1 2009 OBJECTIVE: Recent in vitro studies showed that celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, protects human osteoarthritic cartilage tissue from degeneration. Celecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-92 19234885-5 2009 We investigated whether celecoxib, a selective Cox-2 inhibitor, increases prosthesis migration in total knee replacement (TKR). Celecoxib 24-33 mitochondrially encoded cytochrome c oxidase II Homo sapiens 47-52 18617357-6 2009 When COX-2 antisense cDNA and COX-2 inhibitor celecoxib were combined, the tumor growth inhibition rate was further increased up to 88.78+/-3.10%. Celecoxib 46-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 18617357-7 2009 These results provide evidence that celecoxib has potential therapeutic effect on bladder cancer, and the joint use of COX-2 antisense cDNA with celecoxib may improve their individual therapeutic effect, especially significantly increase the growth inhibitory effect of COX-2 antisense cDNA. Celecoxib 145-154 mitochondrially encoded cytochrome c oxidase II Homo sapiens 270-275 19451093-1 2009 BACKGROUND: We performed a pilot study, looking at the COX-2 inhibitor celecoxib, on newly diagnosed prostate cancer patients in the neo-adjuvant setting using DNA microarray analysis. Celecoxib 71-80 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 19576016-1 2009 OBJECTIVE: To investigate the role of COX-2 inhibitor celecoxib in enhancing the lethal effects of bleomycin in Tca8113 cell line. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 18823436-0 2009 Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. Celecoxib 31-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 54-59 19075637-8 2008 This provided the rationale to target cox-2 enzyme and development of cox-2 selective drugs such as Vioxx and Celebrex. Celecoxib 110-118 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 19567186-9 2009 Celecoxib, the selective COX-2 inhibitor, reduces the expression of COX-2 protein and promotes cell apoptosis induced by CSE in vascular endothelial cells. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 19567186-9 2009 Celecoxib, the selective COX-2 inhibitor, reduces the expression of COX-2 protein and promotes cell apoptosis induced by CSE in vascular endothelial cells. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 18712436-1 2009 BACKGROUND: In 2005 we reported a study on the efficacy of the preoperative use of the selective COX-2 inhibitor celecoxib (Celebrex) for reducing both postoperative pain and opioid requirements in patients undergoing bilateral subpectoral breast augmentation. Celecoxib 113-122 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 18712436-1 2009 BACKGROUND: In 2005 we reported a study on the efficacy of the preoperative use of the selective COX-2 inhibitor celecoxib (Celebrex) for reducing both postoperative pain and opioid requirements in patients undergoing bilateral subpectoral breast augmentation. Celecoxib 124-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 19940363-5 2009 RESULTS: Down-regulation of COX-2 by celecoxib led to up-regulation of E-cadherin mRNA and protein levels in conventional gastric cancer cell lines, whereas expression was down regulated in the early-onset gastric cancer (EOGC) cell line. Celecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 19327236-1 2009 BACKGROUND AND OBJECTIVE: The selective COX-2 inhibitor celecoxib is widely used to treat pain and inflammation in rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Celecoxib 56-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 19013259-13 2009 CONCLUSIONS: That there was a decrease for the celecoxib over the placebo group adds to the body of evidence that relates COX-2 specific inhibitors and cancer incidence. Celecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 122-127 19444759-3 2009 The cells were cultured with 0, 10, or 100 U/mL IL-1beta with or without 1 muM celecoxib, a specific inhibitor of COX-2, for up to 28 days. Celecoxib 79-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 19075637-8 2008 This provided the rationale to target cox-2 enzyme and development of cox-2 selective drugs such as Vioxx and Celebrex. Celecoxib 110-118 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 19141979-1 2008 OBJECTIVE: To determine the effect of a selective COX-2 inhibitor celecoxib on cell proliferation and apoptosis of gastric cancer cell line BGC-823 to seek an effective and safe drug for gastric cancer chemoprevention. Celecoxib 66-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 18997524-4 2008 Perioperative use of the COX-2 selective inhibitor celecoxib seems to provide short-term and long-term postoperative advantages. Celecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 18716040-1 2008 BACKGROUND: Celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, also has anti-proliferative properties and pro-apoptotic effects on different in vivo and in vitro models, two actions that may be efficacious in therapy for endometriosis. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-57 18716040-7 2008 Western blot analysis showed that celecoxib was effective at increasing COX-2 protein at 100 microM in EEC from endometriosis patients (P < 0.05). Celecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 18716040-8 2008 In EEC from endometriosis patients, celecoxib at 25, 50 and 100 microM was also effective in reducing COX-2 activity, reflected in the reduction of prostaglandin E(2) (PGE(2)) synthesis (P < 0.001), and VEGF secretion (P < 0.001; P < 0.05 and P < 0.001), assessed by enzyme-linked immunosorbent assay. Celecoxib 36-45 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 18945614-1 2008 A hitherto unknown class of celecoxib analogs was designed for evaluation as dual inhibitors of the 5-lipoxygenase/cyclooxygenase-2 (5-LOX/COX-2) enzymes. Celecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 139-144 18674517-4 2008 With COX-1/COX-2 ratios between 7.5- and 16-fold they are in the range of Celecoxib (13-fold). Celecoxib 74-83 mitochondrially encoded cytochrome c oxidase II Homo sapiens 11-16 18674517-10 2008 In summary, modification of Eltenac generates moderately selective COX-2 drugs in the range of Celecoxib with respect to potency and selectivity. Celecoxib 95-104 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 18434566-0 2008 Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. Celecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 76-81 18678399-9 2008 Celecoxib, a COX-2 inhibitor was evaluated in an RTOG study in combination with cisplatin and flourouracil with radiation therapy with no apparent effect on DFS and poor rates of locoregional control. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 18083230-0 2008 Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Celecoxib 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 18083230-5 2008 So, we sought to examine the effect of celecoxib, a selective COX-2 inhibitor, on IR-K562 cells. Celecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 18083230-7 2008 This increase in the sensitivity of IR-K562 cells towards celecoxib suggests that the development of resistance in IR-K562 cells is COX-2 dependent. Celecoxib 58-67 mitochondrially encoded cytochrome c oxidase II Homo sapiens 132-137 18083230-11 2008 In conclusion, the present study indicates over-expression of COX-2 and MDR-1 in IR-K562 cells and celecoxib, a COX-2 specific inhibitor, induces apoptosis by inhibiting COX-2 and down-regulating MDR-1 expression through Akt/p-Akt signaling pathway. Celecoxib 99-108 mitochondrially encoded cytochrome c oxidase II Homo sapiens 112-117 18083230-11 2008 In conclusion, the present study indicates over-expression of COX-2 and MDR-1 in IR-K562 cells and celecoxib, a COX-2 specific inhibitor, induces apoptosis by inhibiting COX-2 and down-regulating MDR-1 expression through Akt/p-Akt signaling pathway. Celecoxib 99-108 mitochondrially encoded cytochrome c oxidase II Homo sapiens 112-117 18395100-9 2008 In the more common sporadic setting the APROVe (refecoxib), APC and PreSAP (Celecoxib) trials have shown a significant reduction in adenoma recurrence but important concerns exist regarding cardiovascular toxicity associated with selective COX-2 inhibitors. Celecoxib 76-85 mitochondrially encoded cytochrome c oxidase II Homo sapiens 240-245 18343721-2 2008 In non-myocardial tissue, the cyclooxygenase (COX)-2 inhibitor celecoxib has been shown to COX-independently inhibit Akt signalling. Celecoxib 63-72 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-52 19024521-9 2008 The expression level of COX-2 and VEGF in the gastric cancer tissues was significantly decreased in the celecoxib group compared with those in the control group (P < 0.05). Celecoxib 104-113 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 18485224-1 2008 BACKGROUND: An increasing number of reports is challenging the notion that the antitumor potential of the selective COX-2 inhibitor celecoxib (Celebrex) is mediated primarily via the inhibition of COX-2. Celecoxib 132-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 116-121 18485224-1 2008 BACKGROUND: An increasing number of reports is challenging the notion that the antitumor potential of the selective COX-2 inhibitor celecoxib (Celebrex) is mediated primarily via the inhibition of COX-2. Celecoxib 132-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 197-202 18485224-1 2008 BACKGROUND: An increasing number of reports is challenging the notion that the antitumor potential of the selective COX-2 inhibitor celecoxib (Celebrex) is mediated primarily via the inhibition of COX-2. Celecoxib 143-151 mitochondrially encoded cytochrome c oxidase II Homo sapiens 116-121 18485224-1 2008 BACKGROUND: An increasing number of reports is challenging the notion that the antitumor potential of the selective COX-2 inhibitor celecoxib (Celebrex) is mediated primarily via the inhibition of COX-2. Celecoxib 143-151 mitochondrially encoded cytochrome c oxidase II Homo sapiens 197-202 18485224-2 2008 We have investigated this issue by applying two different analogs of celecoxib that differentially display COX-2-inhibitory activity: the first analog, called unmethylated celecoxib (UMC), inhibits COX-2 slightly more potently than its parental compound, whereas the second analog, 2,5-dimethyl-celecoxib (DMC), has lost the ability to inhibit COX-2. Celecoxib 172-181 mitochondrially encoded cytochrome c oxidase II Homo sapiens 198-203 18485224-2 2008 We have investigated this issue by applying two different analogs of celecoxib that differentially display COX-2-inhibitory activity: the first analog, called unmethylated celecoxib (UMC), inhibits COX-2 slightly more potently than its parental compound, whereas the second analog, 2,5-dimethyl-celecoxib (DMC), has lost the ability to inhibit COX-2. Celecoxib 172-181 mitochondrially encoded cytochrome c oxidase II Homo sapiens 198-203 18255268-4 2008 In this study we showed that the selective COX-2 inhibitor, celecoxib (at the dose of 2mg/kg, but not at the doses of 0.2 or 20mg/kg, p.o. Celecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 18300697-5 2008 METHODS: The CADEUS study included patients treated with COX-2 inhibitors (celecoxib, rofecoxib) or traditional NSAIDs from September 2003 to August 2004. Celecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 18172906-1 2008 OBJECTIVE: To investigate whether the cox-2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases. Celecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 18287347-6 2008 Oleanolic acid induced prostaglandin I2 (PGI2) release by human coronary SMC, an effect that was prevented by celecoxib (a specific inhibitor of Cox-2). Celecoxib 110-119 mitochondrially encoded cytochrome c oxidase II Homo sapiens 145-150 18089846-11 2008 Our findings indicate both COX-2-dependent and -independent mechanisms attributable to celecoxib and support its utility in the management of prostate cancer. Celecoxib 87-96 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 18230053-0 2008 Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 18230053-1 2008 Celecoxib is an NSAID that was developed as a selective inhibitor of COX-2 and approved by the FDA for the treatment of various forms of arthritis and the management of acute or chronic pain. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 69-74 18230053-4 2008 Intriguingly, the two pharmacologic effects, inhibition of COX-2 and suppression of tumor growth, were found to reside in different structural aspects of the celecoxib molecule and, therefore, could be separated. Celecoxib 158-167 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 18230053-5 2008 This dualism enabled the synthesis of close structural analogs of celecoxib that exhibited increased antitumor potency in the absence of COX-2 inhibition. Celecoxib 66-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 137-142 18230053-7 2008 In this review, the authors present the status of preclinical development of anticancer analogs of celecoxib that are COX-2 inactive, with an emphasis on 2,5-dimethyl-celecoxib (DMC) and OSU-03012. Celecoxib 99-108 mitochondrially encoded cytochrome c oxidase II Homo sapiens 118-123 17920040-1 2008 To uncover the full spectrum of its pharmacological activities, the selective COX-2 inhibitor celecoxib is routinely being used at concentrations of up to 100 microM in cell culture. Celecoxib 94-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 78-83 17920040-3 2008 Here, we report a COX-2-independent effect of celecoxib that might have profound consequences for the interpretation of previous results obtained at elevated concentrations of this drug in vitro. Celecoxib 46-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-23 17920040-6 2008 These effects were not achieved by other coxibs (rofecoxib, valdecoxib) or traditional NSAIDs (indomethacin, flurbiprofen), but were mimicked by the COX-2-inactive celecoxib analog, 2,5-dimethyl-celecoxib (DMC), indicating COX-2 independence. Celecoxib 164-173 mitochondrially encoded cytochrome c oxidase II Homo sapiens 149-154 17920040-6 2008 These effects were not achieved by other coxibs (rofecoxib, valdecoxib) or traditional NSAIDs (indomethacin, flurbiprofen), but were mimicked by the COX-2-inactive celecoxib analog, 2,5-dimethyl-celecoxib (DMC), indicating COX-2 independence. Celecoxib 164-173 mitochondrially encoded cytochrome c oxidase II Homo sapiens 223-228 17920040-7 2008 Considering the obvious impact of blocked translation on cellular function, we provide evidence that this severe inhibition of protein synthesis might suffice to explain some of the previously reported COX-2-independent effects of celecoxib, such as the down-regulation of the essential cell cycle regulatory protein cyclin D, which is a short-lived protein that rapidly disappears in response to the inhibition of protein synthesis. Celecoxib 231-240 mitochondrially encoded cytochrome c oxidase II Homo sapiens 202-207 17996386-0 2008 Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 121-126 17996386-1 2008 PURPOSE: The purpose of the study was to elucidate the molecular mechanisms mediating radiosensitization of human tumor cells by the selective cyclooxygenase (COX)-2 inhibitor celecoxib. Celecoxib 176-185 mitochondrially encoded cytochrome c oxidase II Homo sapiens 143-165 18166099-2 2008 In this double-masked, placebo-controlled, randomized clinical trial, the efficacy of celecoxib (COX-2 inhibitor) was evaluated in conjunction with scaling and root planing (SRP) in subjects with chronic periodontitis (CP). Celecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 18289124-1 2008 Celecoxib (Celebrex, Pfizer, NY, USA) is a worldwide top branded COX-2-specific inhibitor. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-70 18642053-6 2008 However, certain conventional NSAIDs and celecoxib, a selective COX-2 inhibitor, have been reported to inhibit synovial hyperplasia by inducing the apoptosis of human synovial fibroblasts. Celecoxib 41-50 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-69 18289124-1 2008 Celecoxib (Celebrex, Pfizer, NY, USA) is a worldwide top branded COX-2-specific inhibitor. Celecoxib 11-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-70 18289124-4 2008 We discovered that the addition of curcumin, a natural COX-2 inhibitor, to celecoxib synergistically (up to 1000%) augments the growth inhibitory effects of celecoxib in in-vitro and in-vivo models of arthritis and cancer, thus rendering effective action of the drug at up to tenfold lower dose. Celecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 18289124-4 2008 We discovered that the addition of curcumin, a natural COX-2 inhibitor, to celecoxib synergistically (up to 1000%) augments the growth inhibitory effects of celecoxib in in-vitro and in-vivo models of arthritis and cancer, thus rendering effective action of the drug at up to tenfold lower dose. Celecoxib 157-166 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 18053191-1 2007 BACKGROUND: COX-2 inhibitors, such as celecoxib, and ubiquitin-proteasome pathway inhibitors, such as bortezomib, can down-regulate NF-kappaB, a transcription factor implicated in tumor growth. Celecoxib 38-47 mitochondrially encoded cytochrome c oxidase II Homo sapiens 12-17 17415779-3 2007 Celecoxib, a COX-2 specific inhibitor, was by far the most potent NSAID, with an IC(50) of 39.9 +/- 1.1 microM, followed by sulindac sulfide (116.5 +/- 2.34 microM). Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 17921715-2 2007 We investigated the role of COX-2 and NF-KB expression in relation to the use of a COX-2 inhibitor (celecoxib) associated to gemcitabine and oxaliplatin in pancreatic cancer. Celecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 17921715-2 2007 We investigated the role of COX-2 and NF-KB expression in relation to the use of a COX-2 inhibitor (celecoxib) associated to gemcitabine and oxaliplatin in pancreatic cancer. Celecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 17959037-1 2007 AIM: To gain insight into the histopathological responses and molecular targets in the inhibition of growth of human gastric cancer treated with celecoxib (a cyclooxygenase [COX]-2 inhibitor) combined with octreotide. Celecoxib 145-154 mitochondrially encoded cytochrome c oxidase II Homo sapiens 174-180 17879239-9 2007 The antioxidant vitamin C (2 mM) reduced CHP and CAA by 20-30% after 24 h of treatment, while the COX-2 inhibitor celecoxib (5 microM) had a minor effect on CHP and CAA, though it decreased the level of H2O2-induced H2AX phosphorylation and ATM activation. Celecoxib 114-123 mitochondrially encoded cytochrome c oxidase II Homo sapiens 98-103 17761345-2 2007 It has been demonstrated that celecoxib, a selective COX-2 inhibitor, can enhance apoptosis of human lupus T cells. Celecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 53-58 17763056-1 2007 Celecoxib, a selective COX-2 inhibitor, primarily used in treatment of osteoarthritis, rheumatoid arthritis and acute pain was encapsulated in microparticles composed of various polyesters, polymethacrylates or cellulose derivatives used alone or blended. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 18473007-0 2007 Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? Celecoxib 66-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 17696334-4 2007 The model compound for the study is the nonsteroidal anti-inflammatory drug celecoxib, a COX-2 selective inhibitor and known CYP2C9 substrate. Celecoxib 76-85 mitochondrially encoded cytochrome c oxidase II Homo sapiens 89-94 17786211-6 2007 Trends in inpatient stay due to MI were tightly coupled to the rise and fall of prescriptions of COX-2 inhibitors, with an 18.5% increase in inpatient stays for MI when both rofecoxib and celecoxib were on the market (P<0.001). Celecoxib 188-197 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 19804301-5 2007 His work linked COX-2 inhibitors such as Celebrex and Vioxx (Merck, NJ, USA) with heart attacks, and prevented Merck"s similar product, Arcoxia, from being approved. Celecoxib 41-49 mitochondrially encoded cytochrome c oxidase II Homo sapiens 16-21 17257745-0 2007 Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 17925765-1 2007 Drug-induced pancreatitis injury due to celecoxib, a first generation Cox-2 inhibitor, has been rarely reported. Celecoxib 40-49 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 17393325-2 2007 This study was performed to identify the antineoplastic mechanism in gastric cancer cells affected by celecoxib, a selective COX-2 inhibitor. Celecoxib 102-111 mitochondrially encoded cytochrome c oxidase II Homo sapiens 125-130 17661725-3 2007 This study analyzes the cardiovascular and cerebral vascular morbidity associated with high doses of the COX-2 inhibitor, celecoxib, in patients with metastatic hormone-refractory prostate cancer (mHRPC). Celecoxib 122-131 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110 17661725-0 2007 A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib. Celecoxib 158-167 mitochondrially encoded cytochrome c oxidase II Homo sapiens 142-147 17685888-0 2007 Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. Celecoxib 25-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 17685888-3 2007 Celecoxib was the first COX-2 inhibitor introduced on the market, and it still remains so, whereas rofecoxib and valdecoxib were withdrawn due to excess cardiovascular (CV) risk. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 17685888-7 2007 in short-treatment, especially in patients with previous experience of GI events and the recommendation of avoiding use of celecoxib in patients with CV history or risk, contribute in the decision-making process of prescribing COX-2 or NSAIDs. Celecoxib 123-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 227-232 17257745-1 2007 In this study, we analyzed the mechanisms of the apoptotic effects of celecoxib on COX-2 deficient gastric cancer cell line, MGC-803. Celecoxib 70-79 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 17257745-6 2007 Our study demonstrated that Akt/GSK3beta/NAG-1 signal pathway may represent as the major mechanism of the COX-2-independent effects of celecoxib on gastric cancer cells. Celecoxib 135-144 mitochondrially encoded cytochrome c oxidase II Homo sapiens 106-111 17504133-5 2007 Initially described as COX-2 "selective" inhibitors, recent reports revealed a nanomolar inhibition activity of the sulfonamide COX-2 inhibitors for several carbonic anhydrase (CA) isoforms, confirmed by X-ray crystal structures for the adducts of celecoxib and valdecoxib with isozyme CA II. Celecoxib 248-257 mitochondrially encoded cytochrome c oxidase II Homo sapiens 128-133 19075973-10 2007 Moreover, we will discuss recent patents of structural analogs of the COX-2 inhibitors celecoxib and valdecoxib, and novel potential pyridazine, triazole, indole, thione derivatives as a future target for the treatment of inflammation, pain and other diseases. Celecoxib 87-96 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 17437847-8 2007 Furthermore, the addition of celecoxib sensitized LNCaP-Neo and LNCaP-COX-2 cells to the cytocidal effects of radiation. Celecoxib 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 17652824-8 2007 As a result of research focused on reduction of the adverse effects of NSAIDs, selective COX-2 inhibitors, such as celecoxib and rofecoxib have been developed. Celecoxib 115-124 mitochondrially encoded cytochrome c oxidase II Homo sapiens 89-94 17293239-0 2007 Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Celecoxib 73-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 17293239-1 2007 PURPOSE: Toward improved glioblastoma multiforme treatment, we determined whether celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, could enhance glioblastoma radiosensitivity by inducing tumor necrosis and inhibiting tumor angiogenesis. Celecoxib 82-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-127 17166726-1 2007 Synthesis of [18F]4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide ([18F]celecoxib), a selective COX-2 inhibitor, is achieved via a bromide to [18F]F- exchange reaction. Celecoxib 101-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 125-130 17323186-3 2007 Several animal and clinical studies have reported the chemopreventive effect of celecoxib, a selective COX-2 inhibitor; and in particular, a few studies have shown that celecoxib prevents the development of gastric cancer. Celecoxib 80-89 mitochondrially encoded cytochrome c oxidase II Homo sapiens 103-108 17323186-3 2007 Several animal and clinical studies have reported the chemopreventive effect of celecoxib, a selective COX-2 inhibitor; and in particular, a few studies have shown that celecoxib prevents the development of gastric cancer. Celecoxib 169-178 mitochondrially encoded cytochrome c oxidase II Homo sapiens 103-108 17207548-1 2007 PURPOSE: To evaluate the potential radiosensitizing effect of the specific COX-2 inhibitor celecoxib (Celebrex) on prostate carcinoma cells in vitro. Celecoxib 91-100 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 17207548-1 2007 PURPOSE: To evaluate the potential radiosensitizing effect of the specific COX-2 inhibitor celecoxib (Celebrex) on prostate carcinoma cells in vitro. Celecoxib 102-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 17207548-3 2007 Western blot analysis and ELISA were used to determine the impact of radiation alone or radiation combined with celecoxib treatment on COX-2 expression and prostaglandin E2 synthesis. Celecoxib 112-121 mitochondrially encoded cytochrome c oxidase II Homo sapiens 135-140 17207548-7 2007 Treatment with celecoxib alone or in combination with IR led to a dose-dependent increase in COX-2 protein expression. Celecoxib 15-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 93-98 17593823-23 2007 CONCLUSION: Both COX-2 specific inhibitor Celecoxib and non-selective inhibitor Aspirin can potentially inhibit the tumor growth and induce apoptosis of SKOV3 cells, and the effect of Celecoxib is more potential than that of Aspirin. Celecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 17499604-3 2007 We aimed to test the hypothesis that in patients with previous ulcer bleeding induced by non-selective NSAIDs, combined treatment with the COX 2 inhibitor celecoxib and the PPI esomeprazole would be better than celecoxib alone for prevention of recurrent ulcer bleeding. Celecoxib 155-164 mitochondrially encoded cytochrome c oxidase II Homo sapiens 139-144 17342386-2 2007 Physiologic concentrations of celecoxib (5-10 microM) inhibited 80% to 90% of PGE(2) production in HT-29 cells that express high levels of COX-2 protein. Celecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 139-144 17342386-6 2007 The effect of celecoxib on cell growth inhibition was higher on the COX-2-positive HT-29 cell line (IC(50)=20 microM) than on the COX-2 deficient SW-480 cell line (IC(50)=35 microM). Celecoxib 14-23 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 17342386-8 2007 These results support the need for additional evaluation of independent COX-2 pathways of celecoxib in chemoprevention of CRC. Celecoxib 90-99 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 17226071-3 2007 Interestingly, low doses of nimesulide and celecoxib increase the levels of Prostaglandin E(2) and COX-2, and protect against subsequent 100% ethanol exposition, suggesting that these drugs may act as "mild irritants" to gastric mucosa. Celecoxib 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 99-104 17305567-0 2007 COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management. Celecoxib 17-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 17097285-2 2007 In the present study, we show that the specific COX-2 inhibitor celecoxib enhances the inhibitory effect of doxorubicin (dox) on human MDA-MB231 breast tumour growth in vivo and in vitro. Celecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 17612044-9 2007 At the turn of this century, there was enormous commercial development following the introduction of two new highly selective COX-2 inhibitors, known as coxibs (celecoxib and rofecoxib) which were claimed to have low GI side effects. Celecoxib 161-170 mitochondrially encoded cytochrome c oxidase II Homo sapiens 126-131 17612053-5 2007 Selective COX-2 inhibitors (celecoxib) as well as naturally occurring anti-inflammatory agents (curcumin) have proven to be effective chemopreventive agents against colonic carcinogenesis. Celecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 16931629-4 2006 Here, we show that acute hypertensive and prothrombotic activities of the COX-2-selective inhibitor celecoxib are revealed only after in vivo inhibition of NO generation. Celecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 74-79 17024689-8 2006 Recent users of COX-2 inhibitors had an increased risk of initiating antihypertensive therapy, regardless of specific drug (celecoxib adjusted OR = 1.7 (95%CI 1.3, 2.1); rofecoxib adjusted OR = 1.7 (95%CI 1.4, 1.9)). Celecoxib 124-133 mitochondrially encoded cytochrome c oxidase II Homo sapiens 16-21 16980601-5 2006 We designed a phase II study to assess the efficacy and toxicity of the combination of TMZ and celecoxib (a COX-2 inhibitor) in patients with advanced melanoma. Celecoxib 95-104 mitochondrially encoded cytochrome c oxidase II Homo sapiens 108-113 17111043-1 2006 OBJECTIVES: The Alzheimer"s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to evaluate the conventional NSAID naproxen sodium and the selective COX-2 inhibitor celecoxib for primary prevention of Alzheimer"s dementia (AD). Celecoxib 177-186 mitochondrially encoded cytochrome c oxidase II Homo sapiens 161-166 16824926-10 2006 Downregulation of COX-2 protein expression caused by celecoxib was observed in SKOV3 cells. Celecoxib 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-23 16939524-1 2006 AIM: To examine the risk of angio-oedema among users of the newer cyclooxygenase (COX)-2 selective inhibitors celecoxib and rofecoxib and other non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) in a population-based case-control study. Celecoxib 110-119 mitochondrially encoded cytochrome c oxidase II Homo sapiens 66-88 17094434-1 2006 BACKGROUND: Celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, has a pro-apoptotic effect on colon adenocarcinoma cells via COX-independent mechanisms. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-57 16755175-1 2006 OBJECTIVE: COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib. Celecoxib 181-190 mitochondrially encoded cytochrome c oxidase II Homo sapiens 11-16 16858202-0 2006 Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. Celecoxib 81-90 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-70 16357062-8 2006 Preincubation of the fibroblasts with celecoxib, a selective COX-2 inhibitor, suppressed CM-induced erbB3 phosphorylation. Celecoxib 38-47 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 16357062-11 2006 IL-1beta-stimulated HRG expression and release were also inhibited by celecoxib, and exogenous PGE(2) restored this inhibitory effect, suggesting the activation of an IL-1beta-COX-2-PGE(2) pathway that culminates in the release of HRG from fibroblasts. Celecoxib 70-79 mitochondrially encoded cytochrome c oxidase II Homo sapiens 176-181 16484869-5 2006 Celecoxib is a potent selective COX-2 inhibitor. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 32-37 16752024-10 2006 CONCLUSION: Celecoxib, a COX-2 selective inhibitor, is as effective as diclofenac SR in treating ankle sprains. Celecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 16827136-0 2006 COX-2 inhibitors celecoxib and rofecoxib prevent oxidative DNA fragmentation. Celecoxib 17-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 16539205-3 2006 Validation in vitro with Saos-2 osteoprogenitor cell lines showed a decrease in osteogenesis potential after the cells were treated with celecoxib, a COX-2 specific inhibitor and anti-inflammatory agent. Celecoxib 137-146 mitochondrially encoded cytochrome c oxidase II Homo sapiens 150-155 18690928-10 2006 Recent signals include amnesia and QTc prolongation with sibutramine; pain activation with sumatriptan; epistaxis with risperidone; psychiatric and visual disturbances with the COX-2 inhibitors celecoxib and rofecoxib and psoriasis with rofecoxib. Celecoxib 194-203 mitochondrially encoded cytochrome c oxidase II Homo sapiens 177-182 16709027-1 2006 Celecoxib (Celebrex) appears to be unique among the class of selective COX-2 inhibitors (coxibs), because this particular compound exerts a second function that is independent of its celebrated ability to inhibit COX-2. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 16709027-1 2006 Celecoxib (Celebrex) appears to be unique among the class of selective COX-2 inhibitors (coxibs), because this particular compound exerts a second function that is independent of its celebrated ability to inhibit COX-2. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 213-218 16709027-1 2006 Celecoxib (Celebrex) appears to be unique among the class of selective COX-2 inhibitors (coxibs), because this particular compound exerts a second function that is independent of its celebrated ability to inhibit COX-2. Celecoxib 11-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 16709027-1 2006 Celecoxib (Celebrex) appears to be unique among the class of selective COX-2 inhibitors (coxibs), because this particular compound exerts a second function that is independent of its celebrated ability to inhibit COX-2. Celecoxib 11-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 213-218 16709027-5 2006 One derivative, 2,5-dimethyl-celecoxib (DMC), which retains the antiproliferative and apoptosis-inducing function, but completely lacks the COX-2 inhibitory activity, is able to mimic faithfully all of the numerous antitumor effects of celecoxib that have been investigated so far, including reduction of neovascularization and inhibition of experimental tumor growth in various in vivo tumor models. Celecoxib 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 140-145 16519515-1 2006 The two cyclooxygenase enzymes, COX-1 and COX-2, are responsible for the committed step in prostaglandin biosynthesis and are the targets of the nonsteroidal antiinflammatory drugs aspirin and ibuprofen and the COX-2 selective inhibitors, Celebrex, Vioxx, and Bextra. Celecoxib 239-247 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 16519515-1 2006 The two cyclooxygenase enzymes, COX-1 and COX-2, are responsible for the committed step in prostaglandin biosynthesis and are the targets of the nonsteroidal antiinflammatory drugs aspirin and ibuprofen and the COX-2 selective inhibitors, Celebrex, Vioxx, and Bextra. Celecoxib 239-247 mitochondrially encoded cytochrome c oxidase II Homo sapiens 211-216 16391871-1 2006 Selective COX-2 inhibitors such as celecoxib and NS-398 are being evaluated as chemopreventive and therapeutic agents for bladder and other cancers. Celecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 16391871-12 2006 COX-2 selective inhibitors NS-398 and celecoxib produced dose-dependent growth inhibition of bladder cancer cells associated with a significant reduction in S-phase. Celecoxib 38-47 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 16373709-11 2005 Significant down-regulation of COX-2 and EGFR expression was observed in the BxPC-3 and HPAC cells treated with the combination of erlotinib (1 micromol/L) and celecoxib (10 micromol/L) compared with celecoxib- or erlotinib-treated cells. Celecoxib 160-169 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 16297351-12 2005 The IC50 values for the effect of celecoxib, PC-406 and PC-407 on COX-2 were 4.8, 8.9, and 1.9 nmol/L respectively. Celecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 66-71 16297351-13 2005 The IC(50, COX-1)/IC(50,COX-2) ratios for celecoxib and PC-407 were 8.3 and 14.4, respec-tively. Celecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 16297351-15 2005 CONCLUSION: Derivatives of celecoxib via substitution with an isopropyl or naphthyl group at the 5 position in the pyrazole ring still have analgesic effects and the ability to selectively inhibit COX-2. Celecoxib 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 197-202 16518289-1 2005 Drug-induced liver injury due to celecoxib, a first generation Cox-2 inhibitor, has been rarely reported. Celecoxib 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 16760127-1 2006 It has been reported that when ovarian carcinoma cell lines are exposed to various concentrations of celecoxib, a COX-2 inhibitor, cell growth is decreased in a dose dependant manner. Celecoxib 101-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-119 16412030-3 2006 There is a large amount of data that suggest traditional NSAIDs, as well as the new cyclooxygenase (COX)-2 selective inhibitors such as rofecoxib and celecoxib, have a role in the setting of primary and secondary prevention, and adjuvant therapy of both sporadic colorectal carcinoma and familial adenomatous polyposis. Celecoxib 150-159 mitochondrially encoded cytochrome c oxidase II Homo sapiens 84-106 16401468-4 2006 We examined the variability in degree and selectivity of COX-2 inhibition in humans in response to celecoxib and rofecoxib. Celecoxib 99-108 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 17154669-7 2006 Selective COX-2 inhibitors (celecoxib and rofecoxib [withdrawn from the market]) are well tolerated by almost all aspirin-sensitive asthmatic patients. Celecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 16373709-11 2005 Significant down-regulation of COX-2 and EGFR expression was observed in the BxPC-3 and HPAC cells treated with the combination of erlotinib (1 micromol/L) and celecoxib (10 micromol/L) compared with celecoxib- or erlotinib-treated cells. Celecoxib 200-209 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 16230415-0 2005 Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Celecoxib 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 93-98 16255660-4 2005 Celecoxib was the first COX-2 inhibitor introduced and the only remaining one on the US market. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 16563251-6 2005 RESULTS: COX-2 expression in monocytes in patients with AMI (0.92 +/- 0.13) was significantly higher than that in the control subjects (0.19 +/- 0.08), and decreased by 66% after atorvastatin (compared with that on routine therapy, P < 0.05); IL-6 secretions of monocytes in the AMI group (204.8 +/- 45.6 ng/L) increased dramatically compared with those in the control group (40.9 +/- 1.2 ng/L, P < 0.05), and reduced dramatically by 58% when incubated with 10 micromol/L celecoxib (P < 0.05) in a concentration-dependent manner; plasma levels of CRP in the AMI group (43.3 +/- 14.9 mg/L) significantly increased compared with those in the control group (1.7 +/- 0.8 mg/L), and reduced by 62% after atorvastatin (compared with those in the routine therapy group, P < 0.05). Celecoxib 478-487 mitochondrially encoded cytochrome c oxidase II Homo sapiens 9-14 16230415-0 2005 Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Celecoxib 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 177-182 16230415-5 2005 Celecoxib"s radiation-enhancing effect was observed in COX-2-expressing A549 and NCI-H460 cells but was not observed in the COX-2 nonexpressing MCF-7 and HCT-116 cells. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 16230415-6 2005 Celecoxib"s radiation-enhancing effects in A549 cells were shown to disappear after the administration of COX-2 knocked down. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 106-111 16230415-7 2005 In contrast, the HCT-116 cells were radiosensitized by celecoxib after being transfected with COX-2 expression vector. Celecoxib 55-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 94-99 16230415-10 2005 Celecoxib or NS-398 effected no changes or attenuated radiation-induced G(2)-M arrest in the COX-2-overexpressing cells but further enhanced the radiation-induced G(2)-M arrest in the COX-2 low-expressing cells. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 184-189 16230415-11 2005 Celecoxib"s radiation-enhancing effects seem to occur in a COX-2 expression-dependent manner in the cancer cells. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 16230415-13 2005 Celecoxib may exert an inhibitory effect on enhanced radiation-induced G2-M arrest in the COX-2-overexpressing cells, which may allow the arrested cells to enter mitosis and die after radiation, but may also further enhance radiation-induced G2-M arrest in the COX-2 low-expressing cells, by virtue of another mechanism. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 16230415-13 2005 Celecoxib may exert an inhibitory effect on enhanced radiation-induced G2-M arrest in the COX-2-overexpressing cells, which may allow the arrested cells to enter mitosis and die after radiation, but may also further enhance radiation-induced G2-M arrest in the COX-2 low-expressing cells, by virtue of another mechanism. Celecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 261-266 15891886-5 2005 We now show that treatment of tumor cells with the nonselective COX-1/COX-2 inhibitor indomethacin or the selective COX-2 inhibitor celecoxib leads to decreased expression of the MHC class I molecules Ld and Kd . Celecoxib 132-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 116-121 15993933-1 2005 BACKGROUND: A pilot study was undertaken to determine the feasibility of examining a COX-2 inhibitor (Celecoxib) as a chemopreventive agent in women at increased risk of ovarian cancer undergoing risk reducing salpingoophorectomy. Celecoxib 102-111 mitochondrially encoded cytochrome c oxidase II Homo sapiens 85-90